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ABSTRACT
E-cadherin is the most crucial membrane protein for the formation of tight and 
compact cell-cell adhesions in epithelial cells. E-cadherin based cell-cell 
junctions (adherens junctions) are highly dynamically regulated, for example 
during epithelial to mesenchymal transition (EMT) when E-cadherin at cell-cell 
contacts is down-regulated, leading to a loss of cell-cell adhesion. In addition to 
its structural role, E-cadherin has been shown to be involved in several signalling 
pathways during cell proliferation, differentiation and cell survival. However the 
molecular mechanisms of E-cadherin-mediated signalling are largely unknown. 
E-cadherin binding proteins, (3-catenin and pl20-catenin (p i20), can translocate 
to the nucleus, and bind and regulate the activity of transcription factors 
TCF/LEF-1 and Kaiso respectively. The influence of E-cadherin in these 
pathways is not fully understood. E-cadherin has been shown to be cleaved by 
metalloproteases and also by y-secretase. In this thesis I have examined E- 
cadherin cleavage and the role of cleaved E-cadherin in signalling.
The conditions inducing the cleavage of E-cadherin in epithelial cell lines were 
investigated. It was found that the y-secretase cleavage product of E-cadherin (E- 
cad/CTF2) was produced in MDCK cells in response to stimuli leading to EMT: 
treatment with hepatacyte growth factor and activation of Ras. p i20 was shown 
to specifically enhance the nuclear localisation of E-cad/CTF2. p i20 was also 
found to induce the ubiquitination of E-cad/CTF2. Biochemical assays were used 
to show that p i20 binds to a RING-fmger containing protein, ret finger protein 
(RFP), which also enhances ubiquitination and nuclear translocation of E- 
cad/CTF2. The role of ubiquitination and phosphorylation of E-cad/CTF2 in its 
nuclear translocation was investigated. In the nucleus, E-cad/CTF2 was shown to 
bind specifically to DNA. Its association with DNA is enhanced by both p i20 
and RFP. The transactivation potential of E-cad/CTF2 was investigated. It was 
shown that nuclear E-cad/CTF2 regulates p-catenin-TCF/LEF-1- and pi 20- 
Kaiso-mediated signalling pathways.
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CHAPTER 1
15
1 INTRODUCTION
1.1 Cell-cell junctions
In multi-cellular organisms, individual cells are often connected to each other via 
cell-cell adhesions to form three-dimensionally structured tissues. Formation of 
tight and compact cell-cell adhesions restricts cell movement and provides cells 
with a positional cue for the establishment of cell polarity. Different tissues have 
different requirements for cell-cell adhesion strengths. In connective tissues the 
extracellular matrix (ECM) is abundant, cells are sparsely distributed, and direct 
cell-cell contacts are of relatively low importance for the mechanical strength of 
the tissue. However in epithelial tissues, the cells are tightly bound to each other 
to form sheets of cells (Figure 1.1). In these epithelial tissues, the extracellular 
matrix is very sparse and forms a thin barrier, known as the basal lamina, to 
which the epithelial sheet is bound via cell-matrix adhesions (Figure 1.1). 
Epithelial cells have a defined polarity, with the apical side facing the the lumen 
and the basolateral side facing the basal lamina (Figure 1.1).
Microvilli
Cell-cell 
adhesion 
complex
Basolateral
(ECM)
Cel 1-Matrix 
adhesion 
com plexes
Figure 1.1 Epithelial cells in an epithelial sheet. Within an epithelial cell sheet, 
individual cells are tightly connected to each other via cell-cell adhesion complexes. 
They are also adhered to the extracellular matrix (ECM), which in epithelial tissue forms 
a thin basal lamina via cell-matix adhesion complexes such as hemidesmosomes and 
focal adhesions.
Apical
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Epithelial sheets are of vital importance to the organs of animals, lining all the 
cavities, lumens and free surfaces, including the respiratory, digestive, 
circulatory and renal tracts, as well as the skin. Epithelial sheets are either simple 
containing only one layer of highly polarised cells such as the lining of the small 
intestine as depicted in Figure 1.1, or stratified containing several layers of less 
polarised cells such as in skin. The basic function of the epithelium is to act as a 
barrier to the movement of water, solutes and cells between body compartments. 
However this function is highly regulated and specialised in different epitheilia 
to allow secretion, absorption, protection, transcellular transport, sensation 
detection, and selective permeability, depending on the specific requirements of 
the epithelium. Tight cell-cell contacts are vital for this barrier function, and are 
also important for various other processes that occur during development and 
during adult life. For example, during morphogenesis, cell shape and motility 
changes direct the transformation of uniform sheets of cells into specialized 
three-dimensional structures (Hogan, 1999). While this requires dynamic 
remodeling of some cell-cell adhesions (see section 1.4 for more detail), some 
groups of cells must maintain their tight adhesion. Furthermore, during wound 
healing, groups of cells must move together coordinately to close the wound 
without disrupting their cell-cell contacts (Gumbiner, 1996; Vasioukhin and 
Fuchs, 2001). Cell-cell contacts are also of importance in the nervous system and 
in endothelia (Dejana, 2004; Yamada and Nelson, 2007).
It has long been understood that tight cell-cell adhesions are mediated by specific 
structures at the interface between cells, known as cell-cell junctions. Electron 
microscopy allowed the identification of three main structures at the cell-cell 
contacts of the epithelium, which correspond to three main types of cell-cell 
junctions mediating cell adhesion (Farquhar and Palade, 1963). These junctions 
are depicted in Figure 1.2.
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Figure 1.2 Cell-cell junctions in epithelial cells. (A) Schematic representation of the 
three major types of cell-cell adhesion junctions in epithelial cells. Tight junctions are 
found at the apical side of the cells and link cells together through the binding of claudin 
and occludin proteins. These form a water-tight barrier between the cells. Cadherin 
proteins form the core o f the Adherens junction. Both tight junctions and adherens 
junctions are linked to the actin cytoskeleton. Desmosomes are formed by the 
interaction between desmosomal cadherins and are linked to intermediate filaments. (B) 
Electron micrograph showing tight junctions, adherens junctions and desmosomes 
formed between two murine intestinal epithelial cells. Schematic and electron 
micrograph taken from Perez-Moreno et al., 2003.
Tight junctions, or zonula occludens, the most apical of the junctional complexes 
in a polarised epithelial cell, are formed by claudin and occludin proteins (Aijaz 
et al., 2006). These junctions can act as a seal preventing the passage of water, 
small molecules and ions through the space between the cells. Moreover, tight 
junctions block the movement of membrane proteins between the apical and 
basolateral surfaces of the cell (Shin et al., 2006), which is important for the 
specialised functions of the two surfaces and for the maintainance of cellular 
polarity.
Positioned directly basally to the tight junctions are structures known as the 
adherens junctions, or zonula adherens (Figure 1.2). These junctions are held
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together by Ca2+-dependent transmembrane molecules known as cadherins (Yap 
et al., 1997). There is much evidence to suggest that establishment of adherens 
junctions is a crucial early event in epithelial sheet formation and polarisation 
(Braga and Yap, 2005; Yeaman et al., 1999). Many studies have shown that the 
prior formation of adherens junctions is required for the formation of other 
junctional complexes, and that this may involve cadherin-triggered signalling 
(Baida et al., 1993; Kohler et al., 2004; Tunggal et al., 2005; van Hengel et al., 
1997). Both tight junctions and adherens junctions are linked to the actin 
cytoskeleton.
Desmosomes are specialised intercellular junctional complexes which are 
attached to the intermediate filament cytoskeleton (Kowalczyk et al., 1999). Cell­
cell adhesion at desmosomes is mediated through the desmosomal cadherins 
desmocollin and desmoglein. The crucial role of desmosomes in cell-cell 
adhesion is highlighted by a number of diseases resulting from defective 
desmosomes (McMillan and Shimizu, 2001). The formation of desmosomal cell­
cell junctions stabilises cell-cell contacts initiated by adherens junctions and 
specifically blocking the formation of desmosome formation in epidermis 
disrupts adherens junctions (Vasioukhin et al., 2001b). Thus mature adherens 
junctions may require desmosomes for their stability.
In addition to the junctional complexes described above, gap junctions are found 
more basolaterally and are more widespread, being found in most animal tissues. 
Gap junctions constitute a cluster of channels, thus allowing small water-soluble 
molecules to be passed between adjacent cells. This allows cells to be coupled 
metabolically (Evans et al., 2006).
Adhesion at cell-cell junctions is mediated by interactions between cell adhesion 
molecules (CAMs). CAMs mediate cell-cell adhesion through dimerisation with 
other CAMs in adjacent cells. This may be heterophilic or homophilic 
dimerisation. In epithelial cells E-cadherin and claudins function as CAMs at 
adherens junctions and tight junctions, respectively. There are many other CAMs 
found at cell-cell contacts including a group of immunoglobulin (Ig)-like CAMs, 
which contain at least one Ig domain. For example, Junctional adhesion
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molecules (JAMs) are a group of Ig-like CAMs found in epithelial and 
endothelial cells which are involved in recruitment of cell polarity proteins 
(Ohno, 2001). Other members of the Ig-like CAM family can be found in many 
different cell types and are important in the regulation of a variety of cellular 
processes including cell adhesion and migration (Brummendorf and Lemmon, 
2001). Nectins are a group of Ig-like CAMs which play a number of roles in cell­
cell adhesion in epithelia and also at synapses (Irie et al., 2004). Their adhesive 
activity is through homophilic dimerisation of nectin molecules. Initial nectin- 
based cell-cell adhesion is important for the formation of adherens junctions and 
subsequent formation of tight junctions (Irie et al., 2004). Formation of nectin- 
based cell-cell contact leads to the recruitment of cadherins to the adhesion site 
through afadin and catenin molecules. Nectins also involved in the recruitment of 
JAMs, claudins and occludin to cell-cell contacts (Irie et al., 2004). Furthermore, 
nectin-based cell-cell adhesion is also thought to important in mediating contact 
inhibition of cell proliferation and cell movement (Fujito et al., 2005).
There is a wealth of evidence implicating the involvement of cell-cell junctions, 
particularly the adherens junction, in cellular signalling, although the molecular 
mechanisms are not fully understood (Fagotto and Gumbiner, 1996; Jamora and 
Fuchs, 2002; Perez-Moreno et al., 2003; Wheelock and Johnson, 2003a). In this 
thesis a novel pathway for signalling from adherens junctions is investigated.
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1.2 The adherens junction
1.2.1 The cadherin superfamily
The transmembrane core of the adherens junction consists of glycoproteins 
known as classical cadherins which were first identified as calcium-dependent 
mediators of cell-cell adhesion (Yoshida-Noro et al., 1984). The name cadherin 
stems from “calcium-dependent cell-cell-adhesion system”. A large number of 
cadherin genes have now been identified which form the cadherin superfamily. 
This includes classical cadherins, desmosomal cadherins, protocadherins and 
atypical cadherins (Yagi and Takeichi, 2000). All members of the cadherin 
superfamily contain multiple tandem copies of the extracellular (EC) repeat 
within their extracellular domain. EC repeats are involved in the binding of Ca 
ions, which is crucial for the adhesive activity of cadherins (Takeichi, 1990).
E-cadherin, which is expressed mainly in epithelia, is the prototype and best- 
characterised member of the classical cadherins. Other classical cadherins which 
have also been well characterised include N-cadherin and VE-cadherin that are 
mainly expressed in neuronal tissues or in endothelium respectively. However 
the classical cadherin family is large and there are many other important 
members (Steinberg and McNutt, 1999; Wheelock and Johnson, 2003b). 
Different members of the classical cadherin family have distinct properties. For 
example, increased expression of 'mesenchymal’ cadherins (N-cadherin, R- 
cadherin, and cadherin 11) increases the motility and invasiveness of epithelial 
cells (Feltes et al., 2002; Hazan et al., 2000; Nieman et al., 1999b). Desmosomal 
cadherins are crucial adhesive proteins in the desmosomes as described in section 
1.1. Protocadherins typically contain 6 or 7 EC repeats in their extracellular 
domain regions, but protocadherins with as many as 11 or as few as 4 EC repeats 
have been identified. Their intracellular regions are highly variable compared to 
classical cadherins. Although there is evidence that they can mediate cell-cell 
adhesion, it is considered to be much weaker than that mediated by the classical 
cadherins (Frank and Kemler, 2002; Suzuki, 1996).
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1.2.2 Components o f the adherens junction
As single-pass transmembrane proteins, classical cadherins mediate cell-cell 
adhesion at the adherens junction via Ca2+-dependent homophilic interactions 
with other cadherins expressed in adjacent cells (Figure 1.3). These trans dimers 
with cadherins in adjacent cells also form cis dimers with cadherins in the same 
cell membrane. This enables cadherin dimers to cluster to form the mature 
adherens junction, a process known as the ‘zipper’ model (Figure 1.3) 
(Gumbiner, 1996). The intracellular domain of classical cadherins interacts with 
members of a family of armadillo-repeat-containing proteins known as catenins 
(Perez-Moreno and Fuchs, 2006). Interactions with catenins occur via two 
Cadherin Homology (CH) domains: CH2 domain (located at the membrane 
proximal region) and CH3 domain (located at the distal region). These domains 
are conserved between classical cadherins. The CH2 and CH3 domains of 
classical cadherins interact with pl20-catenin (p i20) and p-catenin, respectively 
(McCrea et al., 1991; Reynolds et al., 1994) (Figure 1.3). Plakoglobin is highly 
homologous to p-catenin and usually associates with desmosomal cadherins, but 
can also act in an analogous way to p-catenin by associating with classical 
cadherins (Knudsen and Wheelock, 1992). Furthermore, E-cadherin specifically 
binds other proteins. The CH2 domain of E-cadherin also interacts with Hakai, 
an E3 ubiquitin ligase which regulates the stability of E-cadherin-based cell-cell 
contacts (discussed further in section 1.4.4) (Fujita et al., 2002; Tricaud et al., 
2005). C3G, a guanine nucleotide exchange factor for the small GTPase Rapl, 
also interacts transiently with the CH3 domain of E-cadherin and is important for 
the establishment of cell-cell contacts (Hogan et al., 2004).
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Figure 1.3 Core components of the adherens junction and a current model for how 
a-catenin may promote bundling of actin filaments at sites of cell-cell contacts.
Classical cadherins contain five extracellular (EC) repeat domains which mediate 
calcium-dependent homophilic interactions between cadherin molecules from 
neighbouring cells. Cadherin trans dimers also dimerise in cis which leads to the 
formation of cadherin clusters, thus forming the core of the adherens junction. Through 
the juxtamembrane CH2 domain (shown in pink), cadherins bind to p120. Through the 
membrane distal CH3 domain (shown in blue), cadherins bind to p-catenin (p) which 
links them to a-catenin (a), a-catenin is known to link the cadherin/catenin complex to 
actin bundles. The mechanism by which a-catenin can promote the association o f the 
actin cytoskeleton to adherens junctions is being actively researched but a current 
model suggests that a-catenin binds to p-catenin as a monomer, but can dissociate from 
p-catenin and dimerise. Dimeric a-catenin is proposed to inhibit Arp2/3-mediated actin 
filament branching and therefore promote the formation of bundled actin filaments. 
Schematic adapted from Weis and Nelson, 2006.
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1.2.3 Roles of P-catenin and a-catenin  at the adherens junction in 
linking to the actin cytoskeleton
p-catenin binds to another catenin protein known as a-catenin. a-catenin can 
bind directly to filamentous actin (Pokutta et al., 2002; Rimm et al., 1995) and 
also binds to several actin-binding proteins (Kobielak and Fuchs, 2004). a - 
catenin plays a crucial role in the remodeling of the actin cytoskeleton into radial 
actin cables and genetic studies in mice have shown a-catenin is required for 
sustained adhesion between cells during morphogenesis (Adams et al., 1998; 
Torres et al., 1997; Vasioukhin et al., 2001a). It has long been considered that a - 
catenin’s interaction with both the classical cadherin complex and actin provides 
the link between the adherens junction and the actin cytoskeleton which is vital 
for its adhesive function. However a series of recent experiments have raised 
doubt over the the molecular basis of the link from the adherens junction to the 
actin cytoskeleton (Drees et al., 2005; Weis and Nelson, 2006; Yamada et al., 
2005).
Some cell lines lacking endogenous a-catenin can form cell adhesions, albeit less 
well than those ‘rescued’ with ectopic a-catenin (Imamura et al., 1999; Watabe- 
Uchida et al., 1998). Direct binding studies using purified proteins and 
measurement of protein dynamics in live cells have indicated that the binding of 
a-catenin to the E-cadherin/p-catenin complex complex and actin are mutually 
exclusive (Drees et al., 2005; Weis and Nelson, 2006; Yamada et al., 2005). 
When E-cadherin, a-catenin and p-catenin purified receombinant proteins were 
mixed, a fraction of a-catenin, but not E-cadherin or p-catenin bound to actin. a -  
catenin can form homodimers which compete with p-catenin for a-catenin 
binding (Yamada et al., 2005). To ensure these results were not simply due to the 
formation of a-catenin dimers preventing the interaction of a-catenin with p- 
catenin, a chimera comprising the a-catenin binding site of p-catenin fused to a - 
catenin was produced. This chimera did not interact with actin, suggesting that 
a-catenin cannot bind to actin and the E-cadherin/p-catenin complex 
simultaneously (Drees et al., 2005). Futhermore, fluorescence recovery after 
photobleaching measurements in live cells showed that E-cadherin, p-catenin
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and a-catenin had almost identical recovery times but those of actin were much 
faster (Yamada et al., 2005). If a stable complex existed between the E- 
cadherin/catenin complex and actin, it would be expected that diffusion 
properties would be more similar.
Further experiments are required to fully understand the links between the E- 
cadherin/catenin complex and actin, but a model has been proposed (Figure 1.3) 
(Weis and Nelson, 2006). This model suggests that a local concentration of a - 
catenin monomers is produced in proximity to the E-cadherin/p-catenin clusters, 
via its binding to p-catenin. a-catenin can interchange between its monomeric 
state (where it is bound to p-catenin) and its dimeric state in the cytosol. Dimeric 
a-catenin can potently inhibit the Arp2/3 complex which promotes the branching 
of actin filaments (Figure 1.3) (Drees et al., 2005). Hence, dimeric a-catenin 
could promote the bundling of actin filaments at the adherens junction. It is also 
possible that other proteins may enable the anchoring of actin filaments at the 
adherens junction. For example nectins are found at adherens junctions and can 
bind 1-afadin, which binds to both actin and a-catenin (Irie et al., 2004).
1.2.4 Roles of p l20  at the adherens junction
p i20 was initially identified as a src substrate and has since been characterised as 
the prototype and most abundant member of the subfamily of p i20 armadillo 
related proteins, which includes 6-catenin, ARVCF and p0071 (Reynolds, 2007; 
Reynolds et al., 1994; Reynolds et al., 1992). There are many splice variants of 
p i20, but typically in mouse and humans, four main isoforms are expressed 
(Keirsebilck et al., 1998). All of the four main human isoforms contain the 
central Armadillo (Arm) repeat region, which contains 10 Arm repeats and is 
required for cadherin binding (Daniel and Reynolds, 1995). Arm repeats 
represent a protein-protein interaction domain and are sequences of 
approximately 45 amino acids which are tandemly repeated. They are found in (3- 
catenin and plakoglobin, as well as many other proteins of diverse cellular 
functions (Peifer et al., 1994). pl20 is now known to have various roles in the 
regulation of cell adhesion via dynamic regulation of the actin cytoskeleton,
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transport of cadherins to the cell membrane and stability of cadherins at the cell 
membrane (Anastasiadis and Reynolds, 2001; Perez-Moreno and Fuchs, 2006; 
Reynolds and Carnahan, 2004).
p i20 has emerged as a key regulator of cadherin turnover, modulating both 
transport and stability of cadherins at the plasma membrane (Xiao et al., 2007). 
A mutated form of E-cadherin which is selectively uncoupled from p i20 but not 
other catenins, was shown to disrupt cell-cell adhesion (Thoreson et al., 2000). 
Cadherin-deficient cells were transfected with either wild type or p i 20- 
uncoupled E-cadherin. Those transfected with wild type E-cadherin formed tight 
cell-cell contacts with a continuous border of actin filaments at the junctions, 
whereas those transfected with pl20-uncoupled E-cadherin formed weaker 
contacts and showed a disorganised actin cytoskeleton (Thoreson et al., 2000). 
Furthermore cell aggregates formed by cells expressing pl20-uncoupled E- 
cadherin were dissociated by pipetting, compared to wild type E-cadherin 
expressing cells where aggregates remained upon pipetting (Thoreson et al.,
2000). By studying cell types with very low expression levels of p i20, or where 
where p i20 expression has been knocked down, it has been shown that a lack of 
p i20 leads to an increase in both the internalisation and degradation of cadherins 
(Davis et al., 2003; Ireton et al., 2002; Maeda et al., 2006; Xiao et al., 2003; Xiao 
et al., 2005). Cadherins are also destabilised by targeted p i20 ablation in mice 
(Davis and Reynolds, 2006). There are a number of possible mechanisms by 
which p i20 could function to regulate cadherin turnover. It has been suggested 
that p i20 could act as a ‘cap’ by shielding sequences in the E-cadherin tail that 
interact with clathrin adaptor proteins (Xiao et al., 2005; Xiao et al., 2007). 
Furthermore, p i20 competes with two other proteins for the binding to E- 
cadherin, Hakai and y-secretase. Hakai leads to the downregulation of E-cadherin 
after phosphorylation by tyrosine kinases and is discussed further in section 1.4.4 
(Fujita et al., 2002; Tricaud et al., 2005). y-secretase binds to and cleaves E- 
cadherin, resulting in the disassembly of adherens junctions, and is discussed 
further in sections 1.4.5 and 1.5 (Marambaud et al., 2002; Wu et al., 2007). Thus 
by competing with Hakai and y-secretase for binding to E-cadherin, p i20 could
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protect E-cadherin from internalisation or degradation. Moreover, p i20 also 
interacts with microtubules (Franz and Ridley, 2004), and some studies suggest 
that cadherin transport to the plasma membrane along microtubule tracks can be 
enhanced by the interaction between p i20 and kinesin motor proteins (Chen et 
al., 2003; Yanagisawa et al., 2004).
Surprisingly, despite this abundance of data showing that p i20 plays a positive 
role in the stability of cadherins at the plasma membrane, some reports have 
suggested that p i20 could act to destablise the adhesive activity of cadherins in 
certain cell types (Aono et al., 1999; Ohkubo and Ozawa, 1999; Ozawa and 
Kemler, 1998). For example, in Colo205 cells which are largely non-adherent 
even though they possess essentially intact E-cadherin-catenin complexes, 
expression of an N-terminally deleted p i20 construct restored adhesiveness 
(Aono et al., 1999). This data could be explained by an aberrant signalling 
pathway in Colo205 cells which could inactivate p 120’s ability to promote 
adhesion. However it is supported by other studies using E-cadherin constructs 
that were truncated or mutated in the pi 20-binding regions, suggesting an 
inhibitory role of p i20 in adhesion in K-562 leukemia cells and L-fibroblasts 
(Ohkubo and Ozawa, 1999; Ozawa and Kemler, 1998). In all of these studies, 
inhibition of adhesion correlated with hyperphosphorylation of p i20, suggesting 
that phosphorylation of p i20 could affect its role in cadherin stability and 
turnover. Further work is required to fully understand these apparent 
contradictions in the role of p i20. It is possible that p i20 in general has a 
positive role in cadherin stability at the plasma membrane, but when certain 
signalling pathways are activated, possibly resulting in p i20 phosphorylation, it 
may also have a negative role (Anastasiadis and Reynolds, 2000).
p i20 is highly phosphorylated at multiple tyrosine, serine and threonine residues 
(Alema and Salvatore, 2007). Thus, as a protein with varied and crucial roles at 
the adherens junction, it is widely thought that p i20 phosphorylation is likely to 
be important in the fine tuning of its activities. However despite the large number 
of phosphorylation sites present, the role of p i20 phosphorylation remains 
incompletely understood. Indeed, although p i20 was first identified as a src 
substrate, the role of src phosphorylation and its possible link to cellular
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transfomation is still not clear (Reynolds, 2007). However, as described further 
in section 1.3.5, a role for src phosphorylation in p i20 signalling has recently 
been described (Hosking et al., 2007). Studies into the effect of tyrosine 
phosphorylation on its association with cadherin have produced apparently 
contrasting results and may reflect a fine and complex regulation of this 
association (Reviewed in Alema and Salvatore, 2006). p i20 also associates with 
the tyrosine kinases Fer, Yes and Fyn as well as several tyrosine phosphatases, 
suggesting that p i20 could act as a scaffold for the recruitment of tyrosine 
phosphorylation modulators, pointing to a role of p i20 in the integration of 
cellular signals (Reynolds and Roczniak-Ferguson, 2004). The role of 
serine/threonine phosphorylation of p i20 is also still largely unclear. However 
serine/threonine phosphorylation of p i20 can be induced by its membrane 
localisation and can influence E-cadherin dynamics at the plasma membrane 
(Fukumoto et al., 2007; Xia et al., 2006). The recent generation of 
phosphospecific p i20 antibodies is likely to accelerate the accumulation of 
knowledge into the role of pi 20 phosphorylation (Xia et al., 2004).
As will be discussed further in section 1.3.2, pl20 plays a crucial role in 
signalling to the actin cytoskelton through the regulation of Rho GTPases. 
Additionally, both P-catenin and p i20 can be localised in the nucleus of cells and 
have roles in the transmission of cellular signals to the nucleus (further described 
in sections 1.3.4 and 1.3.5).
1.3 Signalling mediated by cadherins.
1.3.1 Functional roles of cadherin-mediated signalling
A large body of evidence has accumulated implicating cadherins in the induction 
of intracellular signals (Knudsen et al., 1998; Perez-Moreno et al., 2003; 
Wheelock and Johnson, 2003a). These signalling pathways include the regulation 
of cell proliferation (Levenberg et al., 1999; Sasaki et al., 2000; St Croix et al., 
1998), cell survival (Fouquet et al., 2004; Kang et al., 2007; Vallorosi et al.,
2000), and differentiation (Goichberg and Geiger, 1998; Larue et al., 1996). 
Hence, in addition to their structural and adhesive roles, cadherins also appear to
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play a vital role in transducing signals particularly during development (Halbleib 
and Nelson, 2006; Perez-Moreno et a l, 2003).
Cadherin-mediated cell-cell adhesion has long been known to suppress cell 
proliferation, a process known as contact inhibition of growth (Hermiston and 
Gordon, 1995b; Navarro et al., 1991; Takahashi and Suzuki, 1996; Watabe et al., 
1994). Both E-cadherin and N-cadherin have been shown to upregulate the 
cyclin-dependent kinase (CDK) inhibitory protein p27 (Levenberg et al., 1999; 
St Croix et al., 1998). The activity of CDKs is required for progression through 
the cell cycle. The tight regulation of CDKs (mediated through binding of cyclins 
or inhibitory subunits such as p27 and also by phosphorylation) is crucial for the 
control of cell proliferation (Morgan, 1995). In a study using cells lacking E- 
cadherin, introduction of E-cadherin expression resulted in reduced proliferation, 
accompanied by an increase in p27 levels (St Croix et al., 1998). Additionally, E- 
cadherin-neutralising antibodies stimulated proliferation of cells endogenously 
expressing E-cadherin, and reduced p27 levels. Crucially, forced expression of 
p27 blocked the stimulation of proliferation induced by cadherin-neutralising 
antibodies, suggesting that p27 upregulation is at least partly responsible for E- 
cadherin-mediated proliferation suppression (St Croix et al., 1998).
Several studies have also indicated a role for E-cadherin in the suppression of 
apoptosis, particularly in protecting cells from detachment-induced apoptosis, 
known as anoikis (Fouquet et al., 2004; Kang et al., 2007; Vallorosi et al., 2000). 
Normal nonhematopoietic cells typically undergo anoikis in the absence of 
attachment to the ECM (Frisch and Screaton, 2001). This is thought to prevent 
ectopic growth at inappropriate body sites, as anchorage-independent growth is a 
defining property of transformed cells (Schwartz, 1997). Several reports have 
indicated that formation of cadherin-based cell-cell adhesions suppresses anoikis 
of epithelial cells under matrix-deficient conditions (Hermiston and Gordon, 
1995a; Peluso et al., 1996; Rak et al., 1999; Tran et al., 2002). A study of anoikis 
in enterocytes showed that upon loss of anchorage, these cells undergo rapid 
apoptosis which involves early loss of E-cadherin executed by lysosomal- and 
proteasomal-dependent degradation (Fouquet et al., 2004). Activation of E- 
cadherin using an E-cadherin-Fc chimera protein, reduces this anoikis, whereas
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treatment with blocking antibodies to E-cadherin increases it (Fouquet et al., 
2004).
The importance of cadherins in development is shown by abnormal tissue 
maturation and embryonic lethality of mice null for specific cadherins (Halbleib 
and Nelson, 2006; Hynes, 1996). There is now good evidence that the role of 
cadherins in development extends beyond their structural role and that through 
induction of signalling, they have a morphoregulatory role (Knudsen et al., 
1998). A direct involvement of N-cadherin signalling in muscle differentiation 
has been indicated by a number of studies, either by activating N-cadherin with 
recombinant N-cadherin ligands, or by blocking N-cadherin with antibodies, or 
with dominant-negative mutants. These studies have linked N-cadherin-mediated 
cell-cell adhesion to upregulation of two myogenic regulatory factor proteins, 
MyoD and myogenin (Goichberg and Geiger, 1998; Holt et al., 1994; Imanaka- 
Yoshida et al., 1998; Linask et al., 1997). Other cadherins such as E-cadherin, R- 
cadherin and M-cadherin can also impact on muscle differentiation (Redfield et 
al., 1997; Rosenberg et al., 1997; Zeschnigk et al., 1995). Muscle is not the only 
cell type whose differentiation has been shown to be affected by cadherins. 
Similar studies have shown effects on thymocyte and erythroid differentiation 
and mammary gland development (Armeanu et al., 1995; Muller et al., 1997; 
Radice et al., 1997). A study by Larue et al. in 1996 showed for the first time that 
specific cadherin types can stimulate specific signals leading to the 
differentiation of different types of tissues. Null mutant mouse embryonic stem 
(ES) cells for E-cadherin were used, which showed an aggregation defect and a 
change in the expression levels of the transcription factor T-brachyury. Although 
aggregation could be restored by overexpression of either E- or N-cadherin, there 
were differences in gene expression and tissue formation depending on which 
cadherin was used to 'rescue’ the cells. Overexpression of E-cadherin but not N- 
cadherin could rescue the wild-type regulation of the expression of T-brachyury 
(Larue et al., 1996). This indicated that specific cadherins can link information 
from the cell surface to gene expression in the nucleus. Additionally, when the 
ES cells were injected subcutaneously into syngenic hosts to form teratomas, the 
E-cadherin-rescued ES cells resulted exclusively in epithelial structures, but N-
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cadherin-rescued ES cells did not have epithelia but instead developed 
neuroepithelia and cartilage (Larue et al., 1996).
It is clear that cadherins have multiple signalling roles and links have been 
shown to exist between cadherins and regulation of the levels of signalling 
proteins such as p27, transcription factors and myogenic regulators. However the 
molecular mechanisms by which cadherins induce signals in order to regulate 
cellular behaviour and modulation of transcription remain incompletely 
understood. The following sections describe what is known about signalling 
mechanisms induced by cadherins and their binding proteins.
1.3.2 Cadherin-mediatated signalling through Rho GTPases
Rho GTPases are a family of small GTPases that act as molecular switches and 
control a wide variety of cell signalling events (Etienne-Manneville and Hall, 
2002). Briefly, Rho GTPases cycle between an active GTP-bound state and an 
inactive GDP-bound state. They can be activated by specific gunanine nucleotide 
exchange factors (GEFs) or inactivated by GTPase activating proteins (GAPs). 
Rho GTPases are most well known for their role in the control of the actin 
cytoskeleton. Rho A, racl and cdc42 promote the formation of actin-rich stress 
fibres, lamellipodia and filopodia, respectively. Lamellipodia and filopodia allow 
the formation of actin-based protrusions and extensions which are important for 
cell motility (Etienne-Manneville and Hall, 2002). As described in section 1.2.3, 
bundled actin filaments are linked to adherens junctions and are vital for their 
adhesive function. Since cadherins are dynamically regulated during 
morphogenesis (described in more detail in section 1.4), their ability to modulate 
their associated actin cytoskeleton is also crucial. The relationship between 
cadherins and Rho GTPase activity is complex and involves both inside-out 
signalling with Rho GTPase activity modulating cadherin function, and outside- 
in signalling with cadherins signalling to Rho GTPases.
That Rho GTPases promote the establishment and maintainance of cadherin- 
based cell-cell contacts was first demonstrated in a study using dominant 
negative Rac, or C3 toxin to block endogenous Rho activity in keratinocytes
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(Braga et al., 1997). Cells were cultured in low calcium medium which prevents 
cadherin-based cell-cell adhesion, as calcium is required for dimerisation of the 
cadherin extracellular domain. Restoring calcium levels with normal medium 
promotes formation of cell-cell contacts in normal keratinocytes, but is blocked 
in the presence of C3 toxin or dominant negative Rac (Braga et al., 1997). This 
study also showed that Rho and Rac are required for the accumulation of actin at 
the sites of cell-cell contact (Braga et al., 1997). One mechanism for inside-out 
signalling from Rho GTPases to cadherins is through the target of Racl and 
Cdc42, IQGAP1. IQGAP1 competes with a-catenin for binding to p-catenin, 
reducing adhesion strength. Active GTP-bound forms of Racl and Cdc42 bind to 
IQGAP1, which inhibits the interaction between IQGAP1 and p-catenin, thus 
strengthening the cadherin/catenin complex (Fukata et al., 1999; Kuroda et al., 
1998). Another small GTPase from the Ras family, Rapl, has been shown to 
positively regulate the formation of E-cadherin based cell-cell contacts in 
epithelial cell lines (Hogan et al., 2004; Price et al., 2004). Through recruitment 
of C3G, a GEF for Rapl, to the E-cadherin intracellular domain, Rapl is 
activated at sites of nascent cell-cell contacts and is required for proper targeting 
of E-cadherin to the membrane (Hogan et al., 2004). Interestingly, Rapl was 
shown to function upstream of Cdc42 in this process.
There is evidence suggesting that cadherin-mediated cell-cell contacts leads to 
the activation of Racl and Cdc42 wheras RhoA activity decreases as cells 
become more confluent, although this may depend on the experimental system 
used (Noren et al., 2001). Several studies by numerous laboratories using 
different techniques have shown that Racl is activated at sites of initial cell-cell 
contact, and some of these studies have implicated a dependence on either 
phosphatidylinositol-3-kinase (PI3K) or receptor tyrosine kinases (RTKs) in the 
cadherin-mediated recruitment of Racl, depending on the cell type (Betson et al., 
2002; Ehrlich et al., 2002; Kovacs et al., 2002). A recent study suggested that 
cadherin ligation leads to Racl activation through upregulation of Vav2, a GEF 
for Racl, via a pathway dependent on Src, Rapl and PI3K (Fukuyama et al.,
2006). Interestingly, uncoupling the interaction between cadherins and p i20
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prevents Racl activation at cell-cell contacts (Goodwin et al., 2003). Indeed, 
p i20 may be an important connection between cadherins and Rho GTPases.
Overexpression of p i20 in NIH3T3 fibroblast cells leads to an unusual 
‘branching’ phenotype with the production of long processes from the cells 
(Reynolds et al., 1996). p i20 has been proposed to bind to and prevent RhoA 
activity by stabilising the GDP-bound form of Rho, which is involved in the 
pl20-induced branching phenotype (Anastasiadis et al., 2000; Magie et al.,
2002). However p i20 can also activate Racl and Cdc42 most likely through its 
interaction with Vav2 (Anastasiadis and Reynolds, 2000; Grosheva et al., 2001; 
Noren et al., 2000). There are some discrepancies in the literature about whether 
p i20 must be free in the cytoplasm to affect the activity of Rho GTPase activity, 
or whether it can regulate them as a part of the adherens junction complex. The 
study described above by Goodwin et al. in 2003 suggests that p i20 binding to 
E-cadherin is required for the activation of Racl. However other studies have 
shown that sequestering p i20 at adherens junctions by expressing E-cadherin 
abolishes its effects on cell morphology (Grosheva et al., 2001). The idea that 
p i20 must be free in the cytoplasm to modulate Rho GTPase activity led to a 
model suggesting that at high cell density and when adherens junctions are 
stable, p i20 is largely associated with cadherin and can not greatly influence 
actin dynamics, p i20 may be released into the cytosol when cell density is 
reduced (for example during wounding), which may lead to the inhibition of 
RhoA and activation of Racl and Cdc42 resulting in an increase in migration 
(Grosheva et al., 2001; Noren et al., 2000). However a recent study suggests that 
mesenchymal cadherins may require the binding of p i20 in order to promote a 
more migratory phenotype (Yanagisawa and Anastasiadis, 2006). Therefore this 
model may be more complex and depend on the specific cadherin-type expressed 
in cells (Anastasiadis and Reynolds, 2001). The situation is further complicated 
by the varied effects of Rho GTPases on cell motility. Although their activities 
are in general required for cell motility, Racl and Cdc42 activation may decrease 
motility in epithelial cells by increasing cell-cell adhesion. The action of 
cadherins, p i20 and RhoGTPases in regulating cell motility vs cell-cell adhesion 
may vary depending on their localisation, abundance or activity level as well as 
the cell type.
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A recent paper from the Reynolds laboratory identified an interesting mechanism 
which may link p 120’s roles in modulation of RhoGTPases and cadherin 
turnover (Wildenberg et a l, 2006). Rho activity is known to be negatively 
regulated by Rac, through activation of pl90RhoGAP. This study suggested a 
crucial role for p i20 in Rho inhibition by Rac. Platelet derived growth factor 
(PDGF) receptor-induced Rac activity was shown to induce translocation of 
pl90RhoGAP to the membrane where it can bind adhesion complexes by 
interacting with p i20 (Wildenberg et al., 2006). Knockdown of p i20 prevented 
Rac from inhibiting Rho. Interestingly, the formation of adherens junctions 
induced by Rac activation was blocked in the absence of pl90RhoGAP 
(Wildenberg et al., 2006). Thus through the pl20-pl90RhoGAP interaction, Rac 
may control both adherens junction assembly and Rho inhibition.
1.3.3 Cadherin-mediated signalling through receptor tyrosine kinases
A number of reports have suggested functional interactions between cadherins 
and receptor tyrosine kinases (RTKs). Most of these studies indicate that 
cadherins can modulate the activity of tyrosine kinase signalling (Wheelock and 
Johnson, 2003a). The link between N-cadherin and the fibroblast growth factor 
(FGF) receptor is the most well characterised. N-cadherin has been suggested to 
facilitate the dimerisation of the FGF receptor and initiate signalling in the 
absense of growth factor (Doherty et al., 2000; Skaper et al., 2001). In these 
studies, the FGF-dependent neurite outgrowth from cultured neurons was 
assayed. Plating neurons on N-cadherin substrates leads to induction of neurite 
outgrowth in the absence of FGF, but required signalling downstream of the FGF 
receptor (Doherty et al., 2000; Skaper et al., 2001). Additionally, another report 
showed that inhibitors of FGF-receptor signalling reduced N-cadherin-mediated 
invasion, further implicating a role for N-cadherin in activation of the FGF 
receptor signalling and the involvement of FGFR signalling in N-cadherin 
function (Nieman et al., 1999b). Furthermore, N-cadherin has also been shown to 
promote ligand-dependent FGF receptor signalling by forming a complex with 
the FGF receptor and stabilising it at the cell surface (Suyama et al., 2002).
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Additionally, E-cadherin has been shown to associate with the epidermal growth 
factor (EGF) receptor (Hoschuetzky et al., 1994). Cell-cell contact has been 
shown to either inhibit EGF-dependent activation of the EGF receptor (Qian et 
al., 2004; Takahashi and Suzuki, 1996) or transiently induce ligand-independent 
activation of the EGF receptor, resulting in the activation of MAP kinases (Pece 
and Gutkind, 2000). This suggests that there could be variation in the links 
between E-cadherin and the EGF receptor in different cell types. A recent study 
used recombinant E-cadherin protein to selectively induce E-cadherin ligation in 
isolated cells, to determine whether E-cadherin ligation alone could affect EGF 
receptor signalling, without the complex process of cell-cell contact formation 
(Perrais et al., 2007). Selective homophilic ligation was shown to inhibit cell 
proliferation and EGF receptor signalling, but not through autophosphorylation 
of the receptor and there was no effect on MAP kinases. Instead, a different 
pathway involving Src and signal transducers and activators of transcription 
(STAT) 5 was inhibited (Perrais et al., 2007). Furthermore, cell-cell contact 
formation has also been reported to recruit PI3K to E-cadherin with a 
concommitant upregulation in phosphorylated tyrosine residues in PI3K (Pece et 
al., 1999). As discussed in section 1.3.2, activation of tyrosine kinases or PI3K 
may be involved in the activation of Racl at sites of cell-cell contacts. Moreover, 
a recent report suggest that PI3K and Akt activation by E-cadherin mediated cell­
cell adhesion may play a role in suppression of anoikis in Ewing tumour cells 
(Kang et al., 2007).
1.3.4 The W nt signalling pathway
In addition to its role in adhesion, (3-catenin has a crucial role in the Wnt 
signalling pathway (Brembeck et al., 2006; Willert and Jones, 2006). Wnts are 
secreted lipid-modified proteins and a large body of evidence has shown that 
Wnts are powerful regulators of cell proliferation and differentiation, particularly 
during embryogenesis (Willert et al., 2003). When cells are stimulated with Wnt, 
P-catenin is translocated into the nucleus where it binds a transcription factor, T- 
cell factor/lymphocyte enhancer factor-1 (TCF/LEF-1), and acts as a 
transcriptional activator (Behrens et al., 1996; Molenaar et al., 1996).
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Several loss of function mutations of Wnt generated in the mouse showed severe 
and varied developmental phenotypes (Parr and McMahon, 1995; Stark et al., 
1994; Yang and Niswander, 1995). Wnt signalling has emerged as a conserved 
mechanism in metazoan animals and controls a variety of processes such as cell 
fate, cell proliferation vs differentiation, cell survival, cell behaviour, and 
migration during morphogenesis (Cadigan and Liu, 2006; Moon et al., 2002; 
Nelson and Nusse, 2004). It is now known that there are numerous signalling 
pathways downstream of Wnt, but this section focuses on the pathway mediated 
by P-catenin nuclear translocation, known as the canonical Wnt signalling 
pathway.
The main components of the canonical Wnt signalling pathway were identified 
by genetic studies in flies where mutants were identified with phenotypes 
consistent with defective Wnt signalling. Genetic studies allowed the ordering of 
these components into a signalling pathway (Figure 1.4), and biochemical studies 
of the vertebrate counterparts have allowed a good understanding of the 
interactions between them (Cadigan and Nusse, 1997). Briefly, in the absence of 
Wnt signalling, P-catenin that is not bound by cadherins at the adherens junction 
is targeted for ubiquitination and degradation in the proteasome, following 
priming phosphorylations by the serine/threonine kinases Casein Kinase I (CK1) 
and glycogen synthase kinase-3 p (GSK-3P) (Polakis, 2002). GSK-3p is found in 
a scaffolding complex with axin and the adenomatous polyposis coli (APC) 
protein, which are also required for the degradation of p-catenin (Behrens et al., 
1998). Wnt binding to its receptor at the cell surface Frizzled, and the co-receptor 
Lipoprotein receptor related proteins 5 and 6 (LRP-5/6), activates dishevelled 
which can interact with the Axin/APC/GSK-3p complex (Cliffe et al., 2003). 
This blocks the Axin/APC/GSK-3p complex from phosphorylating p-catenin. 
Thus P-catenin is stabilized and accumulates in the cytoplasm, resulting in its 
nuclear localisation and induction of transcription via its association with 
TCF/LEF-1 (Behrens et al., 1996).
36
Extracellular
LRP5/6
CK1
APC
^g-catjCytoplasm
TCF
Nucleus
Figure 1.4 The canonical Wnt signalling pathway In the absence of a Wnt signal, p- 
catenin that is not bound to cadherins is targeted for ubiquitination and degradation in 
the proteasome. Phosphorylations by CK1 and GSK-3/3 are required to signal the 
ubiquitination of p-catenin. GSK-3p is found in a complex with APC and axin. Wnt 
signalling through binding to Frizzled (Fz) and LRP5/6 activates dishevelled (dvl) which 
blocks the activity of the Axin/APC/GSK-3p complex. Thus p-catenin is stabilized and 
can enter the nucleus where it can activate transcription through its interaction with 
TCF/LEF-1.
Target genes of the canonical Wnt signalling pathway are varied and include 
many developmental regulators and also genes controlling cell proliferation, cell­
cell interactions and cell-matrix interactions (Hecht and Kemler, 2000; Miller et 
al., 1999). In various cancers, Wnt target genes are also upregulated, including 
matrix metalloproteases, c-myc and cyclin D1 (Crawford et al., 1999; He et al., 
1998; Tetsu and McCormick, 1999). Indeed mutations in Wnt signalling 
components have been identified in several cancers. In particular the APC gene 
is altered in individuals with adenomatous familial polyposis as well as in some 
sporadic colon cancers, where impaired function of APC results in elevated (T 
catenin levels (Moon et al., 2002; Munemitsu et al., 1995).
P-catenin binds to cadherins and TCF/LEF-1 via the same region, and its binding 
to cadherins and TCF/LEF-1 has been shown to be mutually exclusive (Graham 
et al., 2000). Thus it has long been speculated that cadherins could negatively
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regulate p-catenin-mediated Wnt signalling pathways. Indeed transfection of 
cadherins antagonizes the signalling function of P-catenin, suggesting that it may 
regulate the pool of p-catenin available for Wnt signalling by sequestering it at 
the adherens junction (Fagotto et al., 1996). This study has been supported by 
many other reports showing that cadherin sequences as small as 23 amino acids 
can inhibit p-catenin-mediated Wnt signalling as long as they retain their ability 
to bind p-catenin and that transfection of cadherin sequences can also inhibit cell 
growth (Gottardi et al., 2001; Sadot et al., 1998; Simcha et al., 2001; Stockinger 
et al., 2001). However the situation may be more complex as some studies have 
suggested conformational changes of p-catenin may affect whether it can bind to 
cadherin or TCF/LEF-1 (Brembeck et al., 2004; Gottardi and Gumbiner, 2004). 
Gottardi and Gumbiner showed that p-catenin from untreated cells could bind 
both TCF/LEF-1 and cadherin equally well, but that p-catenin from Wnt treated 
cells showed preferential binding to TCF/LEF-1, which they suggested was due 
to a conformational change within the Arm repeats. Therefore it may be that 
other factors are involved in the balance between P-catenin’s function in Wnt 
signalling and at adherens junctions.
1.3.5 The roles of p l20  in signalling to the nucleus
Nucleocytoplasmic shuttling o f p i20
p i20 is found at several cellular locations including the adherens junction and 
microtubules. Additionally, under conditions where cadherins are 
downregulated, p i20 has been shown to be found in the cytosol (Roczniak- 
Ferguson and Reynolds, 2003; van Hengel et al., 1999). In contrast to a -  and P- 
catenins, p i20 has been shown to be metabolically stable in cadherin-deficient 
cells and is found in high levels in the cytosol (Thoreson et al., 2000). 
Furthermore, in some cancers a cytoplasmic localisation of p i 20 accompanied by 
a loss of cadherins, has been reported (Reynolds and Carnahan, 2004; Sarrio et 
al., 2004). A possible role for cytoplasmic p i20 in enhancing metastasis is being 
actively studied and may be related to its ability to enhance motility by 
regulating Rho GTPase activity (Anastasiadis and Reynolds, 2000; Reynolds and
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Carnahan, 2004). It is also possible that p i20 may participate in other signalling 
pathways in the cytoplasm or nucleus.
Nuclear localisation of p i20 has been reported in several cell lines and human 
tumours (Lo Muzio et al., 2002; Roczniak-Ferguson and Reynolds, 2003; van 
Hengel et al., 1999). However, in contrast to (3-catenin, the nuclear localisation 
of p i20 is not generally observed in most cell lines and treatment of cells with 
leptomycin B, an inhibitor of nuclear export, is often required to observe nuclear 
accumulation (Kelly et al., 2004; Roczniak-Ferguson and Reynolds, 2003; van 
Hengel et al., 1999). This suggested that there is rapid nucleocytoplasmic 
shuttling of p i20 which may be subject to tight regulation.
As shown in Figure 1.5, p i20 contains both nuclear localisation sequences (NLS) 
and nuclear export sequences (NES).
Figure 1.5 Domain structure of p120. p120 contains an N-terminal coiled-coil domain, 
and 10 Arm repeat domains. An NLS sequence is found between the sixth and seventh 
Arm repeats. Two NES sequences are also found. There are also many sites of 
phosphorylation in p120 (denoted by asterisks). Schematic adapted from Daniel et al., 
2007.
NLS sequences bind to the importin complex which mediates the nuclear 
localisation of proteins. The importin complex consists of Importin-a, which 
binds directly to the NLS sequence of proteins, and Importin-(3 which mediates 
translocation of proteins through the nuclear pore complex (Lange et al., 2007). 
There is some conflict in the literature about whether the NLS sequence in p i20 
(located between the sixth and seventh Arm repeats, Figure 1.5) is responsible 
for nuclear localisation of p i20. One study showed that the NLS sequence 
mediated the nuclear localisation of p i20 (Kelly et al., 2004), whereas another 
study showed that deleting the NLS had no effect on p 120’s nuclear localisation,
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but instead suggested that nuclear localisation is mediated by Arm repeats 3 and 
5 (Roczniak-Ferguson and Reynolds, 2003). The discrepancy may be because in 
the Roczniak-Ferguson study, the NLS was deleted rather than mutated which 
could affect protein folding, however it raises the interesting possibility that 
p 120’s nuclear localisation could be intrinsically conferred by its Arm domain. 
Importin-a contains an Arm domain which is the solely functional domain 
within this protein (Conti et al., 1998). An intriguing observation is that |3- 
catenin binds directly to Importin-13 and is imported into the nucleus in the 
absence of Importin-a (Fagotto et al., 1998; Yokoya et al., 1999). Other 
Armadillo-domain-containing proteins have been shown to be localised in the 
nucleus, suggesting that the Arm domain may be sufficient for nuclear 
localisation, raising the possibility that p i20 and other Arm-domain containing 
proteins could function as nuclear transport proteins (Daniel, 2007).
At present the signals triggering nuclear localisation and/or export of p i20 are 
incompletely understood. Glis2, a transcription factor which binds p i20, has 
been shown to induce substantial nuclear localisation of p i20 (Hosking et al., 
2007) and overexpression of a transmembrane adhesion protein Mucin-1 
correlates with p i20 nuclear localisation (Li and Kufe, 2001). It will be 
interesting to determine whether cadherin engagement or cell-cell contact 
formation has an impact on p i20 nuclear localisation.
pl20 binds to and regulates the acivity of two transcription factors
A transcriptional repressor Kaiso was identified several years ago as a p i20 
binding partner in a yeast 2-hybrid screen (Daniel and Reynolds, 1999). Kaiso is 
a member of the BTB/POZ (Broad complex, Tramtrak, Brie a brac/Pox virus and 
zinc finger) subfamily of zinc-finger-containing transcription factors. It contains 
an N-terminal POZ domain which facilitates Kaiso homodimerisation as well as 
heterodimersiation with the histone-deacetylase (HDAC) corepressor NCoR 
(Yoon et al., 2003). It also has three DNA-binding zinc-finger domains at the C- 
terminus, and interestingly p i20 is also known to bind Kaiso within this region 
(Daniel and Reynolds, 1999). Domain mapping indicates that p 120’s Arm 
repeats 1-7 (see Figure 1.5) are necessary and sufficient to mediate Kaiso binding
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(Daniel and Reynolds, 1999). p i20 also binds to cadherins via its Arm repeats, 
although whether cadherins and Kaiso compete for p i20 binding has not so far 
been examined (Daniel and Reynolds, 1995).
Unlike other POZ-ZF transcription factors which recognise and bind only one 
specific consensus sequence, Kaiso was found to have dual-specificity DNA 
binding. Kaiso recognises a sequence-specific consensus sequence on DNA 
TCCTGCnA (known as the Kaiso binding site (KBS)) and also methylated CpG- 
dinucleotides (Daniel et al., 2002; Prokhortchouk et al., 2001). As predicted due 
to the overlapping of the p i20- and DNA-binding regions of Kaiso, p i20 
inhibited Kaiso’s DNA binding to both KBS and methyl-CpG sites (Daniel et al., 
2002; Spring et al., 2005). Furthermore, p i20 relieved Kaiso-mediated repression 
from a minimal promoter (Kelly et al., 2004; Spring et al., 2005). It had been 
suggested that it was possible that p i20 could relieve Kaiso-mediated repression 
by sequestering it in the cytoplasm. However mutating the NLS of p i20 
prevented it from regulating Kaiso-mediated repression, suggesting that nuclear 
localisation of pi 20 was required for this effect (Kelly et al., 2004).
Several Kaiso target genes are also targets of the canonical Wnt signalling 
pathway, including cyclin D l, Siamois and matrilysin (matrix metalloproteinase 
(MMP) 7) (Park et al., 2005; Spring et al., 2005). This implicates p i20 and Kaiso 
in the regulation of the canonical Wnt signalling pathway. Kaiso and TCF were 
shown to bind to each other, and combined activation of TCF by |3-catenin and 
Kaiso derepression by p i20, results in enhanced expression of Siamois (Park et 
al., 2005). Furthermore Kaiso and p i20 regulate the expression of the non- 
canonical Wntl 1 (Kim et al., 2004). Kaiso is also known to repress metastasis- 
associated protein 2 (MTA2) (Yoon et al., 2003). It is thought that Kaiso 
mediates transcriptional repression by recruiting a HDAC corepressor complex 
that includes nuclear corepressor (NcoR) (Kim et al., 2002; Prokhortchouk et al., 
2001; Spring et al., 2005; Yoon et al., 2003).
It is tempting to think that (3-catenin-TCF/LEF-1 - and pl20-Kaiso-mediated 
signalling pathways are highly comparable. Indeed, the finding that they
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converge on a set of shared canonical Wnt gene targets adds weight to this 
argument and it seems that there are many parallels between the two pathways. 
Kaiso overexpression was shown to rescue the Xenopus axis-duplication 
phenotype caused by P-catenin overexpression and also to inhibit p-catenin- 
TCF/LEF-1-mediated activation of some Wnt target genes (Park et al., 2005; 
Spring et al., 2005). However there are some clear differences between P- 
catenin-TCF/LEF-1- and pl20-Kaiso-mediated signalling pathways. P-catenin 
acts as a coactivator upon binding to TCF/LEF-1, whereas pl20 appears to 
relieve Kaiso-mediated repression by removing it from DNA. Furthermore, P- 
catenin is highly unstable in the cytoplasm and requires the presence of a Wnt 
signal to inhibit its degradation in order to participate in nuclear signalling. In 
contrast p i20 is not rapidly degraded in the cytoplasm and so its nuclear 
localisation is likely to be regulated by distinct molecular mechanisms (Thoreson 
et al., 2000). However a recent study has indicated that upon activation with 
Wnt, a dishevelled binding protein Frodo can bind to and stabilise p i20 (Park et 
al., 2006). This suggests that activation of cells with Wnt may also enhance 
pl20-Kaiso-mediated signalling. At present other upstream regulators of p i 20- 
Kaiso signalling are not clearly understood. Since p i20 has been shown to be 
released into the cytoplasm upon down-regulation of cadherins at cell-cell 
junctions, this may also lead to an increased nuclear localisation of p i20 and thus 
could de-repress Kaiso-regulated genes. Further study is required to understand 
whether cadherin function could modulate Kaiso-regulated gene repression, p i20 
phosphorylation could be another potential regulatory mechanism.
Many of Kaiso’s gene targets (MTA2, MMP7, Siamois, cyclin D l) are linked to 
cell proliferation or metastasis leading to the hypothesis that Kaiso may act as a 
tumour suppressor. Surprisingly though, when Kaiso null mice were crossed with 
tumour susceptible Ape (Min/+) mice, they showed a delay in the onset of 
intestinal tumours (Prokhortchouk et al., 2006). Another recent study suggested 
that exposure of tumour cells grown in vitro to the tumour microenvironment 
(using xenograft experiments) can lead to the cytoplasmic localisation and 
downregulation of Kaiso expression (Soubry et al., 2005). Since p i20 
antagonises Kaiso-mediated repression, p i20 may have an oncogenic role
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through its interaction with Kaiso, in addition to its role in signalling through 
Rho GTPases.
A recent study by our lab showed that p i20 binds a Kruppel-like transcription 
factor Gli-similar-2 (Glis2), which was identified in a yeast 2-hybrid screen for 
p i20 binding partners (Hosking et al., 2007). As described above, Glis2 
substantially enhances nuclear localisation of p i20. p i20 induces cleavage of 
Glis2, which is enhanced by coexpression of src (Hosking et al., 2007). Glis2 
contains five tandemly repeated zinc finger domains and pl20-induced cleavage 
removes the fifth zinc finger of Glis2, but does not prevent it from binding to 
DNA. Glis2 can affect neuronal differentiation in the chick neural tube, whereas 
the cleaved form of Glis2 requires p i20 to have a similar effect (Hosking et al., 
2007). Thus through binding to a second transcription factor, p i20 has now also 
been shown to have a signalling function in neuronal differentiation.
1.4 Dynamic regulation of Adherens junctions
1.4.1 Epithelial to mesenchymal transitions
As described in section 1.1, epithelial cells tightly adhere to each other forming 
highly polarised sheets. Although epithelial cells are motile, in general they 
move within the epithelial monolayer and do not detach or move away from the 
monolayer. In contrast mesenchymal cells do not form an organised layer, have 
few intercellular contacts, and lack defined polarity (Thiery, 2003). In culture, 
epithelial cells grow as clusters maintaining complete cell-cell adhesion with 
their neighbours, whereas mesenchymal cells have a spindle-shaped, fibroblast­
like morphology and are highly motile (Thiery and Sleeman, 2006). Epithelial to 
mesenchymal transition (EMT) is loosely defined by the disassembly of cell-cell 
and cell-matrix contacts leading to the loss of epithelial polarity and the 
separation of individual cells. This is accompanied by the acquisition of a 
migratory or mesenchymal-like phenotype (D'Souza-Schorey, 2005; Thiery, 
2003; Thiery and Sleeman, 2006).
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EMT is an important process in the tissue remodelling that occurs during 
embryogenesis. Without EMT, development cannot proceed past the blastula 
stage, which consists of an epithelial sheet surrounding a cavity known as the 
blastocoel (Thiery and Sleeman, 2006). EMT is crucial for the complex process 
of embroyonic gastrulation, which enables the transition from the blastula to a 
three-layered structure. In this stucture, the innermost layer is the primitive gut, 
known as the endoderm; the outermost layer is the epithelium that remains 
external, known as the ectoderm; and between the two is a looser layer of tissue 
composed of mesenchyme cells, known as the mesoderm (Solnica-Krezel, 2006). 
The formation of these three layers is vital for the formation of different organs 
and tissues. The formation of mesenchymal cells from the epithelial layer which 
then migrate into the blastocoel is vital for the production of mesoderm which in 
vertebrates forms skeleton, muscles, heart, kidney and may other organs (Thiery 
and Sleeman, 2006).
Unsurprisingly for such a vital and complex mechanism, EMT is regulated by a 
large number of signals such as Wnts, bone morphogenic proteins (BMPs) and 
many growth factors including FGF, hepatacyte growth factor (HGF), EGF and 
transforming growth factor (TGF)P (Blay and Brown, 1985; Boyer et al., 1989; 
Miettinen et al., 1994; Theriault et al., 2007; Valles et al., 1990; Wang et al., 
2005; Weidner et al., 1990; Yook et al., 2006). It is difficult to follow EMT in 
live organisms, but the process became more amenable to experimentation in the 
1980s when it was discovered that HGF, known as ‘scatter factor’ could convert 
a highly polarised epithelial cell line, Madin-Darby canine kidney (MDCK), into 
migratory fibroblasts by activating the tyrosine kinase receptor c-Met (Stoker et 
al., 1987; Stoker and Perryman, 1985). Indeed there is now a large body of 
evidence linking the activation of tyrosine kinase receptors by growth factors, or 
the activation of the tyrosine kinase Src to the induction of EMT (Behrens et al., 
1993; Stoker and Gherardi, 1991; Thiery, 2003). The small GTPase Ras is 
activated as a result of ligand binding to RTKs, and leads to the activation of 
many intracellular signalling cascades including the PI3K, MAPK, and 
phospholipase C pathways (Downward, 2003). Ras activation itself leads to 
transformation and scattering of epithelial cells resulting in the disruption of cell­
cell contacts, and some studies indicate that several of the pathways downstream
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of Ras may be required to obtain a complete EMT (Janda et al., 2002; Potempa 
and Ridley, 1998; Schoenenberger et al., 1991; Thiery, 2003). As there are so 
many signalling pathways involved in the complex regulation of EMT, and 
downregulation of both cell-matrix and cell-cell adhesion occurs, sections 1.4.3 -
1.4.5 will focus on mechanisms involved in the downregulation of E-cadherin 
during EMT, as E-cadherin is the main cadherin expressed in epithelia and the 
subject of this thesis.
1.4.2 The role of E-cadherin as a tumour suppressor
The majority of human cancers (80-90%) originate from epithelial cells 
(Christofori and Semb, 1999). During the progression of carcinogenesis, most 
tumour cells deriving from epithelial tissues lose their epithelial characteristics, 
particularly in the transition from benign lesions to invasive metastatic cancer. 
This transition involves the perturbation of cell-cell adhesions and cells taking on 
a more migratory and invasive phenotype (Christofori and Semb, 1999; Thiery,
2002). Since the cellular organisation within tumours is highly diverse, it is hard 
to follow individual cells undergoing EMT. However, various carcinoma cell 
lines undergo partial or complete EMT in vitro, and a number of signalling 
pathways have been found to be common to EMTs in development and in 
tumour progression (Thiery, 2002). The putative role of EMT in the progression 
of carcinoma is represented in Figure 1.6.
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Figure 1.6 EMT in tumour progression. An adenoma can develop from local 
proliferation o f a normal epithelia lined by a basement membrane, which can be further 
transformed to form a carcinoma in situ. In a step which may involve an EMT, local 
dissemination o f carcinoma cells can occur producing an invasive carcinoma where the 
basement membrane becomes broken down. During intravasation, cells can enter 
lymph or blood vessels which allows their transport to secondary sites. Schematic taken 
from Thiery, 2002.
It is now known that in most cancers of epithelial origin (including cancers of the 
breast, colon, prostate, stomach, liver, esophagus, skin, kidney and lung), E- 
cadherin is lost as the cancer progresses towards malignancy, and it has been 
proposed that this loss of E-cadherin is a prerequisite for tumour cell invasion 
and metastasis (Birchmeier and Behrens, 1994; Bracke et al., 1996; Christofori 
and Semb, 1999). Indeed, in cases of familial gastric cancers, there is evidence of 
germline mutations in the E-cadherin gene, suggesting that mutation of E- 
cadherin is sufficient to predispose individuals to this cancer (Guilford et al., 
1998). As described in section 1.3.1, E-cadherin could function as a tumour 
suppressor by suppressing proliferation. Additionally, the role of E-cadherin in 
suppressing the invasive capacity of tumour cells has been shown by forced 
expression of E-cadherin in invasive mesenchymal tumour cells (Frixen et al., 
1991; Vleminckx et al., 1991). These studies showed that E-cadherin expression 
prevented the invasiveness of these cells and restored their epithelial phenotype. 
Furthermore, a transgenic mouse model of tumourigenesis was used to show that 
loss of E-cadherin is a cause not a consequence of the progression from non-
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invasive tumours (adenoma) to malignant, invasive tumours (carcinoma) (Perl et 
al., 1998). In this study, mice expressing SV40 T antigen in pancreatic (3 cells 
under the control of insulin, which reproducibly develop (3 cell tumours in a 
multistage tumourigenesis pathway, were crossed with mice expressing either 
wild-type or dominant negative E-cadherin specifically in pancreatic |3 cells. 
Maintainance of E-cadherin during (3 cell tumourigenesis resulted in the blocking 
of tumour development at the stage of adenoma (Perl et al., 1998). In contrast, 
expression of dominant negative E-cadherin resulted in early invasion and 
metastasis (Perl et al., 1998). This result indicates that loss of E-cadherin is a 
rate-limiting step in the progression from adenoma to carcinoma in vivo. Since 
blocking E-cadherin function actively enhances invasion and metastasis, it is 
now crucial to determine whether specific signals evoked by E-cadherin can 
participate in the control of invasiveness of cells.
Several studies have also indicated that during tumour progression, E-cadherin is 
replaced by increased expression of other ‘mesenchymal’ cadherins such as N- 
cadherin or cadherin-11, a phenomenon known as ‘cadherin switching’ 
(Christofori, 2003; Li and Herlyn, 2000; Tomita et al., 2000). Indeed, expression 
of N-cadherin in various cancer cell types has been shown to induce cell motility 
and invasiveness, thus showing the opposite effect of E-cadherin (Hazan et al., 
2000; Islam et al., 1996; Li et al., 2001). At present the functional implications of 
cadherin switching remain incompetely understood. N-cadherin, unlike E- 
cadherin, promotes a more dynamic adhesion state (Christofori, 2003; Li and 
Herlyn, 2000; Tomita et al., 2000), and as described in section 1.3.3, N-cadherin 
can enhance FGF receptor signalling in neurons enhancing neurite outgrowth 
which is related to cell migration and invasion. However greater understanding is 
required to understand the relevance of cadherin switching in EMT and tumour 
progression.
1.4.3 Transcriptional downregulation of E-cadherin
E-Cadherin expression has been shown to be downregulated during EMT by 
several zinc-finger and basic helix-loop-helix (bHLH) transcriptional repressors 
(Peinado et al., 2007). In 2000 it was first discovered that a zinc-finger
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transcriptional repressor Snail represses expression of E-cadherin through an E2- 
box sequence within the E-cadherin promotor (Cano et al., 2000). This study also 
showed that expression of Snail in epithelial cells could promote EMT and 
induce a fibroblastic and invasive phenotype. Furthermore it was shown that 
Snail is expressed in regions of mouse and human carcinomas that are E- 
cadherin-deficient and invasive, but absent from non-invasive carcinomas where 
E-cadherin levels remain high. Similarly the bHLH transcription factor E12/E47 
also represses E-cadherin expression and induces EMT (Perez-Moreno et al.,
2001). Slug, which is closely related to Snail, acts in a similar manner but is a 
less effective at repressing E-cadherin than Snail and E12/E47 (Bolos et al.,
2003). Upregulation of Snail occurs in response to TGFp, in a manner that is 
dependent on Ras activation of MAPK and PI3K signalling pathways (Peinado et 
al., 2003). Furthermore upregulation of Snail was shown to be essential for HGF- 
mediated scattering of HepG2 cells, since knockdown of Snail with RNAi 
prevented scattering (Grotegut et al., 2006). This study showed that HGF- 
mediated induction of Snail also involves MAPK signalling and activity of early 
growth response factor-1. Interestingly, the snail gene is repressed by metastasis 
associated gene 3 (MTA3), a component of the transcriptional co-repressor 
complex NuRD (Fujita et al., 2003). MTA3 is a vital component of a pathway 
activated by the estrogen receptor (ER). Breast carcinomas that are negative for 
ER do not express MTA3, resulting in upregulation of Snail and loss of E- 
cadherin (Fujita et al., 2003). Thus the loss of ER or MTA3, or the upregulation 
of Snail, is associated with poor prognosis in breast cancer.
1.4.4 Downregulation o f E-cadherin at cell-cell contacts by 
endocytosis
As described in section 1.2.4, regulation of E-cadherin trafficking can influence 
the stability of adherens junctions. There is a wealth of evidence implicating 
endocytosis of E-cadherin in the downregulation of adherens junctions during 
EMT (D'Souza-Schorey, 2005). It was first shown by electron microscopy 
studies that loss of adherens junctions is accompanied by accumulation of coated 
vesicles (Warren and Nelson, 1987). It is now understood that cadherins undergo 
constitutive endocytosis and recycling, and that endocytosis is enhanced when
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cell-cell contacts are disassembled, particularly in response to growth factor 
signalling (Kamei et al., 1999; Le et al., 1999; Wrobel et al., 2004).
The small GTPase ARF6 is a known regulator of endosome trafficking and has 
emerged as a regulator of E-cadherin endocytosis (Palacios et al., 2001; Palacios 
et al., 2002; Paterson et al., 2003). HGF stimulation of MDCK cells has been 
shown to activate ARF6, and dominant negative ARF6 blocks HGF-induced 
internalisation of cadherins (Palacios et al., 2001). As described in Section 1.3.2, 
Racl has a well established role in promoting the formation of adherens 
junctions. In 2003, a study was carried out following Racl activation over time 
as cell scattering was induced with HGF treatment or Src activation. It was 
shown that a transient decrease in Racl activity occurs during the disassembly of 
adherens junctions which is accompanied by a depolymerisation of actin at sites 
of cell-cell contact (Palacios and D'Souza-Schorey, 2003). This is then followed 
by the restoration of Racl activation as the cells become more migratory and 
produce lamellipodia (Palacios and D'Souza-Schorey, 2003). This reduction in 
Racl activity during cell scattering was shown to be dependent on ARF6 activity 
(Palacios and D'Souza-Schorey, 2003). It has been proposed that the loss of 
polymerised actin around the adherens junction at the start of scattering may 
‘loosen up’ adherens junctions to facilitate endocytosis (D'Souza-Schorey, 2005). 
The biphasic activation profile of Racl during cell scattering may help to explain 
why Racl activation is involved in both stabilisation of adherens junctions and 
enhancement of migration.
The oncogene and tyrosine kinase Src is known to trigger phosphorylation of E- 
cadherin and (3-catenin and the dissasembly of adherens junctions (Behrens et al., 
1993). Following tyrosine phosphorylation of E-cadherin by Src, phosphorylated 
E-cadherin has been shown to bind a protein called Hakai, which then induces 
the endocytosis of E-cadherin (Fujita et al., 2002). Hakai means ‘destruction’ in 
Japanese and was shown in this study to be an E3-ubiquitin ligase, mediating the 
addition of ubiquitin to the E-cadherin complex. Ubiquitin is a small 8.5 kDa 
protein which has a variey of cellular roles (Pickart, 2001; Sun and Chen, 2004). 
The ubiquitin system and its role in the control of various cellular processes is 
described in more detail in section 1.6. Hakai overexpression was shown to
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induce disruption of cell-cell contacts and E-cadherin intemalisaion. It decreases 
the half-life of E-cadherin and increases the sensitivity of MDCK cells to HGF- 
mediated scattering (Fujita et al., 2002). Ubiquitinated E-cadherin has been 
shown to be targeted to lysosomes for degradation, thus ensuring that cell-cell 
contacts cannot reform (Palacios et al., 2005).
Recently, our lab showed that serine phosphorylation of E-cadherin by CK1 is 
also implicated in the control of E-cadherin endocytosis (Dupre-Crochet et al., 
2007). A CK1 inhibitor was shown to stabilise cell-cell contacts. CK1 interacts 
and colocalises with E-cadherin, and overexpression of CK1 isoforms disrupt 
cell-cell contacts. Serine 846 was identified as the CK1 phosphorylation site in 
E-cadherin and a constitutively phosphorylated mutant at this residue was 
internalised more efficiently than wild-type E-cadherin (Dupre-Crochet et al.,
2007). There are at least seven isoforms of CK1 which are all ubiquitously 
expressed in mammals, and are involved in several cellular processes including 
differentiation and proliferation (Knippschild et al., 2005). Indeed, as described 
in Section 1.3.4, CK1 positively regulates canonical Wnt signalling by 
phosphorylating (3-catenin which promotes its ubiquitination by the APC 
complex. Now it has also been shown to promote the down-regulation of 
adherens junctions.
An important question to be answered from a signalling perspective is what 
happens to the other components of the adherens junctions when cadherins are 
internalised. Some studies suggest that at least some cadherin is internalised 
along with p-catenin (Akhtar and Hotchin, 2001; Ivanov et al., 2004), whereas 
others suggest that catenins dissociate from cadherins after cadherin 
internalisation (Le et al., 1999; Lu et al., 2003). If catenins are released from 
cadherin after internalisation they may form a ‘signalling pool’ in the cytoplasm. 
In particular, the study by Lu et al. suggests that endocytosis in response to EGF 
treatment may specifically enhance p-catenin-mediated signalling. However 
more rigorous examination is required in order to understand whether 
endocytosis of E-cadherin can release catenins in to the cytosol.
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1.4.5 Downregulation of E-cadherin at cell-cell contacts by 
proteolytic cleavage
Proteolytic cleavage of E-cadherin by several proteases has been reported to be 
involved in the destabilisation of adherens junctions during EMT or the 
metastatic progression of cancers (Kuefer et al., 2003; Lochter et al., 1997; 
Marambaud et al., 2002; Noe et al., 2001; Rios-Doria et al., 2003). It was first 
discovered in 1987 that an 80 kDa E-cadherin extracellular domain fragment is 
released in the culture media of tumour cells (Wheelock et al., 1987). It has since 
been determined that E-cadherin extracellular domain is cleaved by the 
metalloproteinases Matrilysin-1 (MMP-7), Stromelysin-1 (MMP-3) and ADAM 
(a disintegrin and metalloprotease) 10 (Lochter et al., 1997; Maretzky et al., 
2005; Noe etal.,2001).
MMPs are a family of proteinases that play a vital role in remodelling the 
cellular microenvironment during morphogenesis, wound healing and tumour 
progression (Lee and Murphy, 2004; Page-McCaw et al., 2007). Their main 
function has been historically considered to be the degradation of the ECM, but 
knowledge of their substrates, and therefore their critical role in regulating the 
response of cells to their environment, has expanded greatly over recent years 
(Stemlicht and Werb, 2001). At least 24 human MMP proteins have been found 
and collectively they have the ability to degrade all the components of the 
extracellular matrix. This function is known to be important to create space for 
cells to migrate during tumour metastasis and developmental processes. However 
they can also produce specific cleavage fragments from their substrates which 
have independent signalling activities and can modify the activity of signalling 
molecules and receptors (Lee and Murphy, 2004; Page-McCaw et al., 2007). 
Many MMPs are soluble and are released by cells into the ECM, whereas others 
are transmembrane proteins with an extracellular catalytic domain. Since they are 
so critical to the regulation of the cellular microenvironment, the activity of 
MMPs is tightly regulated under normal physiological conditions and their 
deregulation is thought to be involved in many disease states including cancer. 
The activities of MMPs in most normal tissues are very low which is partly due
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to low expression of MMPs. Transcription of MMPs can be induced by cytokines 
and growth factors, as well as by some cell-cell adhesion molecules (for example 
MMP-9 expression is induced by intercellular adhesion molecule-1 (ICAM-1) in 
T lymphoma cells) and cell-matrix interactions (Nagase and Woessner, 1999). 
Indeed, as described in sections 1.3.4 and 1.3.5, MMPs are gene targets of both 
the canonical Wnt signalling pathway and Kaiso. Furthermore, the activity of 
MMPs is regulated by their autoinhibitory pro-domains which are destabilized or 
removed in order for MMPs to be active (Page-McCaw et al., 2007), and by 
inhibition by endogenously expressed inhibitors, tissue inhibitors of 
metalloproteinases (TIMPs) (Nagase et al., 2006). ADAMs are a MMP-related 
family of proteins which contain a metalloproteinase domain, and are either 
membrane-anchored or secreted (ADAMTS) (Mochizuki and Okada, 2007). 
ADAMs are known to cleave many transmembrane proteins, as well as ECM 
components, and can also bind to integrins. They are also implicated in cancer 
progression (Mochizuki and Okada, 2007).
In 1997, it was shown that MMP-3 activation in mammary epithelial cells leads 
to a stable EMT and a premalignant phenotype (Lochter et al., 1997). Cells 
showed an increase in invasion and a reduction in E-cadherin and p-catenin 
staining at cell-cell contacts. Other endogenous MMPs and keratinocyte growth 
factor were shown to be upregulated in this system and the phenotypic 
conversion continued in the absence of continued MMP-3 expression (Lochter et 
al., 1997). This study showed that the extracellular domain of E-cadherin was 
shed in cells expressing MMP-3 with the release of an 80 kDa fragment of E- 
cadherin into the culture medium. This was dependent on MMP activity as an 
MMP inhibitor blocked its production (Lochter et al., 1997). It was later shown 
that both MMP-3 and MMP-7 can directly cleave E-cadherin, by treating 
immunoprecipitates of cell lysates (immunoprecipitated with an E-cadherin 
antibody recognizing the cytoplasmic domain) with purified MMP proteins (Noe 
et al., 2001). Both MMP-3 and MMP-7 resulted in the release of E-cadherin 
fragments of approximately 80 kDa that could be detected by Western blotting 
with an antibody recognising the extracellular region of E-cadherin. A fragment 
of around 40 kDa remained on the beads which was detected with an antibody 
recognising the cytoplasmic domain (Noe et al., 2001). Moreover, the released
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80 kDa fragment was shown to induce invasion and inhibit aggregation of cells, 
by using conditioned medium containing the released fragment (Noe et al.,
2001). These effects were blocked if the E-cadherin fragment was first depleted 
from the medium by immunoprecipitation (Noe et al., 2001). More recently a 
vital role for ADAMlO-mediated cleavage of E-cadherin at a similar site to 
MMP cleavage was shown using ADAM 10 deficient fibroblasts or by knocking 
down AD AMI 0 in epithelial cells (Maretzky et al., 2005). Indeed this study 
showed that E-cadherin shedding was blocked in ADAM 10-deficient mouse 
embryos, which resulted in an accumulation of full-length E-cadherin, suggesting 
an in vivo significance for ADAMlO-mediated E-cadherin cleavage. Furthermore 
the authors showed that increased ADAM 10 expression led to increased levels of 
cyclin D1 (Maretzky et al., 2005). The significance of this E-cadherin cleavage 
for the metastatic progression of prostate cancer was indicated by a study of 
prostate cancer tissue samples from different stages of the disease (Kuefer et al.,
2003). Detection of high amounts of the 80 kDa fragment was strongly 
associated with advanced prostate cancer. A cDNA microarray analysis showed 
that several MMPs and ADAMs were also upregulated in metastatic prostate 
cancer (Kuefer et al., 2003). What signals are upstream of MMP-mediated E- 
cadherin cleavage are still under investigation but some studies indicate that 
apoptosis or calcium influx may be involved, at least in cell culture studies (Ito et 
al., 1999; Marambaud et al., 2002). Upregulation of MMP activity has been been 
shown in response to HGF, Ras or Snail activation (Arbiser et al., 1997; Jorda et 
al., 2005; McCawley et al., 1998; Shin et al., 2005; Wang and Keiser, 2000). 
Indeed, HGF treatment of prostate and stomach cancer cells has been reported to 
induce cleavage of E-cadherin by MMP-7 (Davies et al., 2001; Lee et al., 2007).
In 2002, Marambaud et al. showed that in response to treatment with 
staurosporine (which strongly induces apoptosis), the fragment of E-cadherin 
that remains in the cell following MMP-mediated cleavages is further processed 
by protease complex known as y-secretase. The y-secretase complex and its role 
in cellular signalling is discussed in more detail in section 1.5. In response to 
staurosporine treatment or other stimuli inducing cellular stress, a caspase-3 - 
mediated cleavage of E-cadherin also occurs (Keller and Nigam, 2003; 
Steinhusen et al., 2001). Marambaud et al. examined the fragments to identify
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the cleavage sites as shown in Figure 1.7. They termed the 38 kDa MMP 
cleavage product E-cad/C-terminal fragment (CTF)l, the 33 kDa y-secretase 
cleavage product E-cad/CTF2, and the 29 kDa caspase-3 cleavage product E- 
cad/CTF3 (Figure 1.7) (Marambaud et al., 2002).
Figure 1.7 Cleavage products of E-cadherin produced by metalloproteinase, y- 
secretase, and caspase-3 cleavages. The E-cadherin cleavage sites o f MMP, y- 
secretase and caspase-3 were determined by Marambaud et al. in 2003. The sizes of E- 
cad/CTF1, E-cad/CTF2 and E-cad/CTF3 are indicated. EC1-5 denote the extracellular 
E-cadherin repeats. H108 and C36 are epitopes for antibodies to the extracellular and 
cytoplasmic domains of E-cadherin, respectively. The antibody recognising C36 is used 
in this thesis. TM denotes transmembrane domain. Schematic taken from Marambaud et 
al.,2002.
y-secretase-mediated cleavage of E-cad/CTFl was first suggested by the 
accumulation of E-cad/CTFl in mouse fibroblasts from knock-out mice for 
Presenilin-1 (PS1) which is a vital component of the y-secretase complex 
(Marambaud et al., 2002). The authors then showed the accumulation of E- 
cad/CTF2 following treatment of an epithelial cell line A431, with either 
staurosporine or a calcium ionophore (which produces calcium influx which 
induces MMP cleavage of E-cadherin). This accumulation of E-cad/CTF2 was 
blocked with an inhibitor of y-secretase. Furthermore they showed that y- 
secretase-mediated cleavage is involved in the disassembly of adherens junctions 
in A431 cells in response to calcium ionophore (Marambaud et al., 2002). 
Treatment with calcium ionophore leads to a decrease in the amount of full 
length E-cadherin, (3-catenin and a-catenin in the membrane and cytoskeletal 
fraction indicating the disruption of cell-cell contacts. This was concomitant with 
the increase of E-cad/CTF2 in the cytosolic fraction, indicating that E-cad/CTF2 
becomes solubilised into the cytosol (Marambaud et al., 2002). The loss of 0-
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catenin and a-catenin from the membrane and cytoskeletal fraction was delayed 
following treatment with the y-secretase inhibitor (Marambaud et al., 2002). 
Prior to this study, the same group had shown that PS1 interacts with E-cadherin 
at the same E-cadherin sequence which binds p i20 (Baki et al., 2001). They 
showed that p i20 and PS1 compete for binding to E-cadherin, but that PS1 
promotes binding of E-cadherin to p-catenin, enhances the association of the E- 
cadherin/catenin complex with the cytoskeleton and increases cell-cell 
aggregation (Baki et al., 2001). The authors concluded that PS1 may have dual 
functions in its regulation of adherens junction stability. They suggest that under 
conditions where cell-cell adhesion is being promoted, incorporation of PS1 into 
the adherens junction contributes to the stabilisation of cell-cell adhesion, but 
under conditions where cell-cell adhesion is being down-regulated and when 
MMPs are active, the PS 1/y-secretase complex may faciliate cell separation by 
cleaving E-cad/CTFl (Marambaud et al., 2002). Recently it has been shown that 
a metalloprotease toxin B. fragilis toxin, which is secreted by the Bacteroides 
fragilis organism that live in the colon, stimulates y-secretase-mediated cleavage 
of E-cadherin, suggesting a possible role for this cleavage in disease (Wu et al., 
2007).
E-cadherin is also cleaved by another protease, calpain. Calpain is a calcium- 
dependent protease and E-cadherin cleavage by calpain can be induced by 
treatment with a calcium ionophore (Rios-Doria et al., 2003). Calpain cleaves E- 
cadherin intracellularly producing a 100 kDa fragment which can no longer bind 
to p i20 or p-catenin, therefore likely abrogating its adhesive function (Rios- 
Doria et al., 2003). In the same study it was shown using a cDNA microarray 
that calpain is upregulated in localised and metastatic prostate cancer compared 
to normal prostate tissue. The 100 kDa E-cadherin fragment was also 
upregulated in prostate tumours, suggesting that calpain-mediated E-cadherin 
cleavage may occur during progression of prostate cancer (Rios-Doria et al.,
2003).
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1.5 The role of metalloproteinase- and y-secretase- 
mediated cleavages in cellular signalling
In this thesis, the role of the E-cadherin cleavage product (produced by cleavages 
by metalloproteinases and y-secretase) in signalling is examined. In this section, 
the known functions of metalloproteinase and y-secretase cleavages in signalling 
are discussed.
1.5.1 The y-secretase complex
The existance of a y-secretase proteolytic activity was first identified during 
research into Alzheimer’s disease. One theory to explain the pathology of this 
disease of dementia is that it is at least partly caused by the accumulation of 
deposits of a peptide known as amyloid-p (A(3) in the brains of patients (Hardy,
2006). The Ap peptide is an integral part of the transmembrane protein amyloid 
precursor protein (APP). Thus it was recognised that the action of at least two 
proteases was required to release this peptide (Figure 1.8). It has since been 
determined that the extracellular domain of APP is shed by the action of a 
membrane-bound aspartyl protease BACE (P-site APP-cleaving protein), and 
that the resulting C-terminal fragment is further processed at a site within the 
transmembrane region by y-secretase (Wolfe, 2006).
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Figure 1.8 Signalling to the nucleus via y-secretase-mediated cleavage of 
transmembrane proteins, y-secretase mediated cleavages (indicated by red arrow 
heads) and extracellular metalloproteinase cleavages (indicated by blue arrows) are 
known to be involved in the cleavage of amyloid precursor protein (APP). Together 
these cleavages lead to the release of a peptide known as Ap which is thought to be 
associated with the pathology of Alzheimer’s disease. Sequential cleavages by 
extracellular metalloproteinases and y-secretase have been well-characterised in the 
Notch signalling pathway. These cleavages result in the release of intracellular domain 
(ICD) of Notch which translocates to the nucleus and modulates gene transcription. A 
similar mechanism for the release of nuclear-localising ICDs of various membrane 
proteins has also been established, including APP itself, as well as ErbB4, CD44, N- 
cadherin and y-protocadherins. Schematic adapted from Shih and Wang, Cancer 
Research, 2007.
The y-secretase complex has a number of components, of which the first to be 
identified were the Presenilins, PS1 and PS2. PS mutations frequently occur in 
cases of familial forms of AD, and PS knockout mice showed reduced or 
eliminated y-secretase activity (Herreman et al., 2000; Zhang et al., 2000). 
Pharmacological evidence suggested that y-secretase action is also mediated by 
an aspartyl protease activity and it was later demonstrated that two conserved 
aspartates in the transmembrane region of PS1 are indispensable for y-secretase 
activity (Wolfe et al., 1999a; Wolfe et al., 1999b). It has also been shown that PS 
itself is cleaved into two fragments during its maturation to an active protein, 
each of which contribute one aspartate residue, and that transition-state analogue 
Y-secretase inhibitors bind to both fragments but not the non-processed protein
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(Esler et al., 2000; Li et al., 2000). Together these data provide compelling 
evidence that PS proteins form the active site of y-secretase. However at least 
three other components of the complex have been identified (nicastrin, Aph-1 
and Pen-2), and yeast reconstitution experiments have suggested that the 
assembly of all four of these membrane proteins is necessary and sufficient for y- 
secretase activity (Edbauer et al., 2003). However the precise molecular roles of 
nicastrin, Aph-1 and Pen-2 are still subjects of intense reseach.
Many studies have shown that y-secretase cleaves numerous membrane proteins 
and regulates their signalling activities (Figure 1.8) (Fortini, 2002; Medina and 
Dotti, 2003). This was first characterized by the involvement of y-secretase in 
Notch signalling, the study of which played a vital role in the identification of the 
y-secretase complex.
1.5.2 The Notch signalling pathway
Notch signalling is a crucial pathway in the control of cellular differentiation 
events during devlopment (Artavanis-Tsakonas et al., 1999). The Notch receptor 
is a transmembrane protein with a single transmembrane domain and is activated 
by binding to ligands of the Delta/Serrate/Jagged family. Activation of Notch 
results in transcriptional changes due to interactions with the CSL family of 
transcription factors (Artavanis-Tsakonas et al., 1995). In 1998, it was shown 
that Notch signalling required its proteolytic cleavage to release its intracellular 
domain (ICD) and subsequently this process was shown to be dependent on y- 
secretase (De Strooper et al., 1999; Schroeter et al., 1998; Struhl and Greenwald, 
1999). Although it was not possible to observe the ICD of Notch in the nucleus 
by immunostaining due to the low levels of cleavage, evidence of the 
translocation of the Notch intracellular domain into the nucleus was presented 
with a reporter assay using a Notch construct C-terminally tagged with GAL4- 
VP16 (Struhl and Adachi, 1998). It has since been shown that, similarly to APP 
cleavage, cleavage of Notch by y-secretase is preceeded by removal of the Notch 
ectodomain by a member of the ADAM family of proteases ADAM 17 (Brou et 
al., 2000). AD AMI 0 is also implicated in Notch signalling (Hartmann et al.,
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2002). The parallels between APP processing and Notch signalling are shown in 
Figure 1.8.
1.5.3 Metalloproteinase/y-secretase cleavages as a general mechanism  
for signalling from cell-surface receptors to the nucleus
y-Secretase cleavage of several transmembrane molecules following initial 
cleavage by metalloproteinases has emerged as a common mechanism for 
signalling to the nucleus (Fortini, 2002; Medina and Dotti, 2003). In recent years, 
a similar mechanism to Notch signalling has also been described for APP itself, 
ErbB4, CD44 as well as N-cadherin and y-protocadherins (Figure 1.8) (Gao and 
Pimplikar, 2001; Haas et al., 2005; Hambsch et al., 2005; Marambaud et al., 
2003; Ni et al., 2001; Okamoto et al., 2001; Shoval et al., 2007; Uemura et al., 
2006a). For all these transmembrane molecules, intracellular domain fragments 
resulting from y-secretase cleavage are translocated to the nucleus and have 
signalling functions (Figure 1.8).
The first example of a signalling function of a y-secretase cleavage product of a 
cadherin protein came in a study which showed that NMDA-receptor agonists 
enhance y-secretase-mediated cleavage of N-cadherin, and that the N-cadherin 
cleavage product N-cad/CTF2 binds and regulates the CREB binding protein 
(Marambaud et al., 2003). Binding of N-cad/CTF2 was shown to enhance the 
proteasomal degradation of CREB binding protein, thus inhibiting CRE- 
dependent transcription. Two further studies have shown that N-cad/CTF2 
localises to the nucleus of neurons and neural crest cells (Shoval et al., 2007; 
Uemura et al., 2006a). NMDA receptor stimulation in neurons was also shown to 
induce production of N-cad/CTF2, which localised to the the nucleus when 
overexpressed in neurons (Uemura et al., 2006a). Furthermore this study showed 
that N-cad/CTF2 could inhibit p-catenin phosphorylation by GSK3P and 
enhance cellular levels of P-catenin (Uemura et al., 2006a). Moreover it was 
shown that overexpression of N-cad/CTF2 leads to enhancement of p-catenin 
nuclear localisation but only in isolated cells with few cell-cell contacts, as well 
as increased transcription of P-catenin itself and reduced transcription of N-
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cadherin. Increased levels of cyclin D1 protein were also detected (Uemura et al., 
2006a).
Sequential cleavage of N-cadherin by metalloproteases followed by y-secretase 
has been demonstrated (Uemura et al., 2006b). This study showed that 
production of N-cad/CTF2 by treatment with a calcium ionophore could be 
blocked by addition of an inhibitor of metalloproteases. Furthermore an N- 
cadherin construct lacking the ectodomain produced substantial amounts of N- 
cad/CTF2 even in the absence of calcium ionophore, thus suggesting that supply 
of substrate to y-secretase is crucial in regulation of y-secretase-mediated 
cleavage (Uemura et al., 2006b). ADAMlO-mediated cleavage of N-cadherin in 
neural crest cells has been shown to be induced by bone morphogenic protein 
(BMP) 4 (Shoval et al., 2007). BMP4 induces EMT of the neural crest, which is 
prevented by treatment with a specific inhibitor of AD AMI 0. The y-secretase 
cleavage product of N-cadherin N-cad/CTF2, assumed to be the end product of 
ADAMlO-mediated cleavage, was ectopically expressed in neural crest cells and 
rescued their migration in the presence of the specific ADAM 10 inhibitor 
(Shoval et al., 2007). Thus N-cad/CTF2 shows antagonistic properties to full- 
length N-cadherin which inhibits EMT. N-Cad/CTF2 localises in the nucleus of 
neural crest cells and both p-catenin and cyclin D 1 mRNA levels were enhanced 
by N-cad/CTF2 expression (Shoval et al., 2007).
Enhancement of p-catenin-mediated nuclear signalling by nuclear N-cad/CTF2 
was suggested by these two studies (Shoval et al., 20007; Uemura et al., 2006a). 
This is surprising since as described in section 1.3.4, cadherins and TCF/LEF-1 
bind to the same region of p-catenin. There are a number of possible 
explanations. Firstly it has been shown that p-catenin phosphorylation by GSK3P 
is inhibited by N-cad/CTF2, suggesting that its stability may be enhanced by 
production of this cleavage product (Uemura et al., 2006a). Both studies indicate 
transcriptional upregulation of p-catenin itself by N-cad/CTF2. It is also possible 
that gene products such as cyclin D1 may be upregulated by alternative 
signalling pathways induced by N-cad/CTF2. Further research in this area is 
required to fully understand these observations.
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The cytoplasmic domain of y-protocadherins also localises in the nucleus 
following cleavages by metalloproteinases and y-secretase (Haas et al., 2005; 
Hambsch et al., 2005). Furthermore the cytoplasmic domain of y-protocadherins 
was also shown to activate the promoter of y-protocadherin locus (Hambsch et 
al., 2005). Despite this evidence linking cleavage of N-cadherin and y- 
protocadherins to signalling functions in the nucleus, a signalling function for the 
cleaved cytoplasmic domain of E-cadherin has not yet been described.
1.5.4 Regulation of y-secretase
The regulatory mechanisms of y-secretase have not been fully characterised and 
therefore the regulation of the cleavage-mediated signalling pathways described 
in Section 1.5.3 is still not completely understood. As discussed, supply of 
substrate may be crucial in regulating the activity of y-secretase. In all the 
signalling pathways described in Section 1.5.3, cleavage by metalloproteases to 
remove the ectodomain has been shown to be involved. In the case of N- 
cadherin, prior cleavage by metalloproteases is required for y-secretase cleavage 
(Uemura et al., 2006b). Indeed a study in 2000 suggested that the main factor 
influencing y-secretase cleavage of APP and Notch is the length of the short 
extracellular stalk remaining after metalloproteinase cleavage rather than any 
specific amino acid sequences (Struhl and Adachi, 2000). This study showed that 
artificial substrates with extracellular segments exceeding 300 amino acids are 
extremely poorly cleaved by y-secretase and that those with progressively shorter 
segments are cleaved more efficiently, with those with less than 50 amino acids 
being cleaved optimally (Struhl and Adachi, 2000). This suggests that the 
requirement for prior removal of the ectodomain of transmembrane proteins may 
be a general mechanism for regulating y-secretase-mediated cleavage. This idea 
was challenged by a study in Drosophila which showed that metalloproteinases 
could cleave Notch at two nearby sites producing very similar membrane 
anchored C-terminal fragments, but only one of these could be cleaved by y- 
secretase (Lieber et al., 2002). However, it seems that metalloprotease cleavage 
is required prior to y-secretase cleavage of transmembrane proteins, although it
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remains to be determined whether this is due to a general requirement for 
removal of bulky extracellular domain, or due to the production of specific 
cleavage sites.
Y-secretase may also be regulated by assembly of the complex itself. As 
described in Section 1.5.1, PS itself must be cleaved by an as yet unidentified 
presenilinase. Furthermore, most newly synthesized PS is rapidly degraded, and 
exogenous PS has been shown not to increase levels of the processed PS 
fragments, suggesting that PS maturation by cleavage is tightly regulated by 
competition for unknown limiting cellular factors (Medina and Dotti, 2003; 
Thinakaran et al., 1997). Nicastrin has also been implicated in the stabilization 
and maturation of PS (Medina and Dotti, 2003). Moreover since Nicastrin also 
binds the C-terminal membrane-anchored substrates of y-secretase, it has been 
suggested that Nicastrin may be involved in sensing the size of the extracellular 
domain of substrates if this is indeed critical in determining cleavage efficiency 
(Medina and Dotti, 2003). Understanding the roles of the other components of 
the y-secretase complex is likely to provide greater insight into its regulation.
It is also considered that control of y-secretase localisation in the cell may 
regulate its activity (Fortini, 2002; Medina and Dotti, 2003; Uemura et al., 2007). 
Althogh most PS is found in the ER and Golgi, endogenous PS1 has been 
reported to localise at the plasma membrane as an active molecule (Chyung et 
al., 2005). As described in section 1.4.5, PS binds to cadherins and it has also 
been shown that PS binds to PI3K and promotes activation of PI3K by increasing 
the cadherin/PI3K association (Baki et al., 2004). A recent paper showed that 
expression of N-cadherin in CHO (chinese hamster ovary) cells (which express 
very low levels of endogenous cadherins), and the concomitant formation of cell­
cell contacts, lead to an increase in cell surface levels of y-secretase (indicated by 
the presence of both PS and nicastrin at the cell surface) (Uemura et al., 2007). 
GSK3(3 was also shown to phosphorylate PS and inhibit its association with N- 
cadherin, thereby down-regulating the cell surface levels of PS (Uemura et al.,
2007). A model has been proposed whereby N-cadherin-mediated cell-cell 
contacts recruit y-secretase to the cell surface. This may be important for y-
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secretase to cleave cell surface molecules and activate signalling pathways as 
described in section 1.5.3. Furthermore, the recruitment of y-secretase may also 
enhance signalling via PI3K. GSK3|3-mediated phosphorylation of PS may play 
a role in down-regulating these pathways.
Despite reports of active y-secretase at the cell surface, the site of y-secretase- 
mediated cleavage of transmembrane proteins during signalling is not clear. It 
was shown in 2004 that endocytosis of Notch may be required for its cleavage by 
y-secretase (Gupta-Rossi et al., 2004). This study used a Notch construct that is 
similar to the product of metalloprotease-mediated cleavage, which is expressed 
at the plasma membrane and is constitutively cleaved by y-secretase. Blocking 
endocytosis with dominant negative forms of Dynamin or Epsl5 inhibited y- 
secretase-mediated cleavage of this construct (Gupta-Rossi et al., 2004). 
Monoubiquitination of Notch at a specific lysine residue was also shown to occur 
in this study, and mutating this residue inhibited both internalization and y- 
secretase-mediated cleavage of Notch (Gupta-Rossi et al., 2004). Furthermore it 
has been shown that the y-secretase complex is found in the lysosome and is 
activated by low pH (Pasternak et al., 2003). The idea that endocytosis may 
enhance y-secretase activity was given further support by a study showing that 
activation of the (32-Adrenergic receptor leads to the endocytosis of y-secretase to 
late endosomes and lysosomes where there was increased cleavage of APP (Ni et 
al., 2006). In this study blocking transport from early to late endosomes inhibited 
y-secretase activity. Together, these studies raise the possibility that endocytosis 
and ubiquitination may be involved in regulating y-secretase cleavage of its other 
substates. Clarifying the cellular compartments in which y-secretase cleaves its 
substrates may improve understanding of its regulation.
1.6 Ubiquitination in signalling
In Chapter 5 of this thesis, ubiquitination and phosphorylation of cleaved E- 
cadherin are investigated. Phosphorylation is extremely well characterized as a 
covalent modification controlling signalling functions of proteins. There are
63
many specific protein kinases which catalyse the addition of the phosphate group 
to serine, threonine and tyrosine residues of proteins. The addition of the 
phosphate group can act as a docking site for the recruitment of other proteins, or 
may activate or inactivate the active sites of enzymes. Indeed, the activation of 
other kinases by phosphorylation can lead to a signalling cascade, the control of 
which allows fine tuning of signalling pathways in time and space, for example 
in MAPK signalling pathways (Morrison and Davis, 2003). However the roles of 
ubiquitination in signalling are less well characterised. This section briefly 
describes what is understood about the ubiquitin system and its varied roles in 
cell biology.
1.6.1 The ubiquitin system
Ubiquitin is a small 76 amino acid conserved protein of around 8.5 kDa which is 
ubiquitously expressed in all eukaryotic cells. Ubiquitination of a protein usually 
occurs through the formation of a bond between the C-terminal glycine residue 
of ubiquitin and the 8 -amino group of a lysine residue of the protein substrate 
(Pickart, 2001). This reaction requires three enzymes acting in a sequential 
fashion: a ubiquitin activating enzyme (El) which forms a thiol ester bond with 
the carboxyl group of the C-terminal glycine of ubiqutin; a ubiquitin conjugating 
enzyme (E2) which transiently carries the activated ubiquitin molecule through a 
thiol ester bound via the active site cysteine residue of the E2; and a ubiquitin 
ligase (E3) that transfers the activated ubiquitin to the substrate lysine residue 
(Pickart, 2001). Recognition of substrates is mediated by presence and 
accessibility of motifs in the substrate which are recognised by E3 ubiquitin 
ligases. E3 ubiquitin ligases are therefore the specificity determinants in the 
system (Laney and Hochstrasser, 1999). E3 ubiquitin ligases consist of two 
protein families: those that contain HECT domains and those that contain RING 
domains. Although there is little sequence or structural similarity between HECT 
and RING domains, E2 conjugating enzymes can interact with both types of E3 
ligases (Pickart, 2001). It is known that HECT domains contain a conserved 
cysteine residue which forms a thiol ester during catalysis. The RING finger 
domain has a set of cysteine and histidine residues which are ligands to two zinc
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ions. It is thought that RING finger E3 ligases may form a scaffold to link E2 
ligases to substrates (Pickart, 2001). Phosphorylation of substrates has emerged 
as a common signal to trigger their ubiquitination (Pickart, 2001). Indeed, as 
described in section 1.3.4, phosphorylation of P-catenin by CK1 and GSK3p is 
known to trigger its ubiquitination.
1.6.2 Multiple cellular roles of ubiquitination
Ubiquitination of a substrate frequently stops after the addition of one ubiquitin 
molecule (monoubiquitination) or further ubiquitin molecules may be added to 
the lysine residues of ubiquitin molecules already added to the substrate to form 
a chain (polyubiquitination) (Pickart and Fushman, 2004). Ubiquitin conjugation 
to form chains can occur on a number of lysine residues within the ubiquitin 
molecule. Polyubiquitination through lysine 48 residues in ubiquitin are the most 
well characterized and are well known to be involved in targeting the substrate 
protein for degradation in the proteasome (Pickart and Fushman, 2004). Indeed, 
it has been shown that a single lysine-48 linked chain is sufficient to target a 
model substrate to the proteasome (Chau et al., 1989). Monoubiquitination has 
emerged as having differerent roles from lysine-48 linked polyubiquitin and has 
been shown to be involved in endocytosis of transmembrane proteins (including 
both E-cadherin and Notch as described in Sections 1.4.4 and 1.5.4), as well as 
DNA repair and nuclear localisation (Li et al., 2003; Sun and Chen, 2004).
More recently it has emerged that lysine-63 linked polyubiquitin chains also have 
varied cellular roles in DNA damage tolerance, signalling pathways by activating 
a kinase important in the inflammatory response, protein trafficking and nuclear 
import of proteins (Geetha et al., 2005; Pickart and Fushman, 2004). An NMR 
study has shown that lysine-48- and lysine-63-linked ubiquitin chains form 
structurally different conformations (Varadan et al., 2004). Ubiquitin chains 
linked through lysine-48 form a closed conformation with the hydrophobic 
residues forming the interface between the ubiquitin monomers, whereas lysine- 
63 linked ubiquitin chains form an extended conformation with no direct 
interaction between their hydrophobic surfaces (Varadan et al., 2004). It is
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suggested that the exposure of hydrophobic surfaces in lysine-63 linked chains 
may provide docking sites for proteins which may explain its more varied 
functions in signalling. Polyubiquitin chains linked through lysine- 6  residues 
have been shown to be produced by an E3 ubiquitin ligase formed by the tumour 
suppressor BRCA1 when complexed to another protein BARD1. Lysine-6 -linked 
ubiquitin chains which have been shown to be recognised by the proteasome but 
do not trigger degradation (Nishikawa et al., 2004). Indeed these lysine-6 -linked 
ubiquitin chains have been implicated in DNA repair (Morris and Solomon,
2004). Other polyubiquitin chains are less well characterized but lysine-11- 
linked chains have been shown to signal proteasomal degradation in vitro 
(Pickart and Fushman, 2004). Moreover, in yeast, addition of a lysine-48 linked 
polyubiquitin chain can lead to inhibition of a transcription factor Met4 without 
inducing degradation (Flick et al., 2004). This suggests that even lysine-48 
linked ubiquitin chains may have signalling functions beyond their role in 
targeting proteins to the proteasome.
Small ubiquitin-like modifiers (SUMO) are a family of proteins which are highly 
related to ubiquitin. SUMO proteins are larger than ubiquitin at around 12 kDa 
and SUMOylation of substrates occurs by an analogous conjugation method to 
ubiquitination (Johnson, 2004). SUMO proteins are also conjugated to the lysine 
residues of substrates but the enzymes of the SUMO pathway are specific. In 
contrast to ubiquitin, most SUMOylated lysine sites in vivo have only one 
SUMO monomer, but poly-SUMO chains have been observed (Johnson, 2004). 
SUMOylation does not appear to be involved in protein degradation but has been 
shown to trigger nuclear localisation of proteins, as well as having roles in 
transcriptional regulation, maintenance of genome integrity, and signal 
transduction (Seeler and Dejean, 2003).
1.6.3 Ret finger protein, a RING finger domain containing protein
In this thesis, the identification of Ret finger protein (RFP) as a novel binding 
partner of p i20 is described. RFP is a member of an expanding family of RBCC 
(also called TRIM) proteins which all contain a tripartite motif comprising a
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RING finger domain, a B-box domain and a coiled-coil domain (Meroni and 
Diez-Roux, 2005). B-box domains are also zinc-binding domains, and although 
no specific function has been attributed to them, it is thought that they are 
involved in protein-protein interactions, as is the case for the coiled-coil domain. 
A growing number of RBCC/TRIM family members have been shown to have 
E3 ubiquitin ligase activities (Meroni and Diez-Roux, 2005). The biological 
function of RFP is still incompletely understood. In this thesis, evidence that 
RFP is involved in ubiquitination of cleaved E-cadherin is presented. The 
remainder of this section will summarise what is currently known about the 
function of RFP.
RFP was originally identified as the N-terminal half of a fusion protein with the 
RET tyrosine kinase which posseses transforming activity (Takahashi et al., 
1988). RFP is widely expressed in tissues and its nuclear localisation has been 
reported, but its cytoplasmic or nuclear localisation appears to depend on cell 
type. Indeed RFP has been shown to contain a functional NES and activation of 
protein kinase C leads to nuclear export of RFP (Harbers et al., 2001). It has also 
been reported to be associated with the nuclear matrix and to be present in 
nuclear bodies known as PML nuclear bodies (Cao et al., 1998; Isomura et al., 
1992). RFP binds and modulates the activity of several transcription factors 
including Enhancer of Polycomb and also inhibits the activity of Retinoblastoma 
protein (Krutzfeldt et al., 2005; Shimono et al., 2000). Several studies indicate 
that RFP acts as a transcriptional repressor including repressesing transcriptional 
activation by bHLH transcription factors (Bloor et al., 2005; Matsuura et al., 
2005; Shimono et al., 2000). However, it is thought that RFP may have dual 
transcriptional functions and could participate in the activation of transcription 
when in complex with some transcription factors (Shimono et al., 2005; Shimono 
et al., 2000; Townson et al., 2006). Indeed, in a recent study, RFP was shown to 
be necessary for estrogen receptor-mediated expression of cyclin D l, and using 
chromatin immunoprecipitation (ChIP), it was found to bind the promotor region 
of an estrogen receptor regulated gene (Townson et al., 2006). DNA binding of 
RFP has also been shown in an in vitro DNA binding assay (Isomura et al., 
1992). Although no clear picture of the biological role of RFP has emerged, it
67
seems likely that RFP is involved in regulation of transcription of several genes 
and may have both activating and repressive functions.
1.7 Aims of the project
The broad aim of this thesis project is to add to the understanding of the 
mechanisms of signalling pathways induced by E-cadherin. In particular the aim 
is to determine whether there is a signalling role for Y-secretase-mediated 
cleavage of E-cadherin (as has been shown for other transmembrane proteins, 
described in section 1.5.3), in addition to its role in down-regulating adherens 
junctions.
Specific aims of this project:
• To investigate the stimuli inducing production of the E-cadherin cleavage 
product E-cad/CTF2 (Chapter 3)
• To determine whether E-cad/CTF2 localises to the cell nucleus and what 
regulates its nuclear localisation (Chapters 4 and 5)
• To examine the roles of E-cad/CTF2 in the nucleus (Chapter 6 ).
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CHAPTER 2
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2 MATERIALS AND METHODS
2.1 Molecular Biology
2.1.1 Polymerase Chain Reaction
PCR reactions were performed in a final volume of 100 pi containing 10 ng 
template DNA (2 pi of a 5 ng/pl stock), 0.2 mM dNTPs ( 8  pi from a 2.5 mM 
stock solution) (Amersham), 1 pi Vent polymerase (New England Biolabs), 10 
pmol of each oligonucleotide primer (1 pi of a 100 pM stock) (MWG Biotech) 
and 10 pi Vent polymerase lOx buffer (NEB). DNA was amplified in a 
thermocycler (Jencons-PLS) as follows: lx at 95 °C for 5 min, 30-35x [95°C for 
1 min, 52-55°C for 1 min, 72°C for 2 to 3 min] and lx 72°C for 10 min. PCR 
products were purified using the QIAquick® PCR Purification Kit (Qiagen) 
according to the manufacturers instructions.
2.1.2 DNA restriction digests
Plasmid DNA and PCR products (2.5-10 pg DNA per reaction) were were mixed 
with 2 pi restriction enzyme buffer (NEB), 2 pi of lOx Bovine Serum Albumin 
(BSA, NEB), and 1 pi (10 - 20 units) of each restriction enzyme (NEB) in a final 
volume of 20 pi using distilled H2O (dE^O) and were incubated for 1 hr at either 
25°C or 37°C. Reaction mixes were prepared as indicated in Table 2.1:
Type Mini-prep analysis Cloning (vector) Cloning (Insert)
Amount o f  DNA 2.5-5 jig 5-10 pg 10 pg
H20 10.5 pi 11 jil 7 pi
lOx BSA 2 1*1 2 jil 2 pi
lOx Buffer 2 1*1 2 pi 2 pi
DNA 5 Pi 4 jil 8 jil
Enzyme (10-20 units) l p l l p l l p l
Table 2.1 Details of restriction digest reactions used for mini-prep analysis and cloning 
of the constructs prepared in this thesis.
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Cut vectors were further treated with Alkaline Phosphatase (Roche). 113 pi H2O, 
15 pi AP buffer (Roche), and 2 pi AP were added to the 20 pi vector restriction 
digest mixture, and incubated at 37°C for 1 h. 1 pi of 0.5 M EDTA was then 
added to the mixture and the reaction was heated at 75 °C for 10 min.
2.1.3 Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate DNA samples at 100 volts for 1 
hour. Gels were made up using 1% agatose in TAE (Tris-acetate 50x stock: 2 M 
Tris Acetate 100 mM Na2EDTA (National Diagnostics), diluted with dEt20). 
Ethidium bromide was added to the gel to a final concentration of 0.5 pg/ml in 
order to detect DNA under UV light. DNA samples were mixed with 6  x DNA 
loading buffer (0.25% Xylene cyanole (w/v), 0.25% Bromophenol blue (w/v), 
40% sucrose (w/v) made up in dH20). DNA fragment sizes were estimated by 
comparing with migration of bands from the 1Kb DNA ladder (Promega). The 
QIAquick® Gel Extraction Kit (Qiagen) was used to extract and purify DNA 
bands from agarose gels, according to the manufacturers instructions.
2.1.4 DNA ligation reactions
Ligation reactions were carried out using the reaction mixes detailed in Table 
2.2:
Type Vector Ligation 
Control
Ligation Insert Ligation 
Control
Vector (pi) 2 2 -
Insert (pi) - 7 7
1 Ox ligation buffer (pi) 2 2 2
ATP (10 mM) (pi) 1 1 1
T4 DNA ligase (pi) 1 1 1
H20  (pi) 14 7 9
Table 2.2 Details o f ligation reactions used in the preparation of constructs in this thesis.
Reactions were carried out using lOx DNA ligase buffer (Roche) and T4 DNA 
ligase (5 U/pl, Roche). Reaction mixes were incubated overnight at 16°C. For
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blunt end ligations, lpl T4 DNA Polymerase (Roche) and 2pl dNTP were added 
to the restriction digest mixture, and incubated at 37°C for 30 min. The reaction 
mixture was then heated at 75 °C for 10 min, and ligation reactions were carried 
out as detailed in table 2.2.
2.1.5 Preparation of competant E. coli.
The XL-1 Blue strain of E. coli was streaked on an LB agar plate and grown 
overnight at 37°C. 3 ml of L-Broth (Luria-Bertani medium: 1% bacto-tryptone 
(DIFCO laboratories), 0.5% bacto-yeast extract (DIFCO laboratories), 1% 
sodium chloride made up in de-ionised water) was inoculated with a single 
colony from the plate. After overnight growth at 37°C with agitation this culture 
was used to inoculate 250 ml of SOB (2% bacto-tryptone (w/v), 0.5% bacto- 
yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM MgCk, 10 mM MgS0 4 , pH 6.7 
-7 .0 ). The SOB culture was grown at 18°C with agitation until an OD600 reading 
of approximately 0.6 was obtained. The culture was placed on ice for 10 min and 
then centrifuged at 4°C for 10 min at 2500 x g. The pellet was resuspended in 80 
ml of ice-cold TB (10 mM Pipes, 55 mM MnCh, 15 mM CaCh, 250 mM KC1, 
pH 6.7) and placed on ice for 10 min. Following centrifugation at 4°C for 10 min 
at 2500 x g, bacteria were then gently resuspended in 20 ml ice-cold TB. 
Dimethyl sulfoxide (DMSO, Sigma) was added to a final concentration of 7% 
and cells were placed on ice for a further 10 min. 500 pi aliquots were frozen in 
liquid nitrogen and stored at -80°C. Competency was tested by transforming cells 
with pBluescript vector. Briefly, cells were transformed by heat shock (see 
section 2.1.7) with 0.1 ng and 0.001 ng of pBluescript. A high level of 
competency was indicated by the growth of 10,000 and 1,000 colonies 
respecitively.
2.1.6 E.coli transformation by ‘heat shock’
Competent E.coli were thawed on ice. DNA to be transformed was placed in 1.5 
ml microfuge tubes (1 pi of plasmids for amplification, 10 pi of ligation 
mixtures) and mixed with 50 pi competent cells and placed on ice for 5 min. The
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cells-DNA mix was incubated at 42°C for 45 sec then immediately returned to 
ice for 5 min. 200 pi of SOC medium (Invitrogen) was added and the cells were 
incubated with moderate agitation for 10 min (amplification) or 30 min 
(ligation). 200 pi of transformed bacteria were plated onto LB agar plates 
containing either ampicillin (50 pg/ml) or kanamycin (30 pg/ml) for selection 
and incubated overnight at 37°C.
2.1.7 DNA mini preps from bacterial cultures
3 ml of LB containing appropriate antibiotics were inoculated with individual 
bacterial colonies and grown overnight with agitation at 37°C. Cultures were 
centrifuged at 5000 x g for 30 sec. Supernatants were removed and pellets were 
resuspended in 400 pi TENS buffer (1 mM Tris/Cl pH 7.5, 1 mM EDTA pH 8, 
0.1N NaOH, 0.5% SDS). Tubes were gently inverted five times. 200 pi of 3M 
NaOAc, pH 5.2 was added to each tube and mixed thoroughly. The solutions wer 
centrifuged at 5000 x g for 10 min, and supernatants (approx. 600 pi) were 
transferred to clean tubes. 600 pi of isopropanol (BDH laboratory supplies) was 
added to each tube, then the solutions were vortexed and centrifuged at 5000 x g
for 10 min. The supernatant was removed and the pellets were rinsed carefully
with 70% ethanol. DNA pellets were left to air dry for 10 min then resuspended 
in 40 pi dH20 with 10 pg RNase A and incubated at 37°C for 10 min. 5 pi of 
each preparation was examined by restriction enzyme digestion, as detailed in 
table 2.1.
2.1.8 DNA maxi preps from bacterial cultures
Maxi preps of DNA were prepared using GenElute HP Plasmid Maxiprep Kit ® 
(Sigma) according to the manufacturers instructions. DNA was eluted using 5 ml 
of dH20 pre-warmed to 37°C, then ethanol (EtOH) precipitated by adding 500 pi 
of 3M NaOAc, pH 5.2 and 12.5 ml of 100% EtOH and centrifuging at 5000 x g 
for 30 min at 4°C. Supernatants were discarded and pellets were resuspended in 
1 ml 70% ice-cold EtOH and centrifuged at 5000 x g for 10 min. Pellets were left 
to air dry and resuspended in 500 pi of dH20.
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2.1.9 Determination of DNA concentration
The concentration and purity of DNA maxi preps and mini preps were examined 
by spectrophotometry (Abs26o/28o) and by comparison with standards using gel 
electrophoresis, respectively.
2.1.10 Site directed mutagenesis
Amino acid changes were carried out using the Quikchange® Site-Directed 
Mutagenesis Kit (Stratagene) according to. the manufacturers instructions using 
the primers outlined in table 2.6.
2.1.11 DNA constructs used for experiments in this thesis
Table 2.3 describes constructs used in this study that were prepared by other 
members of the Fujita lab.
Construct Vector Insert
pcDNA-HA-E-cad/CTF2 pcDNA-HA E-cadherin (cytoplasmic domain), 
mouse
This construct was produced by Dr. Yasuyuki Fujita
pcDNA-FLAG-p!20 pcDNA-FLAG p i20 isoform IB, full-length, mouse
This construct was produced by Dr. N. Serpente
pcDNA-HA-p 120 pcDNA-HA p i20 isoform IB, full-length, mouse
This construct was produced by Dr. N. Serpente
pcDNA-FLAG-Hakai pcDNA-FLAG Hakai, full-length, mouse
This construct was produced by Dr. N. Serpente
pcDNA-FLAG-RFP pcDNA-FLAG Ret Finger Protein, full-length, mouse
This construct was produced by Dr. N. Serpente
pBSSR-HA-Ub pBSSR Ubiquitin, full-length, mouse
This construct was produced by Dr. Y. Fujita
pCW7-His-Ub pCW7 Ubiquitin, full-length, mouse
This construct was produced by Dr. Y. Fujita
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pBTM-ECad 1 pBTM E-cadherin, amino acids 734 -  822, 
mouse
This construct was produced by Dr. Y. Fujita
pBTM-ECad2 pBTM E-cadherin, cytoplasmic domain (amino 
acids 734 -  884), mouse
This construct was produced by Dr. Y. Fujita
pBTM-ECad3 pBTM E-cadherin, amino acids 771 - 822,
mouse
This construct was produced by Dr. Y. Fujita
PBTM-ECad4 pBTM E-cadherin, amino acids 771 - 884, 
mouse
This construct was produced by Dr. Y. Fujita
pBTM-ECad5 pBTM E-cadherin, amino acids 771 - 848, 
mouse
This construct was produced by Dr. Y. Fujita
pcDNA-HA-ubiquitin (K 11, pcDNA3.1 Full length o f  mouse ubiquitin amplified
27 ,29 , 48, 63 R) from pBSSR-HA-ubiquitin with all
lysine residues mutated to arginine.
This construct was produced by Dr. Y. Fujita
pcDNA-HA-ubiquitin (K48R) pcDNA3.1 Full length o f  mouse ubiquitin amplified 
from pBSSR-HA-ubiquitin with lysine 
48 mutated to arginine.
This construct was produced by Dr. Y. Fujita
pcDNA-HA-ubiquitin (K63R) pcDNA3.1 Full length o f  mouse ubiquitin amplified 
from pBSSR-HA-ubiquitin with lysine 
63 mutated to arginine.
This construct was produced by Dr. Y. Fujita
Table 2.3 Details o f constructs used during this research that were obtained from other 
members of the Fujita Lab.
Table 2.4 describes constructs used during this research which were provided by 
other members of the research community.
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Construct Source
pGL3-control vector Kindly donated by Dr. Carien Niessen
pGL3-4xKBS Kindly donated by Dr. Carien Niessen
pLK-E-cadherin (762AAA764) Kindly donated by Dr. Carien Niessen
pME 18S-FLAG-ADAM 10 Kindly donated by Dr. Eiichiro Nishi
pTOP-FLASH Kindly donated by Prof. Walter Birchmeier
pFOP-FLASH Kindly donated by Prof. Walter Birchmeier
pcHllO-LacZ Kindly donated by Prof. Walter Birchmeier
pcDNA-myc-P-catenin Kindly donated by Prof. Walter Birchmeier
pFA-CMV Kindly donated by Dr. Julie Pitcher
pFR-luciferase (firefly) Kindly donated by Dr. Julie Pitcher
pCMV-Renilla Kindly donated by Prof. Walter Birchmeier
pcDNA-myc-Kaiso Kindly donated by Dr. Juliet Daniel
pGL3-Basic-2.3kb-HMat Kindly donated by Dr. Juliet Daniel
pGL3-myc Kindly donated by Dr. Hiroyoshi Ariga
pGL3-cyclin D1 Kindly donated by Dr. Hiroyoshi Ariga
Table 2.4 Constructs used in this research provided by other members of the research 
community.
Table 2.5 describes a series of constructs prepared by PCR and subcloning.
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Construct Vector PCR Template Enzymes used
E-cad/CTF2 pcDNA3.1 pBAT-E-cadherin BamHI/Notl
Primer 1:
5’GGAATTCGCGGCCGCGGTACCATGCGGAGGAGAACGGTGGTC 3 ’
Primer 2:
5 ’ GG AATT CGG AT CCT AGT CGTCCT CGCC ACC3 ’
Amplification o f  the enire cytoplasmic domain o f  mouse E-cadherin (amino acids 734 -  884)
E-cad/CTF3 pcDNA3.1 pBAT-E-cadherin BamHI/Notl
Primer 1:
5’ATTCGCGGCCGCGGTACCATGAATGTGTATTACTATGATGAAGAAGGAGG3’
Primer 2:
5’ GG AATT CGG ATCCT AGT CGTCCT CGCC ACC 3 ’
Amplification o f  mouse E-cadherin amino acids 753 - 884
E-cad/CTF2(AAA) pcDNA3.1 pLK-Ecadherin
(762AAA764)
BamHI/Notl
Primer 1:
5’GGAATTCGCGGCCGCGGTACCATGCGGAGGAGAACGGTGGTC3’
Primer 2:
5 ’ GG AATT CGG AT CCT AGT CGT CCT CGCCACC3 ’
Amplification o f  entire cytoplasmic doman o f  human E-cadherin (with triple alanine mutation at
residues 762 -  764)
E-cad/CTF2-NLS- pCMV-myc-nuc pBAT-E-cadherin Notl
myc (Invitrogen)
Primer 1:
5 ’GGAATTCGCGGCCGCGGTACCATGCGGAGGAGAACGGTGGTC3’
Primer 2:
5 ’ GG AATT CGG ATCCT AGT CGTCCTCGCC ACC3 ’
Amplification o f  the enire cytoplasmic domain o f  mouse E-cadherin (amino acids 734 -  884).
Constructed jointly with Anthony Wadlow
E-cad/CTF2 pCMV-myc-nuc pLK-Ecadherin Notl
(AAA)-NLS-myc (Invitrogen) (762AAA764)
Primer 1:
5 ’ GG AATT CGCGGCCGCGGTACC ATGCGG AGGAG AACGGTGGTC 3 ’
Primer 2:
5 ’GG AATTCGG ATCCT AGT CGT CCTCGCCACC3 ’
Amplification o f  entire cytoplasmic doman o f  human E-cadherin (with triple alanine mutation at
residues 762 -  764). Constructed jointly with Anthony Wadlow
GFP-E-cad/CTF2- pcDNA/TO/GFP pcDNA-E- EcoRI/Xho 1
NLS cad/CTF2-NLS
Primer 1:
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5 ’CGGCGCCTCGAGGCGGAGGAGAACGGTGGTC3’
Primer 2:
S’CGGCGCCGAATTCCTATGCGGCCCCATTCAGATCCa’
Amplification o f  the enire cytoplasmic domain o f  mouse E-cadherin (amino acids 734 -  884). 
Kindly constructed by Anthony Wadlow
pCAN-Myc-CKl a pCAN-myc pCS2-CK la BamHI/Notl
Primer 1:
5’CGAATTCGGATCCGCATGGCGAGCAGCAGCGGCTCC3’ 
Primer 2:
5,GGAATTCGCGGCCGCTTAGAAACCTGTGGGGGTTTGGGCC3, 
Amplification o f  full length Rat C K la
pCAN-M yc-CKle pCAN-myc pCS2-CKle Clal/Notl
Primer 1:
5’CATCGATGTCGACACATGGAGCTGAGAGTGGGGAAC3’ 
Primer 2:
5 ’GGTCGACGCGGCCGCTCATTTCCCAAGGTGGTCAAATGGC3 ’ 
Amplification o f  full length Xenopus laevis CK le
Table 2.5 Constructs prepared by PCR amplification and subcloning.
Table 2.6 describes constructs that were prepared by site-directed mutagenesis.
Construct Template Primers
pcDNA-E-
cad/CTF2(K740R)
pcDNA-E-
cad/CTF2
(Lysine
Arginine)
Primer 1:
5 ’GGAGAACGGTGGTCAGAGAGCCCCTGCTGCC3’ 
Primer 2:
5 ’GGCAGCAGGGGCTCTCTGACCACCGTTCTCC3’
pcDNA-E-
cad/CTF2(K740R,
K818R)
pcDNA-E-
cad/CTF2
(K740R)
(Lysine
Arginine)
Primer 1:
5 ’ C GATGAAAAC C TGAGGGCAGC C GACAGC G3 ’ 
Primer 2:
5 ’CGCTGTCGGCTGCCCTCAGGTTTTCATCG3’
pcDNA-E-
cad/CTF2(RRRR)
pcDNA-E- 
cad/CTF2 
(K740R,K818R) 
(Lysine -> 
Arginine)
Primer 1:
5 ’CGAGTGGGGCAACCGATTCAGGAGGCTGGCGGA
CATGTACGGCGGTGGCG3’
Primer 2:
5 ’CGCCACCGCCGTACATGTCCGCCAGCCTCCTGA
ATCGGTTGCCCCACTCG3’
Table 2.6 Details o f constructs that were prepared by site-directed mutagenesis.
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Table 2.7 describes constructs that were prepared by restriction digests of other 
constructs.
Construct Insert (original construct) Restriction Enzymes
pGEX-RFP Full length o f  mouse Ret finger 
protein (pcDNA-FLAG-RFP)
N otl
pFA-CMV-ECadl E-cadherin amino acids 734 -  822 
(pBTM-ECadl)
EcoRI, Pstl
pFA-CMV-ECad2 E-cadherin amino acids 734 -  884 
(pBTM-ECad2)
EcoRI, Pstl
Table 2.7 Constructs prepared by restriction digests of other constructs. All fragments 
were cloned into indicated vectors that had been cut with the same enzymes, followed 
by alkaline phosphatase treatment.
Table 2.8 describes siRNA oligos designed to knock-down p i20 protein in 
human cells (ordered from Eurogentec).
Name of Oligo Sequence
p l20  1 Sense:
r ( CAGCAGAACUCCUCUUGGA) dTdT  
Antisense:
r ( UCCAAGAGGAGUUCUGCUG) dTdT
p l20  2 Sense:
r ( CAGCAGUCAUUCAUAUGAU) dTdT  
Antisense:
r ( AUCAUAUGAAUGACUGCUG) dTdT
non-silencing 
control siRNA (AF 
488)
Purchased from Qiagen
Table 2.8 siRNA oligos used for transient transfections.
2.1.12 DNA sequencing
All constructs prepared during this thesis were verified by automated DNA 
sequencing (MWG Biotech).
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2.2 CELL BIOLOGY
2.2.1 Cell lines and culture conditions used
The cell lines human epithelial A431, human breast adenoma MCF-7, Madin- 
Darby canine kidney (MDCK), Human Embryonic Kidney (HEK) 293, and 
human colon adenocarcinoma SW620 were cultured in Dulbecco’s Modified 
Eagle medium (DMEM, Gibco) supplemented with 10% complete fetal calf 
serum (FCS, PAA laboratories), lOOU/ml penicillin/streptomycin (Gibco) and 
1% GlutaMAX™ (Gibco) (DMEM/10%FGS/pen/strep/glu). MDCK cells stably 
expressing E-cadherin-myc were kindly produced by Dr. S. (Dupre-Crochet et 
al., 2007), and cultured as above except that medium was supplemented with 800 
pg/ml of G418 (Calbiochem). MDCK cells stably expressing GFP-RasV12 in 
tetracycline-inducible manner were kindly produced by Dr. Y. Fujita, and 
cultured as above except that tetracycline-free fetal calf serum was used (PAA 
laboratories) and medium was supplemented with 5 pg/ml of blasticidin 
(Invitrogen), and 400 pg/ml of Zeocin (Invitrogen). Cells were grown in 
incubators at 37°C in 5% CO2 .
2.2.2 Freezing and thawing cultured cells
To freeze cultured cells, aliquots containing lxlO7 cells were suspended in 1 ml 
of DMEM/10%FCS/pen/strep/glu supplemented with 10% DMSO and frozen at 
-80°C for 48 hrs before being stored permanently in liquid nitrogen.
To thaw cells, the aliquots were partially thawed at 37°C before being added to 
10 ml of pre-warmed medium in a 15 ml tube. Cells were centrifuged at 200 x g 
for 5 min, resuspended in 5 ml of DMEM/10%FCS/pen/strep/glu, plated in 60 
mm culture dishes and incubated overnight. Cells were then grown in fresh 
medium.
2.2.3 Passaging of A431, MCF-7, MDCK, HEK293 and SW620 cells
Cultured cells were passaged when they reached 80-90% confluency. Cells were 
washed using sterile phosphate-buffered saline (PBS) then treated with 1 ml
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trypsin/EDTA (Gibco) per 90 mm culture dish for 2 min at 37°C. Dishes were 
gently tapped and the cells were resuspended in 9 ml of culture medium. Cells 
were counted using a haemocytometer and plated at the appropriate densities for 
experiments.
2.2.4 Transfection of HEK293 cells using Ca2P0 4
l xl06 cells per dish were plated in 90 mm dishes 24 hr before transfection so that 
that they were at a confluency of 30-50% at the time of transfection. A maximum 
of 15 pg of plasmid DNA per transfection was mixed with 450 pi dfhO and 50 
pi 2.5 M CaCh and briefly centrifuged. The DNA mixture was added dropwise 
to 500 pi of 2x Hepes buffer (42 mM HEPES, 2 mM Na2HP0 4 *2 H2 0 , 0.5 M 
NaCl, 20 mM KC1, pH 7.05, 0.22 pm filtered), vortexing after each dropwise 
addition. The solutions were left to stand for 5 min at RT and then added 
dropwise to the cells. Cells were incubated with the transfection solution for 4-6 
hours before the medium was changed. 24 hrs after transfection, cells were used 
for examination of cell lysates, nuclear fractionation, reporter assays, 
immunoprecipitation and immunofluorescence experiments.
2.2.5 Transfection of MDCK, MCF-7, SW620 and COS-1 cells using 
Lipofectamine 2000™  reagent
Cells were plated at 2x106 cells per dish in 90 mm dishes, or at 2x105 cells per 
well in a 6 well plate so that they were 50-90% confluent at time of transfection. 
Cells were transfected 24 hours later with Lipofectamine 2000™ reagent 
(Invitrogen) according to the manufacturers instructions. Medium was changed 2 
times after 3 hours. After a further 24 hours cells were used for examination of 
cell lysates, reporter assays and immunofluorescence experiments.
2.2.6 Transfection of HEK293 with siRNA using Hi-PerFect® reagent
5 nmol of lypholysed siRNA oligos from Qiagen were resuspended in 250 pi 
siRNA Suspension Buffer (Qiagen), resulting in a 20 pM solution. Samples were 
heated for 1 min at 90°C, then incubated at 37°C for 1 h, then stored at -20°C. 
Cells were plated in 24 well plates (5xl04 cells per well) 24 hours before 
transfection. 1.5 pg of each siRNA oligo was mixed with 9 pi of Hi-PerFect®
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reagent (Qiagen) in 100 pi serum free, antibiotic free DMEM. The resulting 
solution was incubated at RT for 15 min, and then added dropwise to the cells. 
24 hours after siRNA transfection, cells were then transfected with E-cad/CTF2. 
After a further 48 hours, cells were either lysed in Triton-X-100 lysis buffer or 
used for nuclear fractionation. Table 2.6 describes siRNA oligos that were used 
in this thesis.
2.2.7 Establishment of MDCK cells stably expressing GFP-E- 
cad/CTF2-NLS in a tetracycline-inducible manner.
MDCK cells previously transfected with pcDNA6/TR using Lipofectamine 2000, 
and selected in medium containing 5 pg ml'1 of blasticidin (Invitrogen) were 
transfected again with pcDNA4/TO/GFP-E-cad/CTF2-NLS using Lipofectamine 
2000. The doubly transfected cells were selected in medium containing 10 % 
tetracycline-free FCS (PAA, UK), 5 pg ml*1 of blasticidin, and 400 pg ml"1 of 
Zeocin (Invitrogen). For selection, cells were split 24 hours after transfection at 
dilutions of 1:5, 1:20, 1:150 and 1:500 (2 plates were used per dilution). After a 
further 24 hours, selection antibiotics were applied. After 1-2 weeks, colonies 
were picked up using filter papers soaked in trypsin.
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2.2.8 Reagents used in cell biology experiments
Table 2.9 gives details of the primary antibodies that were used in this thesis. 
Concentrations of the stock solutions and working dilutions used for 
immunofluorescence and western blotting are shown.
Prim ary Antibody Stock Cone. W orking dilution  
(W estern  
blotting)
W orking dilution  
(Im m unofluorescence)
Mouse anti-E-cadherin (BD  
Transduction Laboratories) 0.25 mg/ml 1:3000
Mouse anti-FLAG, Clone 
M2 (Sigma) 4.9 mg/ml 1:100
Mouse anti-FLAG, Clone 
M2 POD (Sigma) 1 mg/ml 1:5000
Mouse anti-Myc clone 4A6 
(Upstate) 0.3 mg/ml 1:2000 1:100
Rat anti-HA Clone 3F10 
(Roche) 0.2 mg/ml 1:100
Mouse anti-ppl20 (BD 
Biosciences) 0.25 mg/ml 1:1000
Mouse anti-N-cadherin (BD  
Transduction Laboratories) 0.25 mg/ml 1:1000
Mouse anti-GM130 (BD  
Transduction Laboratories) 0.25 mg/ml 1:250
Mouse anti-BiP/GRP78 
(BD Transduction 
Laboratories)
0.25 mg/ml 1:250 -
Mouse anti-Lamp-1 (BD 
Transduction Laboratories) 0.25 mg/ml 1:250
Rat anti-tubulin (Abeam)
1.01 mg/ml 1:1000
Rabbit anti-CBP (Santa 
Cruz) 200 pg/ml 1:1000
Rabbit anti-RFP (IBL)
0.1 mg/ml 1:1000
Mouse anti-Ubiquitin 
(Zymed) 0.5mg/ml 1:500 -
Rabbit anti-SUMO 
(Abgent) 0.25 mg/ml 1:500 -
Table 2.9 Details of primary antibodies used in Western blotting and
immunofluorescence experiments.
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Table 2.10 describes the inhibitors that were used during this research. Details of 
the stock solutions and treatment conditions are provided.
Inhibitor Function Details
MG 132 (Sigma) Proteasome (20S and 26S  
subunits) inhibitor.
4 pi o f  50 mM stock (20 pM final 
cone) added to 10 ml DMEM  
culture medium and incubated for 
6 hr.
y-secretase inhibitor X  
(Calbiochem)
Inhibitor o f  y-secretase Added to DMEM culture medium 
at 12.5 nM for 6 hr.
Staurosporine (Upstate) Inhibitor o f protein kinase C 
and other protein kinases 
(potent inducer o f  apoptosis)
Added to DMEM culture medium 
at 1 pM for 6 hr.
IC261 (Calbiochem) Inhibitor o f  Casein Kinase 1 Added to DMEM culture medium 
at 5 pg/ml for 4 hr.
Okadaic Acid 
(Calbiochem)
Inhibitor o f  protein 
phosphatases PP1 and PP2A
Added to DMEM culture medium 
at 3.13 ng/ml for 4 hr.
Table 2.10 Details of inhibitors used during this research, including their functions and 
the conditions for treatments.
Table 2.11 describes other treatments used during this research.
Treatm ent Function Details
Hepatocyte Growth 
Factor (HGF) Human 
Recombinant 
(Chemicon)
Activates the tyrosine kinase 
receptor, c-Met.
Added to DMEM culture medium 
at 50 ng/ml and incubated for 24 
hr.
Ultra Violet (UV) Induction o f apoptosis 2X or 3X auto-crosslink (1600) 
using UV stratalinker 1800 
(Stratagene) followed by 
incubation for 6 hr
X-phosphatase (New  
England Biolabs)
De-phosphorylation o f  proteins 
and nucleic acid.
100 units added to 
immunoprecipitated proteins for 
30 minutes at 30 °C
Table 2.11 Details of other treatments used during this research, including their 
functions and the conditions used.
2.2.9 Immunofluorescence microscopy
Cells were plated onto glass coverslips (13 mm, No. IV2, BDH) at densities as 
described in sections 2.2.4 and 2.2.5, and transfected. After 24 hours, cells were 
washed twice with PBS, then fixed in 1 ml 3% paraformaldehyde-PBS for 15 
min at RT. After washing with PBS, cells were permeabilised in 0.5% Triton X- 
100-PBS for 15 min, then blocked with DMEM containing 10% FCS for 1 hr.
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Primary antibody, diluted in DMEM/10% FCS as detailed in table 2.9 was added 
for 1 hour before washing 5 times with PBS, incubated. Cytochrome 2 (Cy2) or 
Rhodamine-Red-X-conjugated secondary antibodies (Jackson 
Immunochemicals) were added at 1:100 in DMEM/10% FCS for 1 hour, and 
washed 5 times with PBS. Hoechst solution (1:5000 dilution, Molecular Probes) 
was added to coverslips for approximately 1 min and washed 5 times with PBS. 
The coverslips were then mounted onto glass slides using Mowiol (5 
pl/coverslip, Calbiochem). To obtain epifluorescence images, a Zeiss 
Axipoplan2 microscope using a 40x 1.3 oil immersion objective was used at 
room temperature (Zeiss). Images were captured using a C4742-95 digital 
camera (Hamamatsu) and Openlab software (Improvision). Confocal images 
were obtained with a Bio-Rad confocal mounted on a Nikon Optiphot 2 
microscope using a 60x 1.4 oil-immersion objective at room temperature, or a 
Leica SPE confocal microscope with a 63x 1.3 oil-immersion objective at room 
temperature. Images were aquired using Laser Sharp software (Bio-Rad) or Leica 
Application Suite, respectively. Merged images were split using Image J 
software (National Institute of Health). The ratio of nucleus/cytoplasm 
fluorescence intensity in confocal images were analysed by measuring 
fluorescence intensity in a region (diameter 1.97 pm) using Image J. Brightness 
and contrast were adjusted using Photoshop CS (Adobe).
2.2.10 Phase construct microscopy
To obtain phase-contrast images, a Leica DM IRB microscope using a lOx 0.25 
air objective was used at room temperature (Leica). Images were captured using 
an Orca camera (Hamamatsu) and Openlab software (Improvision).
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2.3 PROTEIN BIOCHEMISTRY
2.3.1 Preparation of cell lysates
Cultured cells were scraped in 1 ml of cold PBS, and centrifuged at 400 x g for 3 
min at 4°C. Pelleted cells were then lysed in 1 ml of cold lysis buffer (20 mM 
Tris/Cl pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100) supplemented with 5 pg 
ml'1 leupeptin (Sigma), 50 mM PMSF, 7.2 trypsin inhibitor units m l'1 of 
aprotinin (Sigma), and 1.25 mg/ml N-ethylmaleimide before being vortexed 
briefly. 50% of the sample volume of SDS loading buffer was added and the 
resulting solution was heated at 95°C.
SDS-PAGE loading buffer was prepared as follows: 2.7g of SDS was added to
4.5 ml of glycerol, 11.2 ml of 0.5 M Tris/Cl (pH 6.5) and the solution was made 
up to 28.2 ml with dH20. Bromophenol blue was added to a final concentration 
of lmg/100 ml. 14M of 2-mercaptoethanol was added at a ratio of 94:6 (buffer:2- 
mercaptoethanol).
2.3.2 Nuclear fractionations
Cells were washed twice with PBS and trypsinized until well separated and 
centrifuged at 200 x g for 5 min. Pelleted cells were resuspended in 150 pi 2X 
lysis buffer (50 mM Hepes/NaOH pH 7.4, 10 mM EGTA, 5 mM MgCh, 20% 
Glycerol, and 2% NP-40) containing 5 pg ml'1 leupeptin, 50 mM PMSF, 7.2 
trypsin inhibitor units ml"1 of aprotinin, and 10 mM A-ethylmaleimide. The 
resuspension was then triturated with a 25G needle 12 times. After centrifugation 
at 110 X g for 5 min at 4°C, the supernatant was removed and the pelleted nuclei 
were washed twice in IX lysis buffer. The nuclear fractions were then boiled for 
10 min with SDS-PAGE loading buffer, followed by Western blotting, or lysed 
in 1 ml of Triton X-100 lysis buffer followed by immunoprecipitation. Purity of 
nuclear fractions was confirmed by Western blotting with antibodies against 
several compartment-specific markers (Figure 4.7).
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2.3.3 Immunoprecipitations
Cells were scraped in 1 ml ice-cold PBS, and centrifuged at 400 x g for 3 min at 
4°C, then lysed as described in section 2.3.1. Lysates were rotated for 30 min at 
4°C, then centrifuged at 5000 x g, then 100 pi aliquots were removed in order to 
later examine the input. 800 pi of the remaning supernatants were added to 
microfuge tubes containing 100 pi of a 50% slurry of protein G-Sepharose™ 4B 
(Amersham) conjugated to the antibody used for immunoprecipitation (prepared 
by coupling 30 pi of Protein G beads with 5 pi of antibody per reaction in a total 
volume of 500 pi of lysis buffer at 4°C with rotation). Supernatants were rotated 
with antibody beads for 1 hr at 4°C, and centrifuged at 5000 x g for 1 min at 4°C. 
Beads were washed twice in lysis buffer and then resuspended in SDS-PAGE 
loading buffer. Samples were boiled for 10 min at 95°C.
2.3.4 Preparation of GST-RFP
BL21 E.coli were transformed with pGEX-RFP and spread onto agar plates 
containing 50 pg/ml ampicillin. 3 ml of LB containing 50 pg/ml ampicillin (LB- 
amp) was inoculated with a single colony and grown for four hours and then 
added to 200 ml of LB-amp, which was grown overnight at 37°C with agitation. 
20 ml of the overnight culture was used to inoculate 750 ml of LB-amp and 
grown at 37°C with agitation until the OD600 reading was between 0.3-0.4. 
Production of GST-RFP was induced by addition of 750 pi of isopropyl-B-D- 
thiogalactopyranoside (IPTG, Melford Laboratories Ltd) to the 750 ml culture. 
Cultures were incubated for 4 hours at 30°C with gentle agitation and the cells 
were then centrifuged at 3400 x g for 20 min. The cells were washed once with 
40 ml PBS and pellets were stored at -80°C.
Bacterial pellets were thawed on ice, resuspended in 20 ml lysis buffer (20 mM 
Tris/Cl pH7.5, 10% (w/v) Sucrose (Sigma), 1 mM Dithiothreitol (DTT, Sigma), 
1% Triton X-100, Sigma) or in RIPA buffer (150 mM NaCl, 1 % NP-40, 0.5 % 
sodium deoxycholate, 0.1 % SDS, 50 mM Tris/Cl (pH 8.0)), and supplemented 
with 1 mM phenyl methyl sulphonyl fluoride (PMSF, Sigma). Resuspended 
bacterial cells were sonicated on ice (amplitude 5 microns) five times for 30 sec
87
each, with a 1 min interval between each pulse, using a Soniprep 150 (Sanyo). 
The lysate was centrifuged at 50,000 x g for 1 hr at 4°C. The supernatant was 
carefully removed and filtered through a 0.45 pm filter and then 1 ml was added 
to 30 pi of glutathione-Sepharose™ 4B beads (Amersham). The suspension was 
rotated for 1 hr at 4°C, beads were washed before additon of SDS buffer for 
analysis by SDS PAGE.
GST-RFP was isolated from Inclusion Bodies using the Protein Refolding Kit 
(Novagen). Briefly, cells were thawed on ice and resuspended in 75 ml of IX 
Wash Buffer (20 mM Tris-HCl pH 7.5, 10 mM EDTA, 1% Triton X-100). 
Lysozyme was added to a final concentration of 100 pg/ml from a freshly 
prepared 10 mg/ml stock in water and the suspension was incubated at 30°C for 
15 min, then sonicated on ice (amplitude 5 microns) in five 30 sec bursts, with a 
1 min interval between each pulse, using a Soniprep 150 (Sanyo). Immediately 
following sonication, 100 mM phenyl methyl sulphonyl fluoride (PMSF, Sigma) 
was added and the inclusion bodies were collected by centrifugation at 10,000 x 
g for 10 min. The supernatant was removed and the pellet was thoroughly 
resuspended in 75 ml of IX IB Wash Buffer, before centrifugation again at 
10,000 x g for 10 min. The pellet was resuspended again in 75 ml of 1 X IB 
Wash Buffer. The suspension was transferred to a clean centrifuge tube of known 
weight. Inclusion bodies were collected by centrifugation at 10,000 x g for 10 
min. The supernatant was decanted and the last traces were removed by tapping 
the inverted tube on a paper towel. The weight of inclusion bodies was 
determined and inclusion bodies were thoroughly resuspended in IX IB 
Solubilsation Buffer supplemented with 0.3% N-lauroylsarcosine and 1 mM 
DTT to a concentration of 10-20 mg/ml. The suspension was incubated at room 
temperature for 15 min and clarified by centrifugation at 10,000 x g for 10 min at 
room temperature. The supernatant containing solubilised protein was transferred 
to a clean tube, avoiding pelleted debris. To allow protein refolding, the sample 
was dialysed for 3 h at 4°C using a volume of IX Dialysis Buffer (supplemented 
with 0.1 mM DTT), which was 50X that of the solublised protein sample. IX 
Dialysis Buffer was changed and dialysis was continued overnight. Dialysis was 
continued for two additional changes (3 hours each) using IX Dialysis Buffer
without DTT. The dialysed protein solution was centrifuged at 10,000 x g for 10 
min at 4°C. The solution was then aliquoted and stored at -80°C. Protein 
concentration was determined by SDS-PAGE with BSA standards.
2.3.5 GST pull-down assays
Cells were scraped in 1 ml ice-cold PBS, and centrifuged at 400 x g for 3 min at 
4°C, then lysed as described in section 2.3.1. Lysates were rotated for 30 min at 
4°C, then centrifuged at 5000 x g, then 100 pi aliquots were removed in order to 
later examine the input. 800 ul of the remaning supernatants were added to 
microfuge tubes containing 100 pi of a 50% slurry of glutathione-Sepharose™ 
4B conjugated to GST alone or the GST-RFP (prepared by coupling 30 pi of 
glutathione-Sepharose™ beads with 20 pg of GST/GST-RFP per reaction in a 
total volume of 500 pi of lysis buffer at 4°C with rotation). Supernatants were 
rotated with glutathione beads for 1 hr at 4°C, and centrifuged at 5000 x g for 1 
min at 4°C. Beads were washed twice in lysis buffer and then resuspended in 
SDS-PAGE loading buffer. Samples were boiled for 10 min at 95°C.
2.3.6 Nickel precipitation of HIS-tagged proteins
Cells were scraped in 1 ml ice-cold PBS, and centrifuged at 400 x g for 3 min at 
4°C, then lysed as described in section 2.3.1. Lysates were rotated for 30 min at 
4°C, then centrifuged at 5000 x g, then 100 pi aliquots were removed in order to 
later examine the input. 800 pi of the remaning supernatants were added to 
microfuge tubes containing 100 pi of a 50% slurry of Ni-NTA Agarose (Qiagen) 
(30 pi used for each precipitation, centrifuged and washed with lysis buffer). 
Supernatants were rotated with Ni-NTA Agarose for 1 hr at 4°C, and then 
centrifuged at 5000 x g for 1 min at 4°C. Beads were washed twice in lysis buffer 
and then proteins were eluted from the beads using 150 pi of 250 mM Imidazole 
in PBS, by shaking for 30 min at 4°C. SDS-PAGE sample buffer was added and 
samples were boiled for 10 min at 95°C.
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2.3.7 DNA-Cellulose binding assays
Cells were lysed in 750 pi buffer containing 10 mM Hepes/NaOH pH 7.4, 0.1% 
Triton X-100, 100 mM NaCl, 10% glycerol, and 0.05 mM EDTA supplemented 
with 5 pg ml'1 leupeptin, 50 mM PMSF, 7.2 trypsin inhibitor units ml'1 of 
aprotinin, and 10 mM vV-ethylmaleimide. Lysates were sonicated on ice 
(amplitude 4 microns) in three 15 sec bursts, with a 30 sec interval between each 
pulse, using a Soniprep 150 (Sanyo), and clarified by centrifugation at 5000 x g 
for 20 min. 50 pi of cell lysate or purified protein (75 ng) was incubated with 25 
pi DNA-cellulose (GE Healthcare) or cellulose (Sigmacell cellulose type 50; 
Sigma) in 100 pi of lysis buffer for 1 h at 4°C. For competition assays, cell 
lysates were pre-incubated with the indicated amounts of DNA (sonicated, calf 
thymus; GE Healthcare) or RNA (calf-liver type IV; Sigma) and rotated for 30 
min at 4°C, and then added to DNA-cellulose beads. After rotation, the beads 
were washed four times with 1 ml lysis buffer with vortexing, and the amounts of 
protein retained on the beads were determined by Western blotting.
2.3.8 Protein concentration quantification
To ensure equal loading in SDS-PAGE, the protein concentration of lysates was 
quantitated using the Dc Protein Assay reagent (Bio-Rad) and measured on a 
VERSAmax microplate reader (Molecular Devices).
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2.3.9 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Polyacrylamide gels were prepared as described in Table 2.12, using reagents 
from Sigma.
Reagent 10% 10%
(mini)
12% 12%
(mini)
Stacking Stacking
(mini)
dH20 12 ml 3 ml 10 ml 2.5 ml 9.5 ml 3.2 ml
1.5 M Tris/Cl pH 8.8 10 ml 2.5 ml 10 ml 2.5 ml - -
0.5 M Tris/Cl pH 6.8 - - - - 3.75 ml 1.25 ml
50% Glycerol 8 ml 2 ml 8 ml 2 ml - -
40% Acrylamide 10 ml 2.5 ml 12 ml 3 ml 1.5 ml 500 pi
10% SDS 400 pi 100 pi 400 pi 100 pi 150 pi 50 pi
TEMED 40 pi 10 pi 40 pi 10 pi 15 pi 5 pi
10% APS 100 pi 25 pi 100 pi 25 pi 150 pi 50 pi
Table 2.12 Constituents of polyacrylamide running and stacking gels.
Protein samples were mixed with SDS loading buffer and heated to 95°C for 10 
min before loading. Gels were run in Bio-Rad Protean II™ or Mini Protean II™ 
tanks using Laemmli buffer (National Diagnostics). Protean II gels were run at 9 
mA (one gel) or 18 mA (two gels) overnight at RT or at 35 mA (one gel) or 70 
mA (two gels) in four hours. Mini protean II gels were run at 25 mA for 1 hour. 
ColorBusrt marker (Sigma) was loaded as a molecular weight marker.
2.3.10 Coomassie staining of polyacrylamide gels
Coomassie stain (0.04% w/v Brilliant blue R, 5% v/v methanol and 5% v/v 
glacial acetic acid) was added to polyacrylamide gels and gently rocked for 1 hr. 
Gels were destained using several changes of polyacrylamide gel destain (40% 
methanol and 10% glacial acetic acid) until the protein bands could be clearly 
detected. Gels were dried onto Whatmann 3M filter paper using a heated, 
vacuum-assisted gel drier (Bio-Rad).
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2.3.11 Western blotting
Polyvinylidene difluoride (PVDF, Millipore) membranes were soaked in 
methanol and then shaken in transfer buffer (25 mM Tris, 192 mM glycine and 
10% methanol) for at least 10 minutes. The gel to be transferred, sponges and 6 
pieces of Whatmann 3M filter paper were also soaked in transfer buffer for at 
least 10 minutes. Proteins from the gel were transferred to the membrane in a 
Bio-Rad Trans-Blot® electrophoretic transfer cell filled with transfer buffer. 3 
filter papers and a sponge were placed on either side of the gel and membrane. 
Transfer was performed either overnight at 220 mA at 4°C, or for 2 hrs at 70 V at 
4°C.
Membranes were blocked with shaking for 1 hour with 3% ‘Marvel’ milk 
powder-PBS. Primary antibody or peroxidase-conjugated anti-FLAG antibodies 
were added, as detailed in table 2.9 for either 1 hr at RT or overnight at 4°C with 
shaking. For peroxidase-conjugated anti-FLAG antibody, membranes were 
washed 5 times for 10 min at RT in PBS-Tween® (0.05% v/v Tween® 20, Sigma). 
For unconjugated primary antibodies, membranes were washed 3 times for 10 
min each at RT in PBS-Tween® and then peroxidase conjugated secondary 
antibodies (Jackson Immunochemicals) were added in 3% milk/PBS for 1 hr at 
RT with shaking. Secondary antibodies were washed using 5 x 1 0  min washes in 
PBS-Tween®. Bands on the membrane were visualised using ECL western 
blotting detection reagents (Amersham) or as prepared in table 2.13 (equal 
volumes of the two reagents were mixed and the membrane was incubated for 2 
min) and high performance chemiluminescence film (Hyperfilm, Amersham) 
according to the manufacturers instructions.
Reagent Enhanced Luminol Reagent Oxidising Reagent
250 mM Luminol 1 ml -
90 mM p-coumaric acid 0.5 ml -
1 M Tris/Cl pH 8.5 10 ml 10 ml
30% Hydrogen peroxide - 70 pi
Total volume (make up with 
autoclaved water)
100 ml 100 ml
Table 2.13 Constituents of ECL reagents.
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2.4 YEAST TRANSACTIVATION ASSAYS
2.4.1 Production of yeast competent cells
Cells from a single colony from a YPD plate were inoculated into 20 ml of YPD 
medium, and incubated at 30°C overnight, starting in the morning. 20 ml of the 
overnight culture were transferred to 300 ml of YPD medium in a one-litre flask, 
and incubated at 30°C until the OD600 reached 0.4-0.5 (2-4 hours). Cells were 
centrifuged at 1000 X g for 10 min at room temperature. The supernatant was 
discarded and the pellet was suspended with 6 ml of LiAc/TE before being 
transferred to a 15 ml tube and centrifuged at 2300 rpm at room temperature. The 
supernatant was discarded and the pellet suspended with 2 ml of LiAc/TE.
YPD medium was produced using 20 g/1 Difco peptone, 10 g/1 Yeast extract, and 
15-20 g/1 agar (for plates only). pH was adjusted to 5.8 and the solution was 
autoclaved. Glucose was added to 2% by adding 50 ml of a 40% stock solution 
(separately autoclaved) to each litre of media.
LiAc/TE solution contains 1 ml of 10 X LiAc (1 M lithium acetate (Sigma) 
adjusted to pH 7.5 with diluted acetic acid and autoclaved); 1 ml of 10 X TE (0.1 
M Tris-HCl, 10 mM EDTA, pH 7.5 autoclaved) and 8 ml of autoclaved H2O.
2.4.2 Production of -T  selection plates
-T selection plates were prepared using 3.35 g of yeast nitrogen base (without 
amino acid) and 8 g of agar in 425 ml of water. The solution was autoclaved and 
kept at 50 -  55°C. Prewarmed, autoclaved solutions were then added as follows: 
25 ml 40% glucose; 50 ml 10 X amino acid solution (300 mg/1 L-Isoleucine; 
1500 mg/1 L-Valine; 200 mg/1 L-Adenine hemisulfate salt; 200 mg/1 L-Arginine 
HCI; 200 mg/1 L-Histidine HCI monohydrate; 1000 mg/1 L-Leucine; 300 mg/1 L- 
lysine HCI; 200 mg/ml L-Methionine; 500 mg/1 L-Phenylalanine; 2000 mg/ml L- 
threonine; 300 mg/1 L-Tyrosine; and 200 mg/1 L-Uracil (all from Sigma); note 
that 200 mg/ml L-Tryptophan was omitted for selection purposes); and 10 ml of
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1M 3-aminotriazole (3-AT) (Sigma), filter sterilised. The solution was mixed 
well and poured onto square plates (25-30 ml per plate).
2.4.3 Transformation into yeast
50 pil yeast cells were mixed with 2.5 pi salmon sperm DNA and 2 pi of plasmid 
to be transformed (if from maxi prep; 5 pi if from mini prep). 300 pi of freshly 
prepared PEG/LiAc solution (8 ml of 50% polyethylene glycol (PEG); 1 ml of 
ml of 10X TE; 1 ml of 10X LiAc) was added and vortexed to mix, before 
incubating at 30°C for 30 min with shaking. 35 pi of DMSO was added and 
vortexed to mix. Cells were heat shocked for 15 min in a 42°C waterbath, then 
chilled on ice and centrifuged for 5 sec at 14000rpm. The supernatant was 
removed and the cells were resuspended in 0.5 ml of TE. Cells were then plated 
on the -T  selection plates.
2.4.4 Filter assay for (3-galactosidase
This assay was used when the colonies were at least 1-2 mm in diameter. Z 
buffer was prepared as follows: 16.1 g/1 Na2HPC>4.7H20; 5.5 g/1 NaE^PO^TEO; 
0.75 g/1 KCL; 0.246 g/1 MgSO4.7H20; pH 7.0). X-gal stock solution was 
prepared by dissolving 5-bromo-4-chloro-3-indolyl-p—D-galactopyranoside (X- 
gal) in N,N-dimethylformamide (DMF) at a concentration of 20 mg/ml and 
stored in the dark at -20°C. Sterile Whatman #1 filters were presoaked in Z 
buffer/X-gal solution (100 ml of Z buffer; 0.27 ml of (3-mercaptoethanol; 1.67 ml 
of X-gal stock solution) as follows: 5 ml of Z buffer/X-gal solution was added to 
a clean 150-mm plate and a 125-mm filter was layered onto the liquid to soak it 
up. A sterile Whatman #1 filter was placed over the surface of the plate 
containing the transformant colonies. Holes were poked through the filter into 
the agar to orient the filter on the agar. The filter was carefully lifted off the agar 
plate with forceps and transferred (colonies facing up) to a pool of liquid 
nitrogen and submerged for 10 sec. After the filter had completely frozen, it was 
removed and allowed to thaw at room temperature. The filter was placed colony 
side up on another filter that was presoaked in Z buffer/X-gal solution as before,
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avoiding trapping air bubbles under the filter. The filters were incubated at 30°C 
or room temperature and checked periodically for the appearance of blue 
colonies.
2.4.5 Liquid culture assay for P-galactosidase
Individual yeast transformant colonies were inoculated into synthetic selection 
media (-T) containing glucose (as for selection plates without agar) and 
incubated at 30°C until the culture reached mid-log phase (OD6oo~ 1.0). For each 
culture, 0.1 ml of culture and 0.7 ml of Z buffer containing (3-mercaptoethanol 
(0.27 ml of (3-mercaptoethanol in 100 m f of Z buffer) were added to a 1.5 ml 
microfuge tube. 50 pi ° f  CHC13 and 50 pi of 0.1% SDS were added and the 
solution was vortexed for 30 sec. 0.16 ml of o-nitophenylgalactoside (ONPG) 
(Sigma) solution (4 mg/ml in 0,1 M phosphate buffer, pH 7.0) was added and 
incubated at 30°C for 1 hour before quenching the reactions with the addition of 
0.4 ml of 1 M Na2CC>3 and centrifuging for 10 min at 14,000 rpm to remove cell 
debris. Absorbance was read at 420 nm and |3-galactosidase activity was 
measured using the following equation: (3-galactosidase units = 1000 x [OD600 /t 
x V x OD600 ] where t = time (min) of incubation and V = volume (ml) of culture 
added to Z buffer.
2.5 MAMMALIAN REPORTER ASSAYS
2.5.1 Mammalian transactivation assays.
HEK293 cells were seeded at 1 x 106 in a 9 cm plate and transfected with pFR- 
luciferase (firefly) and pCMV-Renilla (5OX less than pFR-luciferase (firefly) 
together with pFA-CMV-ECadl and or pFA-CMV-ECad2. After 24 hours cells 
were split into a 48 well plate (5 x 104 per well). After a further 24 hours, Firefly 
and Renilla luciferase activities were measured using the dual luciferase assay kit 
(Promega, Madison, WI) and a Turner Designs TD-20/20 luminometer, 
according to the manufacturer’s instructions.
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2.5.2 Reporter assays using TOP-FLASH or KBS reporter constructs
SW620 cells were transfected with pTOP-FLASH, pFOP-FLASH, pGL3-myc or 
pGL3-cyclin D1 together with E-cad/CTF2 or E-cad/CTF2-NLS-myc. HEK293 
and cells were transfected with pGL3-control vector or pGL3-4xKBS together 
with FLAG-pl20, E-cad/CTF2, E-cad/CTF2-NLS-myc, or E-cad/CTF2(AAA)- 
NLS-myc. For reporter assays using the matrilysin promoter, HEK293 cells were 
transfected with pGL3-Basic-2.3kb HMat together with FLAG-pl20, E- 
cad/CTF2-NLS-myc, or E-cad/CTF2(AAA)-NLS-myc. LacZ was used as a 
control for transfection efficiency in all experiments. Luciferase activity was 
measured using the luciferase assay kit according to the manufacturer’s 
instructions (Promega, Madison, WI) and a Turner Designs TD-20/20 
luminometer. (3-Gal activity was measured using the (3-galactosidase assay kit 
according to the manufacturer’s instructions (Promega) and the VERSAmax 
microplate reader (Molecular Devices).
2.6 COMPUTATIONAL ANALYSIS
All image analysis was performed using Adobe Photoshop, version 6.0. 
Quantitative data was depicted using Microsoft Excel and Quantity One 
software. Sequence alignments were performed using Clustal W software. 
Student’s t tests assuming equal or unequal variance and a two-tailed distribution 
were performed for statistical analysis using Microsoft Excel.
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3 ANALYSIS OF STIMULI INDUCING PRODUCTION 
OF THE E-CADHERIN CLEAVAGE PRODUCT, E- 
CAD/CTF2 
3.1 Introduction
As described in section 1.4.5 (Introduction), multiple proteases are known to 
cleave E-cadherin. Various extracellular metalloproteases cleave E-cadherin, 
removing most of the extracellular domain (Lochter et al., 1997; Maretzky et al., 
2005; Noe et al., 2001). The role of the released extracellular domain as an 
invasion promotor has been well characterised (Lochter et al., 1997; Noe et al., 
2001), but the fate of the remaining fragment, E-cad/CTFl, has not been 
elucidated. E-Cad/CTFl has recently been shown to be cleaved by y-secretase, in 
response to treatment with staurosporine or the Bacteroides fragilis toxin, 
releasing E-cad/CTF2 (Marambaud et al., 2002; Wu et al., 2007). This cleavage 
by y-secretase is of particular interest from a signalling perspective, since many 
intracellular domain fragments of transmembrane proteins released by y- 
secretase-mediated cleavage localise to the nucleus and have signalling functions 
(Section 1.5.3, Introduction) (Fortini, 2002). However the physiological stimuli 
inducing y-secretase-mediated cleavage of E-cadherin have not been addressed. 
In this chapter, various stimuli that influence the cleavage of E-cadherin to 
produce E-cad/CTF2 were investigated.
3.2 Characterisation of cleavage products of E- 
cadherin in epithelial cells
3.2.1 Domain structure of E-cadherin cleavage products
As described in sections 3.1 and 1.4.5 (Introduction), various intracellular 
cleavage products are released following cleavage by different proteases. E- 
Cad/CTFl is the 38 kDa cleavage product induced by extracellular 
metalloproteases that cleave close to the interface between the extracellular and 
transmembrane regions of E-cadherin (Lochter et al., 1997; Maretzky et al.,
98
2005; Noe et al., 2001). E-Cad/CTF2 (33 kDa) is the result of y-secretase 
cleavage, which occurs following removal of most of the extracelluar region by 
metalloproteases (Marambaud et al., 2002; Wu et al., 2007). E-Cad/CTF3 (29 
kDa) results from cleavage by caspase-3 after induction of apoptosis (Keller and 
Nigam, 2003; Marambaud et al., 2002; Steinhusen et al., 2001). The size and 
domain structure of these intracellular cleavage products are shown in Figure 3.1
N TM
p120 (3-Catenin
I I
CH2 CH3 C
Full length 
CTF1 
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CTF3
Figure 3.1 Schematics for the domain structure of full length E-cadherin, E- 
cad/CTF1, E-cad/CTF2, and E-cad/CTF3. The intracellular region of E-cadherin 
contains two CH (cadherin homology) domains, CH2 and CH3, which bind to p 120 and 
fi-catenin, respectively. TM; transmembrane region.
3.2.2 Staurosporine induces y-secretase-mediated and caspase-3- 
mediated cleavage of E-cadherin in epithelial cell lines
First, the proteolytic cleavage of E-cadherin was examined in several epithelial 
cell lines. As previously reported (Marambaud et al., 2002), treatment of the 
human epithelial cell line A431 with staurosporine lead to the production of 
cytoplasmic cleavage products, E-cad/CTF2 and E-cad/CTF3 (Figure 3.2). 
Staurosporine is a potent inhibitor of protein kinase C (PKC) and other protein 
kinases, which strongly induces apoptosis (Tamaoki et al., 1986). E-Cad/CTF2 
was also observed in the human breast adenocarcinoma cell line MCF-7 and 
Madin-Darby canine kidney (MDCK) cells after treatment with staurosporine 
(Figure 3.2). E-Cad/CTFl was also present in all three cell lines (Figure 3.2). 
The identity of a number of other bands between 45 and 100 kDa, particularly in 
MDCK cells, is not known and varies between different experiments. As 
expected, it was observed that treatment with y-secretase inhibitor X specifically
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blocked staurosporine-induced production of E-cad/CTF2 in all three cell lines 
and lead to an accumulation of its precursor E-cad/CTFl (Figure 3.2).
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Figure 3.2 Staurosporine induces y-secretase- and caspase-3-mediated cleavage 
of E-cadherin in epithelial cell lines. A431, MCF-7, and MDCK cells were treated with 
staurosporine (STS) (1 uM) in the presence or absence of y-secretase (y-sec) inhibitor X  
(12.5 nM) for 6 h. Cell lysates were examined by Western blotting with anti-E-cadherin 
antibody. The positions of full length E-cadherin (FL) and the C-terminal fragments E- 
cad/CTF1, E-cad/CTF2, and E-cad/CTF3 are indicated with arrowheads.
3.3 Analysis of stimuli that induce the production of 
E-cad/CTF2
3.3.1 Apoptosis induces production of E-cad/CTF2 in A431 cells
The data in Figure 3.2 indicate that staurosporine induces y-secretase-mediated 
cleavage of E-cadherin. Staurosporine induces apoptosis which is indicated by 
the production of the caspase-3 cleavage product of E-cadherin, E-cad/CTF3 
(Figure 3.2). However it is also a potent inhibitor of protein kinase C and other 
protein kinases. Thus it is difficult to conclude from this data alone whether the 
induction of apoptosis itself stimulates y-secretase-mediated cleavage of E- 
cadherin. To further investigate this possibility, A431 cells were exposed to 
Ultra-Violet light (UV) in order to induce apoptosis. Under these conditions the 
cells showed apoptotic cellular phenotypes of rounding-up, blebbing and an 
increase in cells detached from the plate compared to controls, as observed by 
phase contrast microscopy. Upon exposure to UV, Western blot bands of the 
same molecular size as E-cad/CTF2 and E-cad/CTF3 were produced, which were 
also observed upon treatment with staurosporine (Figure 3.3).
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Figure 3.3 UV treatment induces production of E-cad/CTF2 and E-cad/CTF3 in 
A431 cells. A431 cells were treated with staurosporine (STS) (1 uM) in the presence or 
absence of y-secretase (y-sec) inhibitor X  (12.5 nM) for 6 h or with UV as detailed in 
Table 2.9 (Chapter 2). Cell lysates were examined by Western blotting with anti-E- 
cadherin antibody. The positions of full length E-cadherin (FL) and the C-terminal 
fragments E-cad/CTF1, E-cad/CTF2, and E-cad/CTF3 are indicated with arrowheads. 
Images shown for the first lane and the other four lanes are from the same film.
3.3.2 Hepatocyte Growth Factor (HGF) induces y-secretase-mediated 
cleavage of E-cadherin in MDCK cells.
Next, E-cadherin cleavage in epithelial cells in response to another stimulus that 
leads to the loss of cell-cell contacts was investigated. As described in section 
1.4.1 (Introduction), treatment of MDCK cells with hepatocyte growth factor 
(HGF) activates the tyrosine kinase HGF receptor (c-Met) and induces 
endocytosis of E-cadherin, leading to the disruption of cell-cell contacts and a 
fibroblast-like morphological change (Fujita et al., 2002; Kamei et al., 1999; 
Weidner et al., 1990) (Figure 3.4). The effect of HGF treatment on the 
proteolytic cleavage of E-cadherin was examined. A 33 kDa fragment of the 
same size as E-cad/CTF2 was induced when MDCK cells were treated with HGF 
(Figure 3.5, left). Induction of E-cad/CTF2 by HGF treatment was blocked by 
addition of y-secretase inhibitor X (Figure 3.5, right). These data indicate that E- 
cad/CTF2 is produced by y-secretase cleavage when intercellular adhesions are 
disrupted in epithelial cells by activation of the HGF receptor.
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Figure 3.4 HGF-induced scattering of MDCK cells. MDCK cells were treated with 
HGF (50 ng/ml) for 24 h and examined by phase-contrast microscopy. Scale bars 
represent 50 pm.
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Figure 3.5 HGF induces y-secretase-mediated cleavage of E-cadherin. MDCK cells 
were treated with HGF (50 ng/ml) for 24 h or with staurosporine (1 uM) in the presence 
or absence of y-secretase inhibitor X  (12.5 nM) for 6 h. Cell lysates were examined by 
Western blotting with anti-E-cadherin and anti-a-tubulin antibodies. In right upper and 
lower panels, the film was exposed to the membrane after ECL for 10 seconds and 2 
minutes, respectively. The positions of full length E-cadherin (FL), E-cad/CTF1, E- 
cad/CTF2, and E-cad/CTF3 are indicated with arrowheads. It should be noted that 
staurosporine treatment strongly reduces the amount of full length E-cadherin.
3.3.3 Activation of Ras induces production of E-cad/CTF2 in MDCK 
cells
As described in section 1.4.1 (Introduction), activation of the small GTPase Ras 
also leads to transformation of epithelial cells resulting in the loss of cell-cell 
contacts (Schoenenberger et al., 1991). MDCK cells expressing a constitutively 
active form of Ras (RasV12) in a tetracycline-inducible manner were used to 
analyse the effect of Ras activation on E-cadherin cleavage. In the presence of 
tetracycline, these cells lost tight cell-cell contacts and started scattering (Figure 
3.6). Under this condition, upregulation of E-cad/CTF2 was observed, although
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to a lesser extent to that observed following HGF treatment (Figure 3.7). The 
amount of E-cad/CTF2 induced by Ras activation was not clearly affected by 
treatment with y-secretase inhibitor X (Figure 3.7). Hence at this time the 
possibility cannot be excluded that there may be other proteases involved.
Tet off Tet on 24 h
Figure 3.6 Ras activation leads to scattering of MDCK cells. MDCK cells stably 
expressing RasV12 in a tetracycline-inducible manner were treated with tetracycline (2 
ug/ml) for 24 h and examined by phase-contrast microscopy. Scale bars represent 50 
pm.
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Figure 3.7 Ras activation increases production of E-cad/CTF2. MDCK cells stably
expressing RasV12 in a tetracycline-inducible manner were treated with tetracycline (2
ug/ml) for 24 h, or staurosporine (1 pM) in the presence or absence of y-secretase 
inhibitor X  (12.5 nM) for 6 h. Cell lysates were examined by Western blotting with anti-E- 
cadherin. In the upper and lower panels, the film was exposed to the membrane after 
ECL for 10 seconds and 2 minutes, respectively. The positions of full-length E-cadherin 
(FL), E-cad/CTF1 and E-cad/CTF2 are indicated with arrowheads. It should be noted 
that staurosporine treatment strongly reduces the amount of full length E-cadherin
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3.4 Discussion
This chapter describes an analysis of stimuli that lead to the production of the E- 
cadherin cleavage product, E-cad/CTF2. Three cleavage products of E-cadherin 
(E-cad/CTFl, E-cad/CTF2, and E-cad/CTF3) were previously characterised as 
resulting from cleavage by extracellular metalloproteases, y-secretase and 
caspase-3 respectively (Marambaud et al., 2002). In this previous study 
Marambaud et al. reported that staurosporine treatment leads to the production of 
E-cad/CTF2 via a y-secretase-mediated cleavage in A431 cells. In this chapter it 
is shown that this cleavage also occurs in MCF-7 and MDCK cells and is 
therefore not a cell-type specific event.
Other stimuli have been shown to induce production of E-cad/CTF2: treatment 
with a calcium ionophore or with the Bacteroides fragilis toxin (Marambaud et 
al., 2002; Wu et al., 2007). It is possible that increased production of E- 
cad/CTF2 following treatment with calcium ionophore results from the increased 
production of its precursor, E-cad/CTFl, since metalloprotease cleavage of E- 
cadherin has also been shown to be upregulated with this stimulus (Ito et al., 
1999). However the physiological relevance of E-cad/CTF2 production is still 
not fully understood.
Although staurosporine induces apoptosis of cells, it also potently inhibits PKC 
and other kinases. Here, in order to analyse the effect of inducing apoptosis 
alone, UV irradiation was used. E-Cad/CTF2 was also produced following 
exposure to UV. This indicates that when cells undergo apoptosis, E-cadherin is 
cleaved to produce E-cad/CTF2. The disruption of E-cadherin based cell-cell 
contacts is involved in the onset of anoikis (Fouquet et al., 2004), and is an 
important process enabling apoptotic epithelial cells to round up and exit the 
epithelium (Steinhusen et al., 2001). Therefore it is possible that y-secretase- and 
caspase-3-mediated cleavages of E-cadherin play a role in the down-regulation 
of E-cadherin from sites of cell-cell contacts during apoptosis.
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Here, to study more physiological stimuli, it is shown that activation of the HGF- 
receptor leads to y-secretase-dependent accumulation of E-cad/CTF2 in MDCK 
cells. As described in section 1.4.1 (Introduction), HGF, also known as scatter 
factor, is a paracrine morphogenic factor which regulates cellular growth, 
motility and invasiveness (Stoker and Gherardi, 1991; Weidner et al., 1990). It is 
known that upon stimulation of MDCK cells with HGF, endocytosis of E- 
cadherin is induced, leading to the disruption of cell-cell contacts (Fujita et al., 
2002; Kamei et al., 1999; Weidner et al., 1990). Enhanced production of E- 
cad/CTF2 was also observed by activation of Ras, which also induces disruption 
of E-cadherin-based cell-cell contacts (Schoenenberger et al., 1991). 
Collectively, these data suggest that when E-cadherin is released from cell-cell 
contacts, it may become more accessible to proteases. The amount of E- 
cad/CTF2 induced by activation of the HGF-receptor or Ras is much smaller 
than that of full-length E-cadherin. This observation is quite comparable to y- 
secretase-induced cleavage of Notch. Upon binding with its ligand, Notch is 
cleaved by y-secretase to release its intracellular domain, however the amount is 
too small to be detected in the nucleus by immunostaining (Struhl and Adachi, 
1998; Struhl and Greenwald, 1999). Thus, the main evidence of nuclear 
localisation of Notch has been presented with a reporter assay using a Notch 
construct C-terminally tagged with GAL4-VP16 (Struhl and Adachi, 1998). To 
demonstrate the physiological significance of E-cad/CTF2 in vivo, a similar 
reporter system needs to be applied in the future.
To investigate a potential nuclear signalling role of E-cad/CTF2, as has been 
described for intracellular domain fragments released by y-secretase-cleavage of 
other transmembrane proteins, the fate of this fragment was studied. Chapter 4 
describes the analysis of the fate of this fragment using E-cad/CTF2 expression 
studies.
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CHAPTER 4
106
4 p120 ENHANCES THE NUCLEAR LOCALISATION 
OF E-CAD/CTF2 
4.1 Introduction
The fate of E-cad/CTF2, following its release into the cytosol after cleavage of 
full length E-cadherin, was examined in this chapter. In particular it was 
investigated whether E-cad/CTF2 can localise in the nucleus, as has been 
observed for the y-secretase-cleavage products of N-cadherin and y- 
protocadherins (Haas et al., 2005; Hambsch et al., 2005; Shoval et al., 2007; 
Uemura et al., 2006a). Despite extensive efforts (for more details see Section 
4.5.1), it has not been possible to isolate pure nuclear fractions from the 
epithelial cells A431, MCF-7 or MDCK, thus the nuclear localisation of 
endogenous E-cad/CTF2 could not be biochemically determined. Furthermore, 
the available antibodies against the cytoplasmic domain of E-cadherin are not 
suitable for immunofluorescent staining. In this chapter, expression studies using 
E-cadherin constructs were employed. Using three different approaches, 
employing both cell biology and biochemical techniques, a crucial and specific 
role for p i20 in the nuclear localisation of E-cad/CTF2 was demonstrated.
4.2 Constructs used for expression studies
The constructs used for the expression studies in this chapter are outlined in 
figure 4.1. Firstly, a HA-tagged form of E-cad/CTF2 (Figure 4.1 A) was used to 
examine the fate of this fragment when expressed in several cell lines by 
immunofluoresence microscopy. Secondly, MDCK cells expressing C-terminally 
myc-tagged full length E-cadherin (Figure 4.IB) were used. Following the 
induction of E-cadherin cleavage, the use of this constuct allows the fate of 
cleaved intracellular E-cadherin to be examined by immunofluoresence 
microscopy. Finally, constructs were produced of both of the fragments released 
into the cytosol by E-cadherin cleavage, E-cad/CTF2 (Figure 4.1 C) and E- 
cad/CTF3 (Figure 4.ID), for use in biochemical fractionation studies. E- 
cad/CTF2 and E-cad/CTF3 represent amino acids 734-884 and 753-884 of E-
107
cadherin, respectively. These constructs were produced according to the 
published cleavage sites of y-secretase and caspase-3, respectively (Marambaud 
et al., 2002). A mutant form of E-cad/CTF2 was also constructed: E- 
cad/CTF2(AAA) (Figure 4. IE). This contains a triple alanine mutation within the 
CH2 domain which blocks the binding of E-cadherin with p i20 (Thoreson et al., 
2000).
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Figure 4.1 Schematics of the constructs used in expression studies in this 
chapter. (A) HA-E-Cad/CTF2 construct. Amino acids 734-884 of E-cadherin with an N- 
terminal HA tag. (B) E-Cadherin-myc construct. Full length o f E-cadherin with a C- 
terminal myc tag. (C) E-Cad/CTF2 construct. Amino acids 734-884 of E-cadherin. (D) E- 
Cad/CTF3 construct. Amino acids 753-884 o f E-cadherin. (E) E-Cad/CTF2(AAA) 
construct. Amino acids 734-884 of E-cadherin with a triple alanine mutation within the 
CH2 domain. CH; cadherin homology domains. TM; transmembrane region.
To confirm that the E-cad/CTF2 and E-cad/CTF3 constructs (shown in Figure 
4.1C and 4. ID) were of the same molecular size as the endogenously produced 
E-cadherin cleavage products, cell lysates from HEK293 cells transfected with 
E-cad/CTF2 and E-cad/CTF3 were subjected to SDS-PAGE together with cell 
lysates from MDCK cells that had been treated with staurosporine with and 
without y-secretase inhibitor X (Figure 4.2). As described in chapter 3, treatment 
of MDCK cells with staurosporine induced production of E-cad/CTF2 and E- 
cad/CTF3 (Figure 4.2), and y-secretase inhibitor X blocked the production of E- 
cad/CTF2 (Figure 4.2). Comparison of the Western blot bands showed that 
exogenous E-cad/CTF2 and E-cad/CTF3 expressed in HEK293 cells were of the
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same molecular size as those produced by cleavage of endogenous E-cadherin in 
MDCK cells (Figure 4.2).
MDCK HEK293 
Lysate Lysate
97 
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Staurosporine +  +  — — — —
Y-Sec Inhibitor — +  — — — —
E-cad/CTF3
E-cad/CTF2 +
Figure 4.2 Confirmation of the molecular size of exogenously expressed E- 
cad/CTF2 and E-cad/CTF3 proteins. (Lanes 1-2) MDCK cells were treated with 
staurosporine (STS) (1 uM) in the presence or absence of y-secretase (y-sec) inhibitor X  
(12.5 nM) for 6 h. (Lanes 5-6) HEK293 cells were transfected with E-cad/CTF2 or E- 
cad/CTF3. (Lanes 1-6) Cell lysates were examined by Western blotting with anti-E- 
cadherin antibody. The positions of E-cad/CTF2, and E-cad/CTF3 are indicated with 
arrowheads.
4.3 p120 enhances nuclear localisation of E-cad/CTF2
The HA-tagged E-cad/CTF2 construct described in Figure 4.IB was expressed in 
epithelial cells and its subcellular localisation was examined. When FLA-E- 
cad/CTF2 alone was expressed in MDCK cells, it mainly localised in the 
cytoplasm (Figure 4.3A). Interestingly, coexpression of p i20 enhanced the 
nuclear localisation of HA-E-cad/CTF2 (Figure 4.3A). To quantify this effect of 
p i20, the ratio of pixel intensity was measured within defined regions (diameter 
1.97 pm) of the nucleus and cytoplasm. The quantification results showed that 
coexpression of p i20 significantly increased the amount of E-cad/CTF2 in the 
nucleus (p < 0.002) (Figure 4.3B). A similar effect of p i20 on the nuclear 
localisation of E-cad/CTF2 was observed in human embryonic kidney (HEK) 
293 cells (Figure 4.4) and also MCF-7 cells (Figure 4.5)
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Figure 4.3 p120 enhances the nuclear localisation of E-cad/CTF2 in MDCK cells.
(A) MDCK cells were transfected with HA-E-cad/CTF2 and FLAG-p120. Immunostaining 
was performed with anti-HA and anti-FLAG antibodies. Nuclei were stained with 
Hoechst dye. Images were acquired using confocal microscopy. Scale bars represent 10 
pm. (B) Quantification of p120-induced enhanced nuclear localisation o f HA-E-cad/CTF2 
in MDCK cells. Immunofluorescence intensity with anti-HA antibody was measured 
within a defined region (diameter 1.97 pm) in the nucleus and cytoplasm. The ratio o f 
nucleus/cytoplasm staining intensity was analysed in 20 cells. Error bars represent 
SEM. * p < 0.002.
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Figure 4.4 p120 enhances the nuclear localisation of E-cad/CTF2 in HEK293 cells.
(A) HEK293 cells were transfected with HA-E-cad/CTF2 and FLAG-p120. 
Immunostaining was performed with anti-HA and anti-FLAG antibodies. Nuclei were 
stained with Hoechst dye. Images were acquired using confocal microscopy. Scale bars 
represent 10 pm. (B) Quantification of p120-induced enhanced nuclear localisation of 
HA-E-cad/CTF2 in HEK293 cells. Immunofluorescence intensity with anti-HA antibody 
was measured within a defined region (diameter 1.97 pm) in the nucleus and cytoplasm. 
The ratio of nucleus/cytoplasm staining intensity was analysed in 20 cells. Error bars 
represent SEM. **, p < 0.00007.
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Figure 4.5 Coexpression of p120 induces nuclear translocation of E-cad/CTF2 in 
MCF-7 cells. MCF-7 cells were transfected with HA-E-cad/CTF2 and FLAG-p120. 
Immunostaining was performed with anti-HA and anti-FLAG antibodies. Images were 
acquired using confocal microscopy. Scale bar represents 15 pm.
4.4 The cytoplasmic domain of E-cadherin is 
processed from full-length E-cadherin and is 
translocated to the nucleus upon coexpression of
p120
MDCK cells expressing exogenous full-length E-cadherin with a C-terminal myc 
tag (as described in Figure 4.1C), were used to examine the fate of the 
cytoplasmic domain of E-cadherin following cleavage of the full-length protein. 
When E-cadherin-myc alone was expressed, myc immunostaining was mainly 
observed at cell-cell contacts, which was not affected by coexpression of p i20 
(Figure 4.6A, first and second panels). It was next investigated whether the 
cleaved C-terminus of E-cadherin localises in the nucleus in this system. 
Staurosporine treatment induced nuclear fragmentation and therefore was not a 
suitable treatment to analyse nuclear localisation of cleaved E-cadherin. The 
amount of E-cad/CTF2 induced by HGF treatment was too small to be detected
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with immunostaining. Thus as an alternative, a metalloprotease ADAM (a 
disintegrin and metalloprotease) 10, which cleaves E-cadherin producing E- 
cad/CTFl (Maretzky et al., 2005), was transiently expressed in these cells. Upon 
expression of ADAM 10, myc staining was decreased at cell-cell contacts, 
becoming predominantly localised in the cytoplasm and cells became more 
spread and flattened (Figure 4.6A, third panel). The effect of ADAM 10 
expression on E-cadherin localisation was quantified by counting the percentage 
of cells showing myc staining in the cytoplasm. Expression of ADAM 10 lead to 
cytoplasmic staining in approximately 60 percent of cells, compared with 
approximately 10 percent in mock-transfected cells (Figure 4.6B). Neither 
coexpression of p i20 nor treatment with y-secretase inhibitor X significantly 
affected this effect of AD AMI 0, suggesting that ADAM10 disrupted E-cadherin- 
based cell-cell contacts independently of p i20 and y-secretase (Figure 4.6B). 
Furthermore, the nuclear myc staining was analysed in the cells that lost cell-cell 
contact staining upon expression of ADAM 10. Notably, coexpression of p i20 
with AD AMI 0 substantially increased nuclear myc staining (Figure 4.6A, fourth 
panel, and Figure 4.6C). The nuclear myc staining induced by coexpression of 
ADAM 10 and p i20 was blocked by treatment with y-secretase inhibitor X 
(Figure 4.6A, fifth panel, and Figure 4.6C), suggesting that the nuclear 
localisation of the C-terminus of E-cadherin is dependent on y-secretase- 
mediated processing of E-cad/CTFl. Collectively, data in sections 4.3 and 4.4 
indicate that the y-secretase cleavage product of E-cadherin, E-cad/CTF2, can 
localise in the nucleus of epithelial cells and that this localisation is enhanced by 
pl20.
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Figure 4.6 Nuclear localisation of the cleaved C-terminus of E-cadherin. (A) p120 
induces nuclear localisation of the C-terminus of E-cadherin in ADAM10-transfected 
cells. MDCK cells stably expressing C-terminally myc-tagged E-cadherin were 
transiently transfected with FLAG-ADAM10 and/or HA-p120. y-Secretase inhibitor X  
(12.5 nM) was added for 6 h before fixation where indicated. Immunostaining was 
performed with anti-myc, anti-HA, or anti-FLAG antibodies. Nuclei were stained with 
Hoechst dye. Images were acquired using confocal microscopy. Scale bars represent 15 
pm. (B) Quantification of ADAM10-induced cytoplasmic localisation of E-cadherin. The 
percentage of cells showing cytoplasmic myc-staining was calculated from 20 
transfected cells from two independent transfections. Error bars indicate SEM. (C) 
Quantification of nuclear localisation of E-cadherin. The percentage of cells showing 
loss of myc staining at cell-cell contacts that also showed nuclear myc staining was 
calculated from 20 transfected cells from two independent transfections. Error bars 
indicate SEM.
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4.5 Analysis of nuclear localisation of E-cad/CTF2 by 
biochemical nuclear fractionation in HEK293 cells
4.5.1 Nuclear fractionation in HEK293 cells
HEK293 cells were used to further analyse the nuclear localisation of E- 
cad/CTF2, because highly purified nuclei can be obtained by biochemical 
nuclear fractionation using these cells. In this technique the cells were plated 
sparsely, trypsinised and then lysed in a buffer containing 20% glycerol (for 
further details see section 2.3.8, Chapter 2). Under these conditions the nuclei 
remain insoluble and can be pelleted following centrifugation, and after 
extensive washing, purified nuclei can be observed by light microscopy. The 
purity of the nuclear fractions was confirmed by analyzing the total and nuclear 
fractions by Western blotting with antibodies agains compartment-specific 
markers for the nucleus, plasma membrane, cytoplasm, endoplasmic reticulum, 
Golgi apparatus and lysosome (Figure 4.7).
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Figure 4.1 Characterization of nuclear fractions isolated from HEK293 cells. Total 
and nuclear lysates from HEK293 cells were examined by Western blotting with 
antibodies against different subcellular compartments: anti-CREB binding protein (CBP) 
(nucleus); anti-N-cadherin (plasma membrane); anti-a-tubulin (cytoplasm); anti- 
BiP/GRP78 (endoplasmic reticulum); anti-GM130 (Golgi); anti-Lamp-1 (lysosome).
This technique for nuclear fractionation was not suitable for the epithelial cell 
lines A431, MCF-7 or MDCK. This is because cell aggregates were not well
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separated with trituration in the lysis buffer, most likely due to the increased 
strength of cell-cell contacts in these cell lines. Thus the nuclear pellet was 
contaminated with cell aggregates and were observed in the resuspended pellet 
by light microscopy. Trypsinisation is often used to separate cell aggregates in 
nuclear fractionation techniques. However, trypsinisation leads to cleavage of E- 
cadherin (Perret et al., 2002), and so it would not be possible to analyse 
endogenous E-cadherin cleavage products after treating cells with trypsin.
Several other variations of this method were attempted to purify nuclear fractions 
from these three cell lines. Sonication was tested to break up the cell aggregates. 
However at the amplitudes required to disrupt the cell aggregates, nuclei were 
also disrupted and could no longer be pelleted by centrifugation. E-cadherin- 
based cell-cell contacts are calcium dependent and can be disrupted by treatment 
with ethylene glycol tetraacetic acid (EGTA). Addition of EGTA chelates the 
calcium ions and thus sequester the calcium ions away from E-cadherin (Reddy 
et al., 2005). Thus incubation with EGTA was also used in order to break up the 
cell aggregates. However since calcium regulates the cleavage of E-cadherin by 
metalloproteases and y-secretase (Ito et al., 1999; Marambaud et al., 2002), it 
was necessary to incubate with EGTA at 4°C, to prevent the EGTA from 
affecting cleavage of E-cadherin. Even after overnight incubation, cell 
aggregates remained after lysing and trituration as described above, thus 
contaminating the nuclear fraction.
4.5.2 Coexpression of p l20  enhances the amount of E-cad/CTF2 in 
the nuclear fraction of HEK293 cells
Since it has not been possible to determine whether the cleavage products of 
endogenous E-cadherin localise to the nucleus by examining nuclear fractions of 
A431, MCF-7 or MDCK cells, nuclear fractionation experiments were carried 
out in HEK293 cells. It was first confirmed that coexpression of p i20 increased 
the amount of E-cad/CTF2 in the nuclear fraction, as is expected from the 
immunostaining data in HEK293 cells shown in Figure 4.4 (Figure 4.8, A and 
B). The expression of p i20 did not affect the amount of nuclei in the nuclear 
fraction, indicated by levels of CBP in the nuclear fraction (Figure 4.8B).
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Interestingly, it was also observed that p i20 expression frequently induced a 
series of higher molecular weight modifications of E-cad/CTF2 (Figure 4.8A, 
‘upsmear’ of modifications indicated by double-headed arrow). Studies of this 
modification of E-cad/CTF2 are presented in chapter 5. It should be noted that 
the extent of modifications varied between experiments (compare Figure 4.8A 
with 4.8B). See section 5.6 for further discussion of the modifications of E- 
cad/CTF2 and the variability in the amount of modification between 
experiments.
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Figure 4.8 Coexpression of p120 increases the amount of E-cad/CTF2 in the 
nuclear fraction without affecting the amount of nuclei in this fraction. (A and B)
HEK293 cells were transfected with E-cad/CTF2 and FLAG-p120. Total and nuclear 
lysates were examined by Western blotting with anti-E-cadherin antibody. (A) By kind 
permission of Dr. Yasuyuki Fujita. Double headed arrow indicates ‘upsmear1 of 
modifications induced by p120. (B) Nuclear lysates were also examined by Western 
blotting with anti-CBP antibody.
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4.5.3 Knockown of p l20  using small interfering RNA  
oligonucleotides
To investigate whether p i20 is required for the nuclear localisation of E- 
cad/CTF2 in HEK293 cells, p i20 protein was knocked down using small 
interfering RNA (siRNA) oligonucleotides (oligos). Knockdown of gene 
expression levels with this technique is achieved by the activation of the RNA- 
induced silencing complex (RISC) which destroys mRNAs that contain the 
identical sequence found in the siRNA oligo (Sen and Blau, 2006). Using the 
Eurogentec web-based ordering system, two siRNA oligos were designed (Table 
2.6, Section 2.1.11, Materials and Methods). The sequence of both siRNA oligos 
are found in all of the p i20 human isoforms, and so should knock down all 
isoforms. By searching the NCBI nucleotide database, it was confirmed that the 
sequences of the siRNA oligos did not match any other mRNA sequences apart 
from the p i20 isoforms.
In order to optimize conditions for knockdown of p i20, the two siRNA oligos 
were transiently transfected into HEK293 cells and the levels of protein 
expression were examined after either 72 or 96 hours. A non-silencing siRNA 
control was also tested as well as the effect of the transfection reagent alone. 72 
hours after transfection, efficient knockdown of p i20 expression levels was 
achieved with both p i20 siRNA oligo 1 and p i20 siRNA oligo 2, while there 
was no effect on p i20 expression in the presence of non-silencing siRNA or 
transfection reagent alone (Figure 4.9). After 96 hours, the effect of the 
knockdown of pl20 was much decreased (Figure 4.9). This is most likely 
because of the transient nature of the transfection. Thus, for the following 
experiments, cells were analysed 72 hours after siRNA transfection.
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Figure 4.9 Optimisation of p120 knockdown by transient transfection of siRNA 
oligos. HEK293 cells were transfected with negative (-) control siRNA, p120 siRNA 1, 
p120 siRNA 2 or treated with Hi-Perfect transfection reagent alone. 72 or 96 hours after 
transfection, total lysates were examined by Western blotting with anti-p120 and anti-a- 
tubulin antibodies.
4.5.4 pl20 is required for nuclear localisation of E-cad/CTF2 in 
HEK293 cells
The effect of knocking down the expression of endogenous p i20 on the nuclear 
localisation of E-cad/CTF2 was examined. Expression of siRNA oligos 
efficiently knocked down the expression of endogenous p i20 and strongly 
reduced the amount of E-cad/CTF2 present in the nuclear fraction (Figure 4.10). 
This reduction of E-cad/CTF2 in the nuclear fraction was observed to a greater 
extent with siRNA oligo 2 where greater knockdown of p i20 was observed 
(Figure 4.10). These data indicate that pl20 is required for the nuclear 
localisation of E-cad/CTF2 in HEK293 cells.
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Figure 4.10 Knockdown of p120 decreases the nuclear localisation of E-cad/CTF2.
HEK293 cells were transfected with control siRNA, p120 siRNA oligo 1, or p120 siRNA 
oligo 2 together with E-cad/CTF2, and total and nuclear lysates were examined by 
Western blotting with anti-E-cadherin, anti-p120 and anti-a-tubulin antibodies.
4.5.5 The nuclear localisation of E-cad/CTF2 is enhanced specifically 
by pl20
Next the specificity of the effect of pi 20 on nuclear localisation and modification 
of E-cad/CTF2 was investigated. As described in section 1.2.2 (Introduction), the 
intracellular domain of E-cadherin binds to other proteins. Expression of two 
other E-cadherin binding proteins, (3-catenin and Hakai, did not enhance either 
modification or nuclear localisation of E-cad/CTF2 (Figure 4.11). This suggests 
that these effects are specific to p i20.
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Figure 4.11 E-Cad/CTF2 nuclear localisation is increased by p120, but not by other 
E-cadherin binding proteins. HEK293 cells were transfected with E-cad/CTF2 
together with FLAG-p120, Myc-fi-catenin or FLAG-Hakai, and total and nuclear lysates 
were examined by Western blotting with anti-E-cadherin. By kind permission o f Dr. 
Yasuyuki Fujita.
4.5.6 pl20 does not induce nuclear localisation of E-cad/CTF3.
To further examine the specificity of the effect of p i20 on inducing nuclear 
localisation and modification of E-cad/CTF2, the effect of p i20 on another E- 
cadherin fragment, E-cad/CTF3, that is released into the cytosol following 
cleavage by caspase-3, was investigated. In this experiment the construct of E- 
cad/CTF3 described in Figure 4.ID was used. When E-cad/CTF3 alone was 
expressed, it was not detected in the nuclear fraction (Figure 4.12). The 
expression of p i20 enhanced neither nuclear localisation nor modification of E- 
cad/CTF3 (Figure 4.12). This suggests that effect of p i20 on the enhancement of 
nuclear localisation and modification is specific to E-cad/CTF2.
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Figure 4.12 p120 does not induce nuclear localisation of E-cad/CTF3. HEK293 cells 
were transfected with E-cad/CTF3 with and without FLAG-p120, and total and nuclear 
lysates were examined by Western blotting with anti-E-cadherin. Nuclear fractions were 
also examined by Western blotting with anti-CREB binding protein (CBP) antibody.
4.5.7 E-Cad/CTF3 does not bind to pl20
Since caspase-3 cleavage occurs within the CH2 domain that includes the pi 20- 
binding site, this cleavage may impair binding of E-cad/CTF3 to pl20. To 
examine this possibility, the interaction between p i20 and E-cad/CTF2 or E- 
cad/CTF3 was analysed by coimmunoprecipitation. Indeed it was found that E- 
cad/CTF3 was not coimmunoprecipitated with p i20 while E-cad/CTF2 was 
(Figure 4.13). Together with the data in Figure 4.12, this suggests that pl20 
binding is required for the nuclear localisation of the E-cadherin intracellular 
domain.
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Figure 4.13 E-Cad/CTF3 does not bind to p120. FLAG-p120 was transfected with E- 
cad/CTF2 or E-cad/CTF3 in HEK293 cells. Immunoprecipitation was performed using 
anti-FLAG antibody, followed by Western blotting with anti-E-cadherin and anti-FLAG 
antibodies.
4.5.8 pl20-binding is required for the nuclear localisation of E- 
cad/CTF2
To further investigate the requirement of pi 20 binding for its enhancement of E- 
cad/CTF2 nuclear localisation, a mutant form of E-cad/CTF2 which cannot bind 
to pl20 (E-cad/CTF2(AAA)) was used (described in Figure 4. IE). This is a triple 
alanine mutation within the CH2 domain that prevents binding of E-cadherin to 
p i20 (Thoreson et al., 2000). E-Cad/CTF2(AAA) was not present in the nuclear 
fraction and expression of p i20 did not induce nuclear localisation or 
modification of E-cad/CTF2(AAA) (Figure 4.14). These data suggest that the 
direct interaction with E-cad/CTF2 is required for p i20 to enhance nuclear 
localisation and modification of E-cad/CTF2.
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Figure 4.14 p120 binding is required fo r nuclear translocation o f E-cad/CTF2.
HEK293 cells were transfected with E-cad/CTF2(AAA) with or without FLAG-p120 and 
total and nuclear lysates were examined by Western blotting with anti-E-cadherin 
antibody. Nuclear fractions were also examined by Western blotting with anti-CREB 
binding protein (CBP) antibody.
4.5.9 E-Cad/CTF2 binds to pl20 in the nucleus
Figure 4.13 shows by coimmunoprecipitation that E-cad/CTF2 and p i20 bind to 
each other when expressed in HEK293 cells. In order to determine whether E- 
cad/CTF2 and pi 20 also interact with each other in the nucleus, 
coimmunoprecipiation was perfomed using nuclear fractions from HEK293 cells 
transiently transfected with E-cad/CTF2 and p i20 (Figure 4.15). Small amounts 
of exogenously expressed p i20 were detected in the nucleus, and E-cad/CTF2 
was coimmunoprecipitated with p i20 from the nuclear fraction (Figure 4.15). 
This suggests that p i20 and E-cad/CTF2 interact with each other in the nucleus.
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Figure 4.15 E-Cad/CTF2 and p120 interact in the nucleus. Lysates or nuclear 
fractions of HEK293 cells expressing E-cad/CTF2 and FLAG-p120 were 
immunoprecipitated with anti-FLAG antibody or control IgG, followed by Western blotting 
with anti-E-cadherin and anti-FLAG antibodies.
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4.6 Discussion
This chapter describes the crucial role of p i20 in the nuclear localisation of the y- 
secretase cleavage product of E-cadherin, E-cad/CTF2, using several 
experimental systems. Firstly, by immunofluorescence it was observed that 
coexpression of pi 20 enhances nuclear localisation of E-cad/CTF2 in several cell 
lines. Secondly, the processing of full-length E-cadherin and subsequent nuclear 
localisation of the C-terminus was demonstrated using MDCK cells expressing 
C-terminally tagged full-length E-cadherin. Thirdly, using a biochemical nuclear 
fractionation method, the effect of p i20 on the nuclear localisation was 
confirmed and it was shown that this effect is specific for p i20 as other cadherin- 
binding proteins do not induce nuclear translocation of E-cad/CTF2. The 
requirement of p i20 in E-cad/CTF2 nuclear localisation was also demonstrated 
by using siRNA oligos that knock down endogenous p i20. The direct interaction 
between p i20 and E-cad/CTF2 is also required because E-cad/CTF2(AAA) is 
not detected in the nuclear fraction.
The requirement for the direct binding of p i20 for the nuclear localisation of E- 
cad/CTF2 suggests that p i20 must be free from its role at the adherens junction 
in order to play this role in the nuclear translocation of E-cad/CTF2. p i20 is 
sequestered in multiple cellular locations including adherens junctions and 
microtubules (Chen et al., 2003; Franz and Ridley, 2004; Reynolds et al., 1994; 
Yanagisawa et al., 2004). It has been shown that under conditions where E- 
cadherin is down-regulated, p i20 is released into the cytosol (Roczniak- 
Ferguson and Reynolds, 2003; van Hengel et al., 1999). Data in chapter 3 
indicate that E-cad/CTF2 is produced by y-secretase-mediated cleavage when 
cells are treated with HGF (Figure 3.5). HGF treatment of MDCK cells leads to 
the downregulation of E-cadherin at cell-cell contacts both by endocytosis and by 
transcriptional downregulation (Fujita et al., 2002; Grotegut et al., 2006). This 
suggests that under conditions where E-cadherin at cell-cell contacts is being 
downregulated, E-cad/CTF2 is produced and p i20 may be released into the 
cytosol. The requirement of direct binding to p i20 suggests that regulation of
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p i20 subcellular localisation could therefore impact on the control of nuclear 
localisation of E-cad/CTF2.
The mechanism whereby p i20 mediates nuclear translocation of E-cad/CTF2 is 
not clear. As shown in Figure 4.15, E-cad/CTF2 binds p i20 in the nucleus, 
suggesting that the nuclear translocation of E-cad/CTF2 may be mediated 
directly by the stoichiometrical interaction with p i20. E-cad/CTF2 does not 
contain any classical NLS sequences, but p i20 is subject to nucleocytoplasmic 
shuttling (Roczniak-Ferguson and Reynolds, 2003; van Hengel et al., 1999), and 
so E-cad/CTF2 could potentially be carried in to the nucleus by p i20. However, 
it is also possible that the effect of p i20 is mediated catalytically, for example 
through post-translational modification of E-cad/CTF2.
As described in section 1.3.5 (Introduction), the control of p i20 nuclear 
localisation is complex and not fully understood, p i20 contains both NLS and 
NES sequences, although some data suggest that the Arm repeat regions are 
more important for the control of its nuclear localisation (Roczniak-Ferguson and 
Reynolds, 2003). As described in section 1.3.5 (Introduction), the Arm domain 
of Importin-a is its soley functional domain. |3-catenin has been shown to bind 
directly to Importin-P, and it is possible that p i20 could act similarly to promote 
its own nuclear localisation through its Arm domain. This idea raises the 
possibility that p i20 could also promote the nuclear localisation of other 
proteins.
It should be noted that the nuclear localisation of p i20 is not clearly affected by 
the presence of E-cad/CTF2, and p i20 appears to be mainly localised in the 
cytoplasm even when E-cad/CTF2 is in the nucleus (Figures 4.3, 4.4, 4.5 and 
4.15). This could be due to rapid nucleocytoplasmic shuttling of pl20. pl20 may 
remain localised in the nucleus only under certain conditions. For example, it 
was recently shown that expression of a pi 20-binding transcription factor Glis2, 
induces substantial nuclear accumulation of p i20 (Hosking et al., 2007). Thus it 
is possible that E-cad/CTF2 is carried in to the nucleus via its association with 
pi 20, but then is not exported with pi 20. Indeed as only a small amount of p i 20
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is observed in the nucleus under conditions where a large amount of E-cad/CTF2 
is seen in the nucleus (Figure 4.15), some nuclear E-cad/CTF2 may dissociate 
from p i20 under these conditions. This could be due to the binding of E- 
cad/CTF2 to other nuclear proteins that may allow its retention in the nucleus. In 
order to examine these possibilities, the effect of mutations in the NLS, NES, and 
armadillo repeat regions of p i 20 on the nuclear localisation of E-cad/CTF2 could 
be analysed in the future. Furthermore the identification of other nuclear binding 
partners for E-cad/CTF2 could provide further insight into the mechanism of its 
nuclear translocation.
Another possibility for the mechanism of nuclear transport of E-cad/CTF2 by 
p i20 could be that p i20 binding releases E-cad/CTF2 from sequestration in the 
cytosol by some other cytoplasmic binding partner. Overexpression of known E- 
cadherin-cytoplasmic-domain-binding proteins (Tcatenin and Hakai did not 
affect the nuclear localisation of E-cad/CTF2 (Figure 4.11). Hence unidentified 
binding partners of E-cad/CTF2 may be involved. It is interesting to note that E- 
cad/CTF2 behaves differently to N-cad/CTF2 when overexpressed in cells. 
When N-cad/CTF2 was overexpressed in neurons or neural crest cells, it 
localised predominantly in the nucleus (Shoval et al., 2007; Uemura et al., 
2006a). In contrast, E-cad/CTF2 is predominantly localised in the cytoplasm and 
increased nuclear localisation is only observed upon overexpression of p i20. It is 
possible that binding partners specific to N-cad/CTF2 or E-cad/CTF2 might play 
a role in the control of their subcellular localisation.
In summary, this chapter describes the nuclear localisation of E-cad/CTF2 and 
the role of p i20 in its translocation. This raises the possibility of a role for E- 
cad/CTF2 in the nucleus and that E-cad/CTF2, as has been shown for Notch, 
may transmit cellular signals from the membrane to the nucleus.
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CHAPTER 5
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5 POST-TRANSLATIONAL MODIFICATION OF E- 
CAD/CTF2 
5.1 Introduction
In this chapter, the post-translational modification of E-cad/CTF2 is described. 
During the biochemical fractionation studies described in chapter 4, it was 
observed that multiple higher molecular weight modifications of E-cad/CTF2 
were frequently induced by coexpression of pl20 (Figure 4.8A and 4.11). Here it 
is shown that E-cad/CTF2 is ubiquitinated and a potential E3-ubiquitin ligase for 
E-cad/CTF2 is identified. The role of ubiquitination in nuclear transport of E- 
cad/CTF2 is also investigated. Furthermore, it is also shown that E-cad/CTF2 is 
subject to phosphorylation and that this phosphorylation may also impact on the 
control of the nuclear localisation of E-cad/CTF2.
5.2 Ubiquitination of E-cad/CTF2
5.2.1 Ubiquitination of E-cad/CTF2 was identified using a pull-down 
assay with Nickel beads to precipitate His-tagged ubiquitin
Since p i20 frequently induces multiple higher molecular weight modifications of 
E-cad/CTF2 (Figure 4.8A and 4.11), it was investigated whether they may 
represent ubiquitination of E-cad/CTF2. As described in section 1.6 
(Introduction), ubiquitin is a highly conserved 8.5 kDa regulatory protein that 
can be covalently attached to lysine residues of proteins. Ubiquitin molecules can 
also covalently link to other ubiquitin monomers to form chains. This process is 
known as polyubiquitination and can result in the appearance of multiple slower 
running bands when the protein sample is examined by SDS-PAGE and Western 
blotting. Since a similar ‘upsmear’ of modification of E-cad/CTF2 was often 
observed when p i20 is overexpressed, His-tagged ubiquitin was over-expressed 
together with E-cad/CTF2 and/or p i20 in HEK293 cells and used in a pull-down 
assay to determine whether E-cad/CTF2 is ubiquitinated. His-tagged proteins can 
be precipitated from cell lysates using Nickel conjugated to agarose (DePace et
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al., 1998; Kingsbury et al., 2000). Analysis of total HEK293 cell lysates showed 
that expression of His-tagged ubiquitin (His-Ub) induced modifications of E- 
cad/CTF2 that were of the expected size for the addition of 1 and 2 ubiquitin 
monomers (indicated by arrowheads, Figure 5.1, left panel). pl20 expression 
also induced modification of E-cad/CTF2 of the expected size for the addition of 
one ubiquitin monomer (Figure 5.1, left panel, lane 4). The intensity of both 
higher molecular weight bands induced by His-Ub expression was increased by 
pl20 expression (Figure 5.1, left panel, lane 5). The band of expected size for 
addition of one ubiquitin monomer was precipitated specifically by Nickel beads 
(indicated by arrow, Figure 5.1, right panel, lanes 3 and 5). This suggests that 
p i20 induces ubiquitination of E-cad/CTF2. It should be noted that the extent of 
modifications varied between experiments (see section 5.6 for further discussion 
of this issue). In this experiment higher molecular weight modifications were not 
detected. However the possibility that the higher molecular weight modifications 
previously observed (Figure 4.8A and Figure 4.11) may be due to 
polyubiquitination or other ubiquitin-like modifiers cannot be ruled out.
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E-cad/CTF2 -  +  +  +  +
His-Ub +  -  +  -  +
FLAG-p120 +  -  -  +  +
-  + +  +  +  
+  -  +  -  +  
+  + +
Figure 5.1 E-Cad/CTF2 is ubiquitinated. Nickel (Ni)-agarose beads were incubated 
with lysates of HEK293 cells expressing E-cad/CTF2 together with FLAG-p120 and or 
His-tagged ubiquitin (His-Ub). The proteins bound to the beads were analysed by 
Western blotting with anti-E-cadherin antibody. *, High background was observed with 
this technique and although background was reduced by elution of the proteins bound to 
the Ni-agarose with imidazole, unmodified E-cadherin was non-specifically precipitated 
with the Ni-agarose. Arrowheads indicate modifications of E-cad/CTF2 of the molecular 
size expected for the addition of 1 or 2 ubiquitin monomers. An arrow indicates the band 
induced by expression of both p120 and His-Ub which is specifically precipitated by Ni- 
agarose.
5.2.2 E-Cad/CTF2 and its modified bands are not stabilised by 
treatment with the proteasome inhibitor MG132
Ubiquitination of proteins has a variety of roles such as protein degradation in 
the proteasome, signalling, and intracellular protein transport including nuclear 
import (Geetha et al., 2005; Hochstrasser, 2004; Li et al., 2003; Mukhopadhyay 
and Riezman, 2007; Pickart, 2001; Shcherbik and Haines, 2004). Because 
coexpression of p i20 and ubiquitin did not induce destabilisation of E-cad/CTF2 
it seemed unlikely that ubiquitination targets E-cad/CTF2 for proteasomal 
degradation. To examine whether ubiquitination of E-cad/CTF2 leads to its 
degradation in the proteasome, HEK293 cells expressing E-cad/CTF2 with and 
without p i20 were treated with a proteasome inhibitor, MG132 (Figure 5.2). If 
E-cad/CTF2 was targeted for degradation in the proteasome, treatment with 
MG 132 should result in a stabilisation of E-cad/CTF2 and its modified bands. No 
significant stabilisation of E-cad/CTF2 or the modified bands was observed upon
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incubation with MG132 (Figure 5.2). This indicates that it is unlikely that E- 
cad/CTF2 is being targeted for degradation in the proteasome.
E-cad/CTF2 -  +  +  ■  +  +
FLAG-p120 +  -  +  +  -  +
MG132 -  -  -  +  +  +
Figure 5.2 E-Cad/CTF2 is not stabilised by treatment with MG132. HEK293 cells 
expressing E-cad/CTF2 together with FLAG-p120 were incubated with MG132 (20 uM) 
for 6 h. Total cell lysates were examined by Western blotting with anti-E-cadhenn 
antibody.
5.2.3 Ubiquitination of E-cad/CTF2 can enhance nuclear localisation 
of E-cad/CTF2
As p i20 induces ubiquitination and nuclear translocation of E-cad/CTF2, it was 
investigated whether ubiquitination may play a role in its nuclear translocation. 
When HA-ubiquitin (HA-Ub) was coexpressed with E-cad/CTF2, slower 
migrating bands of E-cad/CTF2 were induced (Figure 5.3, left panel, fourth 
lane). Interestingly, coexpression of ubiquitin also enhanced nuclear localisation 
of E-cad/CTF2 (Figure 5.3, right panel, fourth lane). Coexpression of ubiquitin 
and p i20 further enhanced the amounts of these modified bands and nuclear 
localisation of E-cad/CTF2 (Figure 5.3, left and right panels, sixth lane). A 
mutant form of ubiquitin (Ub (K 11, 27, 29, 48, 63 R) (HA-mut-Ub), which 
cannot form poly-ubiquitin chains, did not affect either nuclear translocation or 
modifications of E-cad/CTF2 (Figure 5.3, left and right panels, fifth and seventh 
lanes). Ubiquitinated forms of E-cad/CTF2 were not usually observed in the 
nuclear fraction (see Section 5.6 for further discussion). These data provide 
further supporting evidence that p i20 potentiates ubiquitination of E-cad/CTF2.
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The enhancement of multiple higher molecular weight modifications by HA-Ub, 
but not by HA-mut-Ub which cannot form polyubiquitin chains, suggests that E- 
cad/CTF2 can be polyubiquitinated. The data in Figure 5.3 also suggest that 
ubiquitination can play a role in the nuclear localisation of E-cad/CTF2. It should 
be noted that the extent of modifications did not always correspond with the 
extent of E-cad/CTF2 nuclear localisation; ubiquitin overexpression has a strong 
effect on inducing ubiquitination of E-cad/CTF2 but a weaker effect on nuclear 
localisation. This suggests that there is also a modification-independent 
molecular mechanism for the nuclear localisation of E-cad/CTF2.
Total lysate Nucleus
WB: E-Cad
E-Cad/CTF2 -  + + + + + +  - + + + + + +  
FLAG-p120+- +  -  - + +  + -  +  - - +  +  
HA-Ub+  -  -  +  -  +  -  
HA-mut-Ub -  -  -  +  -  +
Figure 5.3 Overexpression of ubiquitin enhances the nuclear localisation and 
modification of E-cad/CTF2. HEK293 cells were transfected with E-cad/CTF2 together 
with FLAG-p120 and/or HA-ubiquitin (HA-Ub) or HA-ubiquitin(K11, 27, 29, 48, 63 R) 
(HA-mut-Ub). Total and nuclear lysates were examined by Western blotting with anti-E- 
cadherin antibody.
5.2.4 Lysine 48- and lysine 63- conjugated Ubiquitin are both
involved in the modification and nuclear translocation of E- 
cad/CTF2
As described in section 1.6.2 (Introduction), the type of ubiquitin linkages used 
in the formation of polyubiquitin chains, can affect its molecular function (Sun 
and Chen, 2004; Varadan et al., 2004). It is generally thought that lysine 48- 
linked polyubiquitin chains target proteins to the proteasome for degradation 
whereas lysine 63-linked polyubiquitin chains have other signalling roles (Sun
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and Chen, 2004). However it is now clear that lysine 48-linked polyubiquitin 
chains have other roles besides the targeting of proteins for proteasomal 
degradation (Hochstrasser, 2004). To determine whether E-cad/CTF2 is modified 
by lysine-48- or lysine-63-conjugated polyubiquitin chains, two further ubiquitin 
mutants were used: HA-Ub(K48R) in which lysine residue 48 of ubiquitin is 
mutated to arginine preventing it from forming lysine-48-linked chains; and HA- 
Ub(K63R) in which lysine residue 63 of ubiquitin is mutated to arginine 
preventing it from forming lysine-63-linked chains. As is also shown in Figure
5.3, cotransfection of wild type HA-Ub led to enhancement of modification of E- 
cad/CTF2 (Figure 5.4, left panel, lanes 4 and 5). Cotransfection of wild type HA- 
Ub also enhanced the pl20-mediated-nuclear localisation of E-cad/CTF2 (Figure
5.4, right panel, lane 5). Neither cotransfection of HA-Ub(K48R) nor FLA- 
Ub(K63R) lead to enhancement of modification of E-cad/CTF2 (Figure 5.4, left 
panel, lanes 6-9). This suggests that both lysine-48- and lysine-63-ubiquitin- 
linkages are involved in the modification of E-cad/CTF2. Enhancement of the 
nuclear localisation induced by p i20 was not enhanced by either HA-Ub(K48R) 
or HA-Ub(K63R) (Figure 5.4, right panel, lanes 7 and 9), suggesting the 
involvement of both these types of ubiquitin-conjugations in nuclear 
translocation of E-cad/CTF2.
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E-cad/CTF2 - + + + + + + + + - + + + + + + + +
FLAG-p120 +  - + - + - + -  + +  - + - + - + -  +
HA-Ub ------------ + + ------------------ ------------ + + -------------------
HA-Ub(K48R) ----------------------+ + - - ---------------------- + + - -
HA-Ub(K63R) ---------------------------- +  + -----------------------------+  +
Figure 5.4 Lysine-48- and Lysine-63-conjugated ubiquitination are both involved in 
the modification and nuclear translocation of E-cad/CTF2. HEK293 cells were 
transfected with E-cad/CTF2 together with FLAG-p120 and/or FIA-ubiquitin (FIA-Ub) or 
HA-Ub(K48R) or HA-Ub(K63R). Total and nuclear lysates were examined by Western 
blotting with anti-E-cadherin antibody
5.2.5 Ubiquitination is not the only mechanism for the pl20-induced 
nuclear translocation of E-cad/CTF2
The role of ubiquitination in the nuclear localisation of E-cad/CTF2 was further 
examined by mutating all the lysine residues within E-cad/CTF2 to arginine. The 
location of the four lysine residues in E-cad/CTF2 that are potenital targets for 
ubiquitination are shown in Figure 5.5.
734
CH2
domain
E-cad/CTF2
K
CH3
domain 884
KK
Figure 5.5 Location of lysine residues in E-cad/CTF2. E-Cad/CTF2 contains four 
lysine residues (K) that are potential targets for ubiquitination.
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E-Cad/CTF2(RRRR) was produced by site-directed mutagenesis. In this mutant 
the lysine residues at positions 740, 818, 861 and 863 were all mutated to 
arginine. Thus E-cad/CTF2 (RRRR) cannot be ubiquitinated. No higher 
molecular weight bands of E-cad/CTF2(RRRR) were observed when it was 
coexpressed with pl20 and/or ubiquitin (Figure 5.6, left panel), indicating that 
the modification of E-cad/CTF2 indeed occurs on lysine residues. Coexpression 
of ubiquitin did not induce enhanced nuclear localisation of E-cad/CTF2(RRRR), 
however p i20 was still able to enhance its nuclear localisation (Figure 5.6, right 
panel). Together these data suggest that while ubiquitination can play some role 
in enhancing nuclear localisation of E-cad/CTF2, it is not required for pi 20- 
induced nuclear translocation of E-cad/CTF2. It seems likely that p i20 enhances 
nuclear localisation of E-cad/CTF2 via a ubiquitin-independent pathway.
Total Nucleus
E-cad/CTF2(RRRR)
FLAG-p120
HA-Ub
WB: E-Cad
Figure 5.6 p120 enhances nuclear localisation of E-cad/CTF2(RRRR) in which all 
lysine residues were mutated to arginine. HEK293 cells were transfected with E- 
cad/CTF2(RRRR) together with FLAG-p120 and/or HA-ubiquitin (HA-Ub). Total and 
nuclear lysates were examined by Western blotting with anti-E-cadherin antibody.
5.2.6 The modified bands of E-cad/CTF2 could not be recognised by 
Western blotting with anti-ubiquitin or anti-SUMO antibodies.
As shown in Figures 4.8A and 4.11, coexpression of pl20 frequently enduces 
higher molecular weight modifications of E-cad/CTF2, that are detected in total 
lysates even in the absence of overexpressed ubiquitin. It was next examined 
whether these bands, produced in the absence of overexpressed ubiquitin, could
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be detected by Western blotting with an anti-ubiquitin antibody. Lysates from 
HEK293 cells transfected with E-cad/CTF2 and p i20 were immunoprecipitated 
with anti-E-cadherin antibody and the immunoprecipitates were then examined 
by Western blotting. Western blotting with anti-E-cadherin antibody showed that 
the bands representing modification were immunoprecipitated and that p i20 
enhanced the appearance of the modified bands (Figure 5.7A). When 
imunoprecipitates were analysed with anti-Ubiquitin (Ub) antibody, although 
some background bands appeared in all lanes, no bands could be detected that 
were specifically enhanced by p i20 expression (Figure 5.7B). This does not rule 
out the possibility that the modifications are ubiquitination since the ubiquitin 
antibody may have a lower sensitivity than the E-cadherin antibody. Indeed in 
many cases overexpression of ubiquitin is used to detect ubiquitination of 
proteins (Chung et al., 2004; Matsuzaki et al., 2003).
Since p i20 induces both modification and nuclear localisation of E-cad/CTF2, 
the immunoprecipitates were also analysed by Western blotting with an anti- 
SUMO (small ubiquitin-related modifier) antibody (Figure 5.7C). As described 
in section 1.6.2 (Introduction), SUMO is a 12 kDa protein which is attached to 
proteins in an analogous way to ubiquitination. SUMOylation of proteins 
frequently leads to their nuclear localisation (Johnson, 2004; Seeler and Dejean, 
2003). However no specific pl20-enhanced bands were detected with the anti- 
SUMO antibody (Figure 5.7C).
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Figure 5.7 The higher molecular weight modified bands of E-cad/CTF2 were not 
recognised with anti-Ubiquitin (Ub) or anti-SUMO antibodies. Lysates of HEK293 
cells expressing E-cad/CTF2 with and without FLAG-p120 were immunoprecipitated 
with anti-E-cadherin antibody, followed by Western blotting with (A) anti-E-cadherin, (B) 
anti-Ubiquitin (Ub), and (C) anti-SUMO antibodies. *, heavy chain of IgG.
5.3 Characterisation of a novel p120-binding protein, 
Ret Finger Protein, which is a candidate as a novel 
E3-ligase for E-cad/CTF2
5.3.1 Ret Finger Protein, a novel binding partner of pl20
In sections 5.2 and 5.3, E-cad/CTF2 was shown to be ubiquitinated and this 
ubiquitination was also shown to have a role in its nuclear localisation of E- 
cad/CTF2. As described in section 1.6.1 (Introduction), the final step of the 
ubiquitin-conjugation pathway is carried out by an E3-ubiquitin-ligase. E3- 
ubiquitin-ligases are usually specific for the protein substrate which receives the 
ubiquitin conjugation (Laney and Hochstrasser, 1999). Therefore it is likely that 
p i20 recruits an E3-ligase which can ubiquitinate E-cad/CTF2. As described in 
section 1.4.4 (Introduction) Hakai is an E3-ubiquitin-ligase for full length E- 
cadherin and is involved in down-regulation of E-cadherin at cell-cell contacts, 
by ubiquitinating E-cadherin and triggering its endocytosis (Fujita et al., 2002; 
Tricaud et al., 2005). However Hakai and p i20 were shown to compete for 
binding to the intracellular domain of E-cadherin (Fujita et al., 2002), and so it is
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unlikely that Hakai could be the E3-ubiquitin ligase in this case. Indeed, it was 
shown in Figure 4.11 (Chapter 4) that expression of Hakai alone did not affect 
the ubiquitination or nuclear localisation of E-cad/CTF2, suggesting that another 
E3-ligase may be required for ubiquitination of E-cad/CTF2.
Ret Finger Protein (RFP) was identified as a candidate pi 20-binding protein in a 
Yeast-2-Hybrid screen carried out by Dr. Yasuyuki Fujita. Figure 5.8 shows in 
brief the principle of the Yeast-2-Hybrid screening procedure.
Figure 5.8 Yeast-2-Hybrid screening. The bait gene (X) is fused to the Lex A DNA 
binding domain (bd). Prey genes are fused to the VP16 activation domain (ad). This bait 
construct is transfected into yeast along with a LacZ reporter construct. The LexA bd 
binds to LexA binding sites in the minimal promotor region of the LacZ reporter 
construct. When the gene products o f X  and Y interact, the VP16 activation domain is 
brought into proximity of the promotor region and transcription from LacZ is activated 
(Proof o f concept described in (Fields and Song, 1989)).
In this screen a Hollenberg (mouse embryo) cDNA library was screened using 
the open reading frame of mouse pi 20 protein iso form B as the ‘bait’ gene. RFP 
was identified as a potential binding partner. As described in section 1.6.3 
(Introduction), RFP is a protein whose biological function is not fully 
characterised. It has been shown to regulate transcription and to shuttle in and 
out of the nucleus.
RFP contains three major protein interaction domains: a RING finger domain, a 
B-box domain, and a coiled-coil protein interaction domain (Figure 5.9). It is a 
member of the TRIM/RBCC family of proteins which contain all three motifs 
depicted in Figure 5.9. The yeast-2-hybrid screen showed that the coiled-coil 
region is responsible for the binding to pl20. As described in section 1.6.1, many 
E3-ubiquitin-ligases including Hakai contain RING finger domains, which are 
vital to their function. Thus, RFP is a possible candidate as an E3-ubiquitin- 
ligase for E-cad/CTF2. Indeed, several TRIM/RBCC proteins have been shown 
to have E3-ubiquitin ligase activity (Meroni and Diez-Roux, 2005).
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Figure 5.9 Domain structure of Ref Finger Protein (RFP). RFP contains a RING finger 
domain, a B box domain and a Coiled-coil region.
5.3.2 Confirmation of the interaction of pl20 and RFP
To validate the interaction of p i20 and RFP, a GST pull-down assay was first 
performed. RFP fused to GST in a bacterial expression vector pGEX, was 
constructed (see table 2.5, section 2.1.11 Materials and Methods, for details) and 
expressed in E.coli. Although good expression levels of GST-RFP were 
achieved, GST-RFP could not be solubilised in either Triton-X-100 (Figure 
5.10A) or RIPA (Figure 5.10B) lysis buffers. Therefore GST-RFP could not be 
recovered in the supernatant of the clarified lysate or following precipitation with 
glutathione-sepharose (Figure 5.10 A and B). Bacterially expressed recombinant 
proteins can become accumulated in inclusion bodies (Hoffmann et al., 2001). 
Hence to solubilise GST-RFP, inclusion bodies were solubilised in mildly 
denaturing conditions. Following clarification, the soluble fraction was dialysed 
against a neutral pH buffer containing a reducing agent to encourage correct 
disulfide bond formation. This was then followed by a second dialysis step to 
remove excess reducing agent. GST-RFP could then be precipitated with 
glutathione-sepharose, and its concentration was determined (Figure 5.11).
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Figure 5.10 Insolubility of bacteria Ily expressed GST-RFP. (A and B) E. coli were 
transformed with pGEX-RFP and cultured as described in section 2.3.4 (Materials and 
Methods). After lysis in (A) Triton X-100 lysis buffer and (B) RIPA buffer, lysates were 
sonicated and centrifuged. Aliquots of the original (before centrifugation), supernatant 
and glutathione-sepharose-beads precipitate were analysed on an SDS-PAGE gel and 
proteins were visualized with Coomassie protein staining. Expression of GST-RFP was 
observed in the original (indicated with arrows), but was not solubilised and therefore not 
found in the supernatant or glutathione precipitate.
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Figure 5.11 Determination of the concentration of GST-RFP. GST-RFP-conjugated 
sepharose beads were prepared using 250, 500 and 1000 pi o f GST-RFP protein 
sample (indicated with arrow). GST protein is at 1.3 ug/ul therefore GST-conjugated 
sepharose beads were prepared using 19, 33, 71, 153 and 300 pi of GST protein 
sample. From comparison of the band sizes, it was estimated that the GST-RFP 
concentration is 25 ng/pl.
Next the interaction between p i20 and RFP was examined by GST pull-down 
assay. GST-RFP specifically precipitated p i20 from lysates of HEK293 cells 
(Figure 5.12). To further confirm the interaction between p i20 and RFP, an 
endogenous coimmunoprecipitation was performed. Endogenous p i20 from 
lysates of HEK293 cells was precipitated by anti-RFP antibody but not by 
control IgG (Figure 5.13). Taken together, these data indicate a specific 
interaction between p i20 and RFP.
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Figure 5.12 p120 interacts with RFP in a GST pull-down assay. Beads coupled to 
GST or GST-RFP were incubated with lysates o f HEK293 cells. The proteins bound to 
the beads were analysed by Coomassie staining and Western blotting with anti-p120 
antibody. The arrow and arrowhead indicate the positions of GST-RFP and GST, 
respectively.
Input
WB: p120
WB: RFP
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WB: p120
Figure 5.13 p120 interacts with RFP in an endogenous immunoprecipitation.
Lysates of HEK293 cells were immunoprecipitated by anti-RFP antibody or control IgG. 
Inputs were examined by Western blotting with anti-p120 and anti-RFP antibodies. 
Immunoprecipitates (IP) were examined by Western blotting with anti-p120 antibody. It 
was not possible to examine immunoprecipitates with anti-RFP antibody since the heavy 
chain of IgG is of the same molecular size as RFP.
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5.3.3 RFP enhances modification of E-cad/CTF2
It was next examined whether RFP acts as an E3 ubiquitin ligase for E- 
cad/CTF2. Coexpression of RFP in HEK293 cells lead to enhanced 
ubiquitination of E-cad/CTF2, comparable to that observed with p i20 
overexpression (Figure 5.14). These data provide supporting evidence that RFP 
may act as an E3-ubiquitin-ligase for E-cad/CTF2.
WB: E-Cad
E-Cad/CTF2 -  +  +  +
FLAG-p120 +  -  +  -
FLAG-RFP +  -  -  +
Figure 5.14 RFP enhances ubiquitination of E-cad/CTF2. HEK293 cells were 
transfected with E-cad/CTF2 together with FLAG-p120 or FLAG-RFP. Total cell lysates 
were examined by Western blotting with anti-E-cadherin antibody.
5.3.4 RFP enhances the nuclear localisation of E-cad/CTF2
Since ubiquitination plays a role in increasing the nuclear localisation of E- 
cad/CTF2, and RFP enhances the ubiquitination of E-cad/CTF2, it was next 
investigated whether RFP affects E-cad/CTF2 nuclear localisation. Expression of 
p i20 or RFP increased both ubiquitination and nuclear localisation of E- 
cad/CTF2 (Figure 5.15, left and right panels). Coexpression of p i20 and RFP 
further enhanced the ubiquitination and nuclear localisation of E-cad/CTF2 
(Figure 5.15, left and right panels). These data provide further support for a role 
of RFP in the ubiquitination of E-cad/CTF2 and for the role of ubiquitination in 
nuclear localisation of E-cad/CTF2.
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Figure 5.15 RFP enhances nuclear localisation of E-cad/CTF2. HEK293 cells were 
transfected with E-cad/CTF2 together with FLAG-p120 and/or FLAG-RFP.Total and 
nuclear lysates were examined by Western blotting with anti-E-cadherin antibody.
5.4 Phosphorylation of E-cad/CTF2 and its role in the 
nuclear localisation of E-cad/CTF2
5.4.1 E-cad/CTF2 is phosphorylated
It was observed in several experiments that when expressed in HEK293 cells, E- 
cad/CTF2 appears as a doublet when examined by Western blotting. To 
demonstrate this, part of Figure 5.4 is shown repeated below1, with the doublet of 
E-cad/CTF2 indicated with arrowheads. Interestingly, only the upper band of the 
doublet is found in the nuclear fraction (indicated with an arrow, part of Figure
5.4, repeated below1). It was investigated whether these bands may represent 
different phosphorylation states of E-cad/CTF2. To test whether phosphorylation 
affects the doublet bands of E-cad/CTF2, HEK293 cells expressing E-cad/CTF2 
were first treated with Okadaic Acid (OA), an inhibitor of the protein 
phosphatases PP1 and PP2A. Treatment with OA led to a loss of the lower band
'Part o f  Figure 5.4
(repeat)
Total Nucleus
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of the doublet (Figure 5.16, compare lanes 5 and 6 with lanes 7 and 8). This 
suggests that the doublet represents different phosphorylation states of E- 
cad/CTF2. Coexpression of pi 20 did not significantly affect the phosphorylation 
of E-cad/CTF2 (Figure 5.16).
WB: E-Cad
E-Cad/CTF2 -  - -  - +  +  +  +
FLAG-p120 “ + " + " + “  +
Figure 5.16 Phosphorylation of E-cad/CTF2. HEK293 cells were transfected with E- 
cad/CTF2 and/or FLAG-p120 and then treated with Okadaic acid (OA) (3.13 ng/ml) for 4 
hr. Total cell lysates were examined by Western blotting with anti-E-cadherin antibody.
To further examine the phosphorylation of E-cad/CTF2, lysates of HEK293 cells 
expressing E-cad/CTF2 were immunoprecipitated with anti-E-cadherin antibody 
and then treated with X phosphatase. Immunoprecipitates treated with X 
phosphatase showed a shift from the upper band of the doublet to the lower band 
(Figure 5.17). This provides further evidence that E-cad/CTF2 is phosphorylated. 
Together with previous data showing that only the upper band of the doublet is 
found in the nucleus (Figure 5.4), these data raise the interesting possibility that 
phosphorylation may also regulate the nuclear translocation of E-cad/CTF2.
+OA -OA +OA -OA
 +   
- - - + - +
Input
WB: E-Cad
IP: E-Cad 
WB: E-Cad
E-Cad/CTF2 +  +  + - - -
X-Buffer -  +  +  ■  - f  " f
X -Phosphatase +
Figure 5.17 E-Cad/CTF2 is dephosphorylated by treatment with A phosphatase.
Lysates of HEK293 cells transfected with E-cad/CTF2 were immunoprecipitated by anti- 
E-cadherin antibody and then treated with A buffer with or without A phosphatase (100 
units) for 30 minutes at 30 °C. Cell lysates (Input) and immunoprecipitates were 
examined by Western blotting with anti-E-cadherin antibody.
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5.4.2 Casein Kinase 1 can phosphorylate E-cad/CTF2 and influence 
its nuclear localisation
It was recently shown by the Fujita lab that Casein Kinase 1 (CK1) 
phosphorylates the cytoplasmic domain of E-cadherin resulting in the down- 
regulatation of E-cadherin at cell-cell contacts (Dupre-Crochet et al., 2007). To 
investigate whether CK1 could influence the phosphorylation state and nuclear 
localisation of E-cad/CTF2, HEK293 cells transfected with E-cad/CTF2 together 
with p i20 were treated with IC261, a specific inhibitor of CK1. Treatment with 
IC261 led to a mild increase in the lower, dephosphorylated form of the doublet 
(Figure 5.18), suggesting that treatment with CK1 inhibitor increases the amount 
of the dephosphorylated form of E-cad/CTF2. This suggests that CK1 may be 
involved in the phosphorylation of E-cad/CTF2, but that other kinases are also 
involved. Treatment with IC261 also reduced the amount of E-cad/CTF2 found 
in the nuclear fraction (Figure 5.18). This may suggest that the loss of the 
phosphorylated form of E-cad/CTF2 in these conditions leads to less nuclear 
translocation. However, the effect of IC261 on nuclear localisation is greater than 
the observed effect on the doublet, possibly suggesting that other proteins 
phosphorylated by CK1 could also affect the nuclear localisation of E-cad/CTF2.
Total Nucleus
30- WB: E-Cad
IC261 +  -  +
E-Cad/CTF2 +  +  +  +  +  +  +  +
FLAG-p120 ™ +  ™ +  ™ +  ™ +
Figure 5.18 Treatment with the CK1 inhibitor leads to dephosphorylation of E- 
cad/CTF2 and decreases its nuclear localisation. HEK293 cells transfected with E- 
cad/CTF2 with or without p120 were treated with IC261 (5 ug/ml) for 4 h. Total and 
nuclear lysates were examined by Western blotting with anti-E-cadherin antibody.
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To further investigate the effect of CK1 on the phosphorylation of E-cad/CTF2, 
myc-tagged constructs of two isoforms of CK1 were made (see table 2.3, section 
2.1.11, Materials and Methods, for details). As described in section 1.4.4 
(Introduction), there are at least seven isoforms of CK1 found in human cells, but 
C K la and CKle are the most frequently expressed in tissues (Knippschild et al., 
2005). Thus these two isoforms were used in expression studies. Phosphorylation 
often acts as a priming event for ubiquitination of proteins, for example CK1 
phosphorylation of (3-catenin induces ubiquitination of (3-catenin by the APC 
complex (Polakis, 2002). Since E-cad/CTF2 is subject to both phosphorylation 
and ubiquitination, and both of these post-translational modifications have a 
positive effect on the nuclear translocation of E-cad/CTF2, the effect of 
expressing C K la and CKle on both ubiquitination and nuclear translocation of 
E-cad/CTF2 was examined. Coexpression of C K la or CKle lead to a mild 
upregulation of both ubiquitination and nuclear translocation of E-cad/CTF2 
(Figure 5.19). However, it was difficult to see a clear effect on the doublet bands 
(Figure 5.19). Taken together, these data suggest that CK1 can phosphorylate E- 
cad/CTF2 which enhances both its ubiquitination and nuclear localisation. 
However it seems likely that other kinases are also involved in the 
phosphorylation of E-cad/CTF2.
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WB: E-Cad
E-Cad/CTF2 -  +  +  +  
Myc-CK1a +  "  +  ™ 
Myc-CK1e +  -  -  +
Figure 5.19 CK1 enhances ubiquitination and nuclear localisation of E-cad/CTF2.
HEK293 cells were transfected with E-cad/CTF2 together with CK1a and CK1 s. Total 
and nuclear lysates were examined by Western blotting with anti-E-cadherin antibody.
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5.5 Discussion
In this chapter, the post-translational modification of E-cad/CTF2, and the 
involvement of these post-translational modifications in the regulation of E- 
cad/CTF2 nuclear localisation were described. By expressing ubiquitin 
constructs together with p i20, ubiquitination of E-cad/CTF2 was observed. Pull­
down of His-tagged ubiquitin with Nickel beads showed that lowest band in the 
‘upsmear’ of modifications is ubiquitin. Polyubiquitination was also shown to 
occur using HA-ubiquitin and HA-mutant-ubiquitin that cannot form 
polyubiquitin chains. Both K48- and K63-conjugated ubiquitin chains were 
shown to be involved in the ubiquitination of E-cad/CTF2. The data in this 
chapter also show that ubiquitination of E-cad/CTF2 can enhance its nuclear 
localisation. RFP has been identified as a RING-finger-domain-containing 
protein which binds p i20. Expression of RFP also enhances ubiquitination and 
nuclear localisation of E-cad/CTF2 and is therefore a potential candidate as an 
E3-ubiquitin ligase for E-cad/CTF2. Finally, it was shown that E-cad/CTF2 is 
phosphorylated and only the more phosphorylated form is found in the nucleus. 
CK1 may play a role in the phosphorylation of E-cad/CTF2 and its nuclear 
localisation.
As noted in chapter 4, the amount of ubiquitination varies between experiments. 
Ubiquitinated forms of E-cad/CTF2 are sometimes observed in the nuclear 
fraction (Figure 5,16), but in most experiments, ubiquitinated E-cad/CTF2 
cannot be observed in the nuclear fraction. It is highly likely that despite the 
addition of the .V-ethylmaleimide to inhibit de-ubiquitination, the de- 
ubiquitination of E-cad/CTF2 occurs very rapidly upon cell lysis. Indeed it was 
noted that the ubiquitinated bands were frequently lost when the lysates were 
stored for a longer period. As the process of nuclear fractionation takes longer 
than the preparation of total cell lysates, this could be one explanation for the 
loss of ubiquitinated forms of E-cad/CTF2 from the nuclear fraction. However it 
is also possible that E-cad/CTF2 becomes de-ubiquitinated when it enters the 
nucleus of cells.
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Despite several attempts, it was not possible to detect the ubquitin bands by 
Western blotting with anti-ubiquitin antibody, although ubiquitination could be 
observed upon expression of ubiquitin constructs. While the expression studies 
show that E-cad/CTF2 is ubiquitinated, it cannot be excluded that other 
ubiquitin-like modifiers are involved in the modification of E-cad/CTF2. Mass 
spectrometry could be used to formally identify these bands. However it was not 
possible to detect the modified bands of E-cad/CTF2 on an SDS-PAGE gel using 
either sensitive coomassie, SYPRO® Ruby or silver staining, even when > 5 x 
106 cells were used per experiment. Thus it was not possible to isolate the 
modified bands for identification by mass spectrometry. The inability to detect 
the bands on an SDS-PAGE gel by any of these methods suggests that the level 
of E-cad/CTF2 protein is not very high, or that the levels of ubiquitination is low, 
which could explain why it was not possible to detect ubiquitination with anti- 
ubiquitin antibody.
Induction of ubiquitination by expression of p i20, RFP or ubiquitin did not 
induce destablisation of E-cad/CTF2. Furthermore, the stability of E-cad/CTF2 
or its ubiquitinated forms were not affected by inhibition of the proteasome. 
These data suggest that it is unlikely that ubiquitination of E-cad/CTF2 is 
involved in the targeting of E-cad/CTF2 for degradation in the proteasome. 
Ubiquitination has many other roles in signalling and intracellular transport, 
including nuclear import (Geetha et al., 2005; Hochstrasser, 2004; Li et al., 2003; 
Mukhopadhyay and Riezman, 2007; Pickart, 2001; Shcherbik and Haines, 2004). 
As described in section 1.6.2, different ubiquitin linkages form structurally 
different polyubiquitin chains and are thought to have different roles (Sun and 
Chen, 2004; Varadan et al., 2004). Lysine-48-linked polyubiquitin chains have 
classically been thought to target proteins for degradation, whereas lysine-63- 
linked polyubiquitin chains have roles in signalling and intracellular transport of 
proteins (Sun and Chen, 2004). Lysine-63-linked chains have a more open 
comformation with more hydrophobic surfaces exposed, which may provide an 
interface for the interaction with other proteins. Indeed a recent study showed 
that lysine-63-conjugated polyubiquitination induces the nuclear import of 
neurotrophin receptor interacting factor (NRIF) (Geetha et al., 2005). In this 
chapter, the results using mutant ubiquitin constructs (K48R and K63R) suggest
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that both lysine-48- and lysine-63- linked ubiquitin chains are involved in the 
modification and nuclear import of E-cad/CTF2. It is not clear whether this 
represents polyubiquitin chains with mixed linkages or whether there maybe 
more than one polyubiquitin chain, each containing a single type of linkage, 
conjugated to the different lysine residues within E-cad/CTF2. As described in 
1.6.2, lysine-48-linked chains have also been shown to have roles other than 
targeting proteins to the proteasome (Hochstrasser, 2004). It appears that lysine- 
48-linked chains as well as lysine-63-linked chains are involved in regulating the 
nuclear localisation of E-cad/CTF2, however it cannot be ruled out that other 
types of ubiquitin linkages may also be involved.
While ubiquitination enhances the nuclear localisation of E-cad/CTF2, studies of 
the nuclear localisation of E-cad/CTF2(RRRR), in which all of the lysine 
residues were mutated to arginine thus preventing ubiquination, suggest that 
p i20 can induce nuclear transport of E-cad/CTF2 by a ubiquitin-independent 
mechanism. Nuclear localisation of E-cad/CTF2(RRRR) was not changed upon 
coexpression of ubiquitin. However, p i20 induced nuclear localisation of E- 
cad/CTF2(RRRR), indicating a ubiquitin-independent mechanism. This 
mechanism may involve either direct nuclear import via the interaction with 
p i20 or the release of E-cad/CTF2 from sequestration from another cellular 
location (see section 4.6 for further discussion). How ubiquitination enhances the 
nuclear localisation of E-cad/CTF2 is also still unclear. Addition of ubiquitin to 
the E2-conjugating enzymes UbcM2, UbcH6 and UBE2E2 has been shown to 
enhance their nuclear translocation. The addition of ubiquitin to these proteins 
enhances their binding to importin-11, which promotes their nuclear localisation 
(Plafker et al., 2004). However, as described in section 1.6.1, this linkage is a 
thioester linkage, which results in the ‘ubiquitin charging’ of the E2-conjugating 
enzymes prior to the transfer of ubiquitin to the protein target by E3-ubiquitin- 
ligases. This thioester linkage is different to the linkages between ubiquitin 
monomers in a polyubiquitin chain or between ubiquitin and substrate proteins. It 
is not clear whether polyubiquination or monoubiquitination of proteins can 
enhance their binding to importins. The identification of binding proteins specfic 
to the ubiquitinated forms of E-cad/CTF2 could provide further insight into the 
mechanism of nuclear transport.
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Since p i20 induces ubiquitination of E-cad/CTF2, it is likely that it recruits an 
E3-ubiquitin-ligase in order to facilitate the ubiquitination of E-cad/CTF2. RFP 
was identified as a p i 20-binding protein which contains a RING-finger domain, 
and which also enhances the ubiquitination and nuclear localisation of E- 
cad/CTF2. It is therefore a good candidate as the E3-ligase for E-cad/CTF2. To 
formally establish whether RFP has E3-ubiquitin ligase activity for E-cad/CTF2, 
an in vitro ubiquitination assay should be performed. Knocking down RFP using 
RNAi would also provide further insight into its role in enhancing the 
ubiquitination and nuclear localisation of E-cad/CTF2.
E-Cad/CTF2 was also shown to be phosphorylated and interestingly, ony the 
more phosphorylated form was observed in the nuclear fraction. Data shown in 
Figure 4.2 indicate that endogenously produced E-cad/CTF2 is mostly found in 
the more phosphorylated form, and therefore has the potential to enter the 
nucleus. CK1 was shown to play a role in the phosphorylation of E-cad/CTF2 
and in the regulation of its ubiquitination and nuclear localisation, however it is 
not the only kinase involved. Identification of other kinases that phosphorylate 
E-cad/CTF2 could provide more insight into the regulation of E-cad/CTF2 
nuclear localisation. As described in sections 1.4.4, E-cadherin is known to be 
phosphorylated by both serine/threonine and tyrosine kinases. Whether the 
observed phosphorylation of E-cad/CTF2 is due to phosphorylation on 
serine/threonine or tyrosine residues or both could be determined with the use of 
phospho-specific antibodies. Mutatgenesis of potential phosphorylation sites 
could also be employed to determine which sites are phosphorylated.
In summary, the data in this chapter show that E-cad/CTF2 is ubiquitinated and 
phosphorylated and both these post-translational modifications impact on the 
regulation of its nuclear translocation. Cellular signalling pathways are subject to 
several layers of regulation in order to finely tune the cellular response. 
Therefore it maybe crucial for the nuclear localisation of E-cad/CTF2 to be 
tightly controlled by multiple cellular regulators, including p i20, RFP, CK1 and 
other unidentified kinases.
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CHAPTER 6
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6 NUCLEAR FUNCTIONS OF E-CAD/CTF2
6.1 Introduction
Chapters 4 and 5 describe the regulation of the nuclear localisation of E- 
cad/CTF2. To understand the significance of E-cad/CTF2 in the nucleus, several 
studies were carried out to determine its nuclear function. Firstly, an in vitro 
DNA-binding assay was used to show that E-cad/CTF2 can form a complex with 
DNA. Secondly, transactivation assays were carried out to determine whether E- 
cad/CTF2 also has transactivation potential. Finally, reporter assays were used to 
show that E-cad/CTF2 can regulate j3-catenin-TCF/LEF-l- and pl20-kaiso- 
mediated signalling pathways in the nucleus.
6.2 In vitro DNA binding of E-cad/CTF2
To investigate the role of E-cad/CTF2 in the nucleus, an in vitro DNA-binding 
assay was used to examine whether it can associate with DNA. This assay uses 
native calf-thymus DNA immobilized on cellulose to precipitate DNA-binding 
proteins from cell lysates (Hosking et al., 2007; Johnson et al., 2004; Ritt et al., 
1998; Surmacz et al., 2002). It is particularly useful when, as in the case of E- 
cad/CTF2, the potential DNA binding sites are not identified.
6.2.1 E-Cad/CTF2 associates with DNA
The DNA binding activity of E-cad/CTF2 expressed in HEK293 cells was 
examined. Interestingly, E-cad/CTF2 in the cell lysate bound to DNA-cellulose 
but not to cellulose alone whereas only very minimal binding of E-cad/CTF3 was 
detected (Figure 6.1 A). This suggests that the N-terminal region of E-cad/CTF2 
may be important for this association with DNA since this region is not included 
in E-cad/CTF3 (see Figure 4.1 for details of E-cad/CTF2 and E-cad/CTF3 
constructs). Only the upper, more phosphorylated band of E-cad/CTF2 was 
precipitated by DNA-cellulose (Figure 6.1 A), suggesting that phosphorylation of 
E-cad/CTF2 maybe important for its DNA-binding. The intensities of Western 
blot bands were quantified using densitometry, and the binding of E-cad/CTF2 to
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DNA was found to be significantly higher than that of E-cad/CTF3 (p < 0.004) 
(Figure 6.IB).
DNA- 
cel. cel.
 ~  WB:
_________ E-Cad
+  -  +  -  
-  +  -  +
CTF3
Figure 6.1 E-Cad/CTF2 binds to DNA in an in vitro binding assay. (A)and (B)
HEK293 cells were transfected with E-cad/CTF2 and E-cad/CTF3 and cell lysates were 
incubated with cellulose or DNA-cellulose beads. The amount of proteins bound to the 
beads was examined by Western blotting with anti-E-cadherin antibody. (B) 
Quantification of E-cad/CTF2 DNA binding. The intensities o f Western blot bands were 
quantified with densitometry from three independent experiments. Error bars indicate 
SEM. **, p < 0.004.
6.2.2 E-Cad/CTF2 interacts specifically with DNA
The specificity of the interaction between E-cad/CTF2 and DNA was confirmed 
by performing a competition assay. In this assay, cell lysates were preincubated 
with increasing amounts of DNA or RNA. Preincubation with DNA suppressed 
the binding of E-cad/CTF2 to the DNA-cellulose, whereas preincubation with 
RNA did not (Figure 6.2). This indicates a specific interaction between E- 
cad/CTF2 and DNA, rather than a non-specific ionic interaction.
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Figure 6.2 DNA, but not RNA, inhibits the interaction of E-cad/CTF2 with DNA- 
cellulose beads. Lysates of HEK293 cells expressing E-cad/CTF2 were preincubated 
with 1, 5, or 20 ug of DNA or RNA, followed by incubation with DNA-cellulose beads. 
The amount of E-cad/CTF2 bound to the beads was examined by Western blotting with 
anti-E-cadherin antibody. The intensities of Western blot bands were quantified with 
densitometry from three independent experiments. Quantitation was done jointly with 
Anthony Wadlow. Error bars indicate SEM.
6.2.3 E-cad/CTF2 binds indirectly to DNA
Since there are no known DNA binding sites within the E-cadherin cytoplasmic 
domain, it was examined whether DNA binding was direct by using purified 
GST-tagged E-cad/CTF2 protein. GST-E-cad/CTF2 alone did not bind to DNA 
and required HEK293 cell lysate to interact with DNA (Figure 6.3). Lysates from 
cells overexpressing exogenous p i20 further increased the amount of GST-E- 
cad/CTF2 binding to DNA, suggesting that p i20 promotes the interaction 
between E-cad/CTF2 and DNA (Figure 6.3).
Input Cellulose DNA-Cellulose
66 WB:
E-Cad
GST-E-Cad/CTF2 -  -  +
293 cell lysate +  — —
293 cell lysate (+p120) — +  -
+ + + + + +
Figure 6.3 E-Cad/CTF2 binds indirectly to DNA. GST-E-cad/CTF2 was incubated with 
cellulose or DNA-cellulose beads in the presence or absence of cell lysates of HEK293 
cells transfected either with or without p120. For input, 1/50 of the amount o f GST-E- 
cad/CTF2 added to the beads was examined.
6.2.4 pl20 binds to DNA and enhances the interaction of E-cad/CTF2 
with DNA
To further examine the effect of p i20 on the DNA binding activity of E- 
cad/CTF2, E-cad/CTF2 was expressed with or without exogenous p i20 in 
HEK293 cells. Coexpression of p i20 substantially increased the association of 
E-cad/CTF2 with DNA (Figure 6.4 A). Quantification of Western blot bands by 
densitometry showed that this increase in DNA binding induced by p i20 was 
statistically significant (p < 0.03) (Figure 6.4 B). p i20 also bound to DNA in this 
assay (Figure 6.4 A), suggesting that the association of E-cad/CTF2 with DNA 
could occur via p i20.
159
Lysate Cellulose
DNA-
Cellulose
30
97
WB:
E-Cad
WB:
FLAG
E-Cad/CTF2 -  + +  -  + +  -  +  +
FLAG-p120 + - + + - +  +  -  +
B
E-Cad/CTF2 +  +  
FLAG-p120 -  +
Figure 6.4 p120 enhances the interaction of E-cad/CTF2 with DNA. (A) HEK293 cells 
were transfected with E-cad/CTF2 with or without FLAG-p120, and cell lysates were 
incubated with cellulose or DNA-cellulose beads. The amount of proteins bound to the 
beads was examined by Western blotting with the indicated antibodies. Images shown 
for cellulose and DNA cellulose are from the same film. (B) The intensities of Western 
blot bands were quantified by densitometry from three independent experiments. Error 
bars indicate SEM. * p < 0.03
6.2.5 Direct binding of E-cad/CTF2 to pl20 is required for E- 
cad/CTF2 to associate with DNA
Since p i20 enhances the interaction between E-cad/CTF2 and DNA and it is 
known that E-cad/CTF2 and p i20 can bind to each other in the nucleus (Figure 
4.15, Chapter 4), it was next examined whether p i20 is required for E-cad/CTF2 
to bind to DNA. E-cad/CTF2(AAA), which is unable to bind p i20, was not 
detected on the DNA cellulose, even in the presence of exogenous p i20 (Figure 
6.5). Together with the data in Figure 6.3 and 6.4, this data suggest that E- 
cad/CTF2 binds to DNA via its interaction with p i20.
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Figure 6.5 E-Cad/CTF2(AAA) does not bind DNA. HEK293 cells were transfected as 
with E-cad/CTF2(AAA), and cell lysates were incubated with cellulose or DNA-cellulose 
beads. The amount of E-cad/CTF2(AAA) bound to the beads was examined by Western 
blotting with anti-E-cadherin antibody.
6.2.6 RFP increases the interaction of E-cad/CTF2 with DNA
Since pl20 can also bind RFP and as described in section 1.6.3, RFP can localise 
in the nucleus and bind DNA, the effect of RFP on the DNA binding activity of 
E-cad/CTF2 was examined. Coexpression of RFP lead to an increase in the 
binding of E-cad/CTF2 to DNA, comparable to that observed by coexpression of 
pl20 (Figure 6.6). This suggests that RFP may also be involved in the the DNA 
binding of the E-cad/CTF2-pl20 complex.
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Figure 6.6 RFP enhances the interaction of E-cad/CTF2 with DNA. (A) HEK293 cells 
were transfected with E-cad/CTF2 with or without FLAG-p120 or FLAG-RFP, and cell 
lysates were incubated with cellulose or DNA-cellulose beads. The amount o f E- 
cad/CTF2 bound to the beads was examined by Western blotting with anti-E-cadherin 
antibody. (B) The intensities of Western blot bands were quantified by densitometry from 
two independent experiments. Error bars indicate SEM. * p < 0.025
6.3 Analysis of the transactivation potential of E- 
cad/CTF2
Since E-cad/CTF2 has been shown to bind DNA, it was next examined whether 
it has transactivating properties. Transactivation assays were carried out in both 
yeast and in mammalian cells in culture.
6.3.1 Transactivation assay in yeast
The transactivation potential of E-cad/CTF2 was first investigated in yeast. This 
assay is a variation of the yeast-2-hybrid assay described in Figure 5.8 (chapter 
5). Briefly, cytoplasmic domain regions of E-cadherin were fused to the DNA- 
binding domain (bd) of GAL4 and expressed in yeast, along with a LacZ reporter 
construct. The GAL4 bd binds to the GAL1UAS in the promotor region of the 
LacZ reporter construct. If the cytoplasmic region has the ability to recruit
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transcriptional machinery to the promotor region, transcription from the LacZ 
gene is activated (Figure 6.7).
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Figure 6.7 Transactivation assay in yeast. Regions of the E-cadherin cytoplasmic 
domain were fused to the GAL4 DNA binding domain (bd) and transfected into yeast 
along with a LacZ reporter construct. The GAL4 bd binds to the GAL1UAS in the 
promotor region o f the LacZ reporter construct. If the cytoplasmic domain region of E- 
cadherin has transactivation potential, transcription of LacZ is activated.
6.3.2 Constructs used in yeast transactivation assays
Several truncated regions of the E-cadherin cytoplasmic domain fused to the 
Gal4 DNA binding domain were used in the yeast transactivation assays (Figure
6.8). This allows the identification of specific regions of E-cad/CTF2 that may 
have transactivating properties.
TM CH2 domain CH3 domain
Ecadl
Ecad2
Ecad3
Ecad4
Ecad5
Figure 6.8 Regions of E-cadherin fused to the GAL4 DNA binding domain used in 
yeast transactivation assays.
6.3.3 Filter assay for j3-galactosidase activity in yeast
Transactivation potential of each of the E-cadherin cytoplasmic domain 
constructs described in Figure 6.8 was first examined using a filter assay for the 
activity of the LacZ gene product p-galactosidase. In this assay yeast colonies
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expressing the one of the E-cadherin cytoplasmic domain regions (Ecadl-5) 
fused to the GAL4 DNA binding domain were transferred to a filter. The cells 
were then permeabilised and assayed for (3-galactosidase activity using X-gal 
solution. pBTM, which contains the GAL4 DNA binding domain alone, was also 
transfected as a control. (3-galactosidase catalyses the hydrolysis of X-gal 
yielding a blue precipitate. This results in the appearance of a blue colour in the 
colonies. Using this technique it was shown that all the E-cadherin cytoplasmic 
domain regions, except for Ecad3, have transactivating potential in yeast (Figure
6.9). However, this technique is qualitative and does not provide any quantitative 
information about the amount of transcriptional activation.
pBTM
Ecad2
Ecad4
Ecadl
Ecad3
Ecad5
Figure 6.9 Ecadl, Ecad2, Ecad4 and Ecad5 have transactivating properties in 
yeast. Yeast colonies expressing the indicated E-cadherin cytoplasmic region fused to 
the GAL4 DNA binding region were transferred to a filter, permeabilised and assayed for 
p-galactosidase activity. The appearance of blue colonies represents p-galactosidase 
activity.
6.3.4 Quantitative transactiviation assays in yeast
In order to gain more insight into which regions of the E-cadherin cyoplasmic 
domain are responsible for the transactivating property in yeast, a quantitative 
liquid culture assay for |3-galactosidase assay was performed. In this assay the 
release of o-nitrophenol from the |3-galactosidase substrate o-
nitrophenylgalactosidase (ONPG) is measured. For more details see section 2.4.5 
(Materials and Methods). Liquid cultures of yeast expressing the E-cadherin 
cytoplasmic domain constructs described in Figure 6.8 fused to the GAL4 DNA 
binding domain. pBTM was also transfected as a negative control. The results of 
this assay showed Ecad2 and Ecad4 had the highest transactivating property
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(Figure 6.10). Ecad4 lacks the N-terminal region including the CH2 domain. 
This suggests that the CH2 domain and the N-terminal region are not required for 
transactivation. As expected from the qualitative filter assay Ecad3 has no 
transactivation activity (Figure 6.10). Interestingly, Ecadl, in which the region of 
E-cadherin from the beginning of the CH3 domain to the C-terminal is deleted, 
shows very weak transactivation (Figure 6.10). This suggests that the C-terminal 
end and the CH3 domain may be responsible for most of the transactivation 
property of the E-cadherin intracellular domain. Ecad5, which differs only from 
Ecad4 by the loss of the very C-terminal region but not the CH3 domain, showed 
a large reduction in transactivation (Figure 6.10). This suggests that this region is 
important for transactivation. However, Ecad5 still has some transactivation 
properties, indicating that the CH3 domain is likely to have some role in 
transactivation.
250
200
0
• Ec3 150
3>i
CD. 100
50
o - I
pBTM Ecadl Ecad2 Ecad3 Ecad4 Ecad5
Figure 6.10 Quantification of the transactivating properties of regions of the E- 
cadherin cytoplasmic domain in yeast Liquid cultures of yeast expressing the 
indicated E-cadherin cytoplasmic region fused to the GAL4 DNA binding region were 
assayed for p-galactosidise activity, p-galactosidase activity is expressed in /3-gal units 
(see section 2.4.5, Materials and Methods, for more details).
6.3.5 Mammalian transactivation assay
In order to determine whether the transactivating properties of the E-cadherin 
intracellular domain are also observed in mammalian cells, a transactivation 
assay was performed in HEK293 cells. Ecad2 (described in Figure 6.8) was 
fused to the GAL4 DNA binding domain in a mammalian expression vector (see
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table 2.7, section 2.1.11, Materials and Methods for details). This region was 
chosen as it is equivalent to the region of E-cadherin found in the fragment E- 
cad/CTF2. The principle of the mammalian transactivation assay is very similar 
to the yeast transactivation assay and is shown in Figure 6.11. Briefly, HEK293 
cells were transfected with E-cad/CTF2 fused to the GAL4 DNA binding 
domain, along with a reporter construct containing the firefly luciferase gene and 
the GAL4 UAS in the promotor region. The GAL4 DNA binding domain binds 
to the GAL4 UAS and if E-cad/CTF2 has transactivating properties, luciferase is 
transcribed.
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Figure 6.11 Transactivation assay in mammalian cells.
6.3.6 Transactivation was not induced by E-cad/CTF2 in mammalian 
cells
A transactivation assay was carried out as depicted in Figure 6.11 using E- 
cad/CTF2 fused to the DNA binding domain of GAL4 in HEK293 cells. Firstly it 
was confirmed that E-cad/CTF2 localises to the nucleus when fused to the GAL4 
DNA binding domain. A substantial amount of E-cad/CTF2-GAL4dbd was 
detected in the nuclear fraction of HEK293 cells even in the absence of 
exogenous pl20 (Figure 6.12). This is likely to be because the DNA binding 
domain of GAL4 contains an NLS sequence. Transactivation was not detected 
when E-cad/CTF2 fused to GAL4dbd was expressed in HEK293 cells, compared 
to the control plasmid containing the GAL4 DNA binding domain alone (Figure 
6.13). Interestingly E-cad/CTF2 showed a decrease in reporter activity compared 
to the control (Figure 6.13). This may indicate that in mammalian cells, E-
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cad/CTF2 has a repressive activity, in contrast to its transactivating property in 
yeast cells. However it is difficult to firmly conclude this from this experiment 
alone as any transcription in the control conditions would be at very low basal 
levels. It may be that E-cad/CTF2 has different binding partners in yeast and 
mammalian cells which could explain the differences in the results of 
transactivation assays between the two systems.
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Figure 6.12 Nuclear localisation o f Gal4-BD-E-c
cells were transfected with Gal4-BD-E-cad/CTF2, together with FLAG-p120. Total and 
nuclear lysates were examined by Western blotting with anti E-cadherin antibody.
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Figure 6.13 Transactivation was not induced by E-cad/CTF2 in HEK293 cells.
HEK293 cells were transfected with either Gal4-BD alone or Gal4-BD-E-cad/CTF2, 
together with the luciferase reporter construct and renilla luciferase, and luciferase 
activites were measured. Relative luciferase activity indicates the ratio of firefly/renilla 
luciferase activities from three independent experiments. Error bars indicate standard 
deviation.
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6.4 Effect of E-cad/CTF2 on transcription from p- 
catenin/TCF/LEF-1- and p120/Kaiso-regulated 
promoters
Since the mammalian transactivation assays did not provide conclusive insight 
into the possible role of E-cad/CTF2 in the regulation of transcription in the 
nucleus, the effect on specific signalling pathways was examined using reporter 
assays. As described in Sections 1.3.4 and 1.3.5 (Introduction), two E-cadherin 
binding proteins (3-catenin and p i20 can both localise to the nucleus and interact 
with the transcription factors TCF/LEF-1 and Kaiso respectively. The effect of 
E-cad/CTF2 on transcriptional regulation mediated by j3-catenin-TCF/LEF-l and 
pl20-Kaiso was examined.
6.4.1 Production of nuclear-localised E-cad/CTF2
As shown in Figures 4.3 - 4.6 (Chapter 4), even when E-cad/CTF2 is localised in 
the nucleus, it is also found in the cytoplasm. Cytoplasmic E-cad/CTF2 may 
have other effects on cell behaviour, independent of any effects that it has in the 
nucleus. For example it has been shown that transfected cytoplasmic cadherin 
sequences can down-regulate cell-cell contacts, acting as a dominant negative 
(Nieman et al., 1999a). To ensure that the effect of nuclear E-cad/CTF2 on 
transcription could be evaluated alone, four nuclear localisation sequences (NLS) 
were fused to E-cad/CTF2, to produce E-cad/CTF2-NLS-myc. E- 
Cad/CTF2(AAA)-NLS-myc which cannot bind p i20 was also constructed. The 
localisation of these constructs was examined in HEK293 cells. Both E- 
cad/CTF2-NLS and E-cad/CTF2(AAA)-NLS were found to localise in the 
nucleus and cytoplasmic staining was not detected (Figure 6.14).
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Figure 6.14 Nuclear localisation o f E-cad/CTF2-NLS-myc and E-cad/CTF2(AAA)- 
NLS-myc. HEK293 cells were transfected with E-cad/CTF2-NLS-myc and E- 
cad/CTF2(AAA)-NLS-myc. Immunostaining was performed with anti-myc antibody. 
Nuclei were stained with Hoechst dye. Images were acquired using epifluorescent 
microscopy. Immunostaining was done jointly with Anthony Wadlow. Scale bar 
represents 10 pm.
In order to reveal other functions of E-cad/CTF2 in the nucleus, MDCK cell lines 
stably expressing GFP-E-cad/CTF2-NLS in a tetracycline-inducible manner were 
established. These cells express GFP-E-cad/CTF2-NLS predominantly in the 
nucleus upon treatment with tetracycline (Figure 6.15 A and B). No clear 
differences in cellular phenotype could be observed by analysis with light 
microscopy, but a more detailed assessment of their phenotype is required. These 
cells could be a useful tool for the identification of novel targets of nuclear E- 
cad/CTF2.
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Figure 6.15 Characterisation of MDCK cells stably expressing GFP-E-cad/CTF2- 
NLS in a tetracycline-inducible manner. (A and B) An MDCK cell clone stably 
expressing tetracycline-inducible GFP-E-cad/CTF2-NLS was treated with tetracycline (2 
pg/ml) for 24 hours. (A) Total cell lysates were examined by Western blotting with anti-E- 
cadherin antibody. (B) Nuclei were stained with Hoechst dye. Images were acquired 
using con focal microscopy. Scale bar represents 15 pm.
6.4.2 E-Cad/CTF2 in the nucleus represses transcription from 0- 
catenin-TCF-regulated promoters
To examine p-catenin-mediated Wnt signalling pathways, a TCF/LEF-1 reporter 
plasmid TOP-FLASH was used. This contains TCF/LEF-1 binding sites 
upstream of the luciferase reporter gene (Figure 6.16A). FOP-FLASH was used 
as a negative control which contains a mutation in the TCF/LEF-1 binding sites 
(Figure 6.16A). As described in section 1.3.4 (Introduction), p-catenin binds to 
TCF/LEF-1 at the promotor region and activates transcription. TCF/LEF-1 and 
cadherins have been shown to compete for binding to p-catenin (Gottardi et al., 
2001; Graham et al., 2000; Sadot et al., 1998). The effect of E-cad/CTF2 and E-
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cad/CTF2-NLS on TOP-FLASH and FOP-FLASH reporter activity was 
examined in SW620 cells. SW620 cells are a human colorectal carcinoma cell 
line which express a mutant APC complex. Thus (3-catenin is stabilized and 
enriched in the nucleus. As expected, expression of E-cad/CTF2 strongly 
suppressed the reporter activity of TOP-FLASH (p < 0.0006) (Figure 6.16B). 
Importantly, a comparable effect was also induced by expression of E-cad/CTF2- 
NLS (p < 0.006) (Figure 6.16B), suggesting that nuclear E-cad/CTF2 can inhibit 
transcription from this reporter.
To further investigate the inhibitory role of nuclear E-cad/CTF2 in (3-catenin- 
TCF/LEF-1 -mediated gene expression, the effect of E-cad/CTF2 and E- 
cad/CTF2-NLS on the expression of P-catenin responsive genes c-myc and cyclin 
D1 was examined using reporter assays in SW620 cells. Transcription from the 
c-myc and cyclin D1 promoters was significantly repressed by expression of both 
E-cad/CTF2 (p < 0.005) and E-cad/CTF2-NLS (p < 0.0005) (Figure 6.17). Taken 
together these data suggest that nuclear E-cad/CTF2 can inhibit p-catenin- 
TCF/LEF-1-mediated signalling.
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Figure 6.16 E-cad/CTF2 in the nucleus represses transcription of fi-catenin- 
TCF/LEF-1 target genes in SW620 cells. (A) TOP-FLASH and FOP-FLASH reporter 
plasmids, fi-catenin binds to TCF/LEF-1 and activates transcription from the TOP- 
FLASH reporter plasmid. FOP-FLASH contains mutant TCF binding sites in the 
promotor region. (B) SW620 cells were transfected with pTOP-FLASH, pFOP-FLASH, 
and LacZ, with or without HA-E-cad/CTF2 and E-cad/CTF2-NLS-myc, and luciferase 
and fi-galactosidase reporter activities were measured. Relative reporter activity 
represents the ratio of luciferase/p-galactosidase activities from three independent 
experiments. *, p <  0.006; **, p < 0.0006. Error bars indicate SEM.
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Figure 6.17 E-Cad/CTF2 in the nucleus represses transcription from TCF/LEF-1- 
regulated promoters Nuclear E-cad/CTF2 supresses transcription from c-myc and 
cyclin D1 promoters. SW620 cells were transfected with pGL3-myc or pGL3-cyclin D1 
and LacZ, with or without HA-E-cad/CTF2 and E-cad/CTF2-NLS-myc, and luciferase 
and fi-galactosidase reporter activities were measured. Relative reporter activity 
represents the ratio o f luciferase/p-galactosidase activities from five independent 
experiments. *, p < 0.005; **, p < 0.0005. Error bars indicate SEM.
6.4.3 The relief of Kaiso-mediated transcriptional repression by p l20  
is enhanced by nuclear E-cad/CTF2
Next, the effect of nuclear E-cad/CTF2 on Kaiso-regulated promoters was 
analysed. The pGL3-4x KBS (4 X KBS) reporter plasmid was used, which 
contains four tandem copies of the consensus Kaiso binding site upstream of the 
luciferase reporter gene (Figure 6.18A). When expressed in HEK293 cells, a 
substantial repression of reporter activity was observed from the 4 X KBS 
construct, compared to the pGL3 control vector alone (Figure 6.18B), suggesting 
repression of transcription mediated by endogenous Kaiso protein binding to 
Kaiso binding sites in the promotor region. With the 4 X KBS construct, the 
effects of p i20, E-cad/CTF2, and E-cad/CTF2-NLS on reporter activity were 
examined in HEK293 cells. As previously shown (Kelly et al., 2004), a 
significant increase in reporter activity was observed in the presence of 
exogenous p i20, indicating that p i20 relieved the repression mediated by 
endogenous Kaiso protein (p < 0.038) (Figure 6.19). Interestingly, this pl20- 
mediated increase in reporter activity was significantly enhanced by 
coexpression of E-cad/CTF2 (p < 0.037) (Figure 6.19). Enhancement of reporter
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activity was also observed with E-cad/CTF2-NLS (p < 0.025), suggesting that 
this effect of E-cad/CTF2 can indeed occur in the nucleus (Figure 6.19). 
Expression of E-cad/CTF2(AAA)-NLS did not enhance reporter activity (Figure 
6.19), suggesting that p i20 binding is required for E-cad/CTF2 to enhance 
transcription.
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Figure 6.18 Reporter assays using pGL3- 4 X  KBS (A)The addition of 4 X Kaiso 
binding sites (KBS) to the promotor region of the pGL3 control luciferase reporter vector 
results in suppression o f transcription due to the recruitment of the transcriptional 
repressor Kaiso. p120 relieves Kaiso-mediated repression by releasing Kaiso from the 
DNA (B) HEK293 cells were transfected with pGL3, pGL3- 4 X KBS (4 X  KBS) and 
LacZ, and luciferase and fFgalactosidase reporter activities were measured. Relative 
reporter activity represents the ratio of luciferase//3-galactosidase activities from three 
independent experiments. Error bars indicate SEM.
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Figure 6.19 E-Cad/CTF2 in the nucleus relieves Kaiso-mediated transcriptional 
repression. HEK293 cells were transfected with pGL3-4x KBS (4x KBS) and LacZ, with 
or without FLAG-p120, HA-E-cad/CTF2, E-cad/CTF2-NLS-myc, and E-cad/CTF2(AAA)~ 
NLS-myc, and luciferase and fi-galactosidase reporter activities were measured. 
Relative reporter activity represents the ratio o f luciferase/fFgalactosidase activities from 
five independent experiments. * p < 0.038; **, p < 0.037; ***, p < 0.025. Error bars 
indicate SEM.
To further examine the ability of nuclear E-cad/CTF2 to relieve Kaiso-mediated 
repression the effect of E-cad/CTF2-NLS on expression of the MMP7 gene (also 
known as matrilysin) was also analysed using reporter assays. Kaiso has been 
shown to bind to and repress transcription from the matrilysin promoter (Spring 
et al., 2005). The promoter region of matrilysin also contains TCF/LEF-1 
binding sites. To exclude the influence of TCF/LEF-1, HEK293 cells were used 
in which |3-catenin is not localised in the nucleus. Expression of p i20 or E- 
cad/CTF2-NLS alone had no effect, but coexpression of E-cad/CTF2-NLS and 
p i20 significantly enhanced transcription from the matrilysin promotor (2.3 kb 
Hmat) in HEK293 cells (p < 0.006) (Figure 6.20). E-Cad/CTF2(AAA)-NLS had 
no effect on transcription from this promotor (Figure 6.20), suggesting that p i20 
binding is required for nuclear E-cad/CTF2 to enhance transcription of the 
matrilysin gene.
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Figure 6.20 Nuclear E-cad/CTF2 enhances transcription of matrilysin. HEK293 cells 
were transfected with a matrilysin promoter-1uciferase reporter containing the 2.3 kb 
human matrilysin promoter (pGL3-Basic-2.3kb HMat) and LacZ, with or without FLAG- 
p120, E-cad/CTF2-NLS-myc, and E-cad/CTF2(AAA)-NLS-myc, and luciferase and ft- 
galactosidase reporter activities were measured. Relative reporter activity represents the 
ratio of luciferase/p-galactosidase activities from three independent experiments. * p < 
0.006. Error bars indicate SEM.
6.4.4 E-Cad/CTF2 interacts with Kaiso in the presence of p l20
Since p i20 relieves Kaiso-mediated repression through binding to Kaiso, it was 
examined whether E-cad/CTF2 can also bind to Kaiso, using a GST pull-down 
assay. Exogenous Kaiso protein expressed in HEK293 cells specifically bound to 
GST-E-cad/CTF2, only in the presence of exogenous pl20 (Figure 6.21). 
Collectively, the data in sections 6.4.3 and 6.4.4 suggest that E-cad/CTF2 forms 
a complex with Kaiso via p i20 and that E-cad/CTF2 can enhance the effect of 
p i20 on Kaiso-mediated gene regulation.
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Figure 6.21 E-Cad/CTF2 interacts with Kaiso in the presence o f p120. Beads 
coupled to GST or GST-E-cad/CTF2 were incubated with lysates of HEK293 cells 
expressing myc-Kaiso and/or FLAG-p120. The proteins bound to the beads were 
analysed by Coomassie staining and Western blotting with anti-myc and anti-FLAG
antibodies. The arrow and arrowhead indicate the positions of GST-E-cad/CTF2 and
GST, respectively. By kind permission of Dr. Mihoko Kajita.
178
6.5 Discussion
This chapter describes studies investigating the role of E-cad/CTF2 in the 
nucleus. E-Cad/CTF2 forms a complex with DNA via p i20. RFP also enhances 
the interaction with DNA. The transactivation potential of E-cad/CTF2 is 
examined and differences between its activity in yeast and mammalian cells were 
determined. E-Cad/CTF2 is also shown to have different effects on the regulation 
of (3-catenin-TCF- and pl20-Kaiso-mediated signalling pathways in the nucleus.
An interesting finding from this chapter is that E-cad/CTF2 binds to DNA. The 
association of E-cad/CTF2 and DNA is not direct, as E-cad/CTF2 requires p i20 
for its DNA binding. It is not clear whether p i20 binds directly to DNA. This 
could be addressed with the use of purified p i20 protein. Only the more 
phosphorylated form of E-cad/CTF2 was detected in the complex with DNA, 
indicating that phosphorylation could also be involved in the regulation of the 
DNA-binding activity of E-cad/CTF2. RFP expression also enhances the DNA 
binding of E-cad/CTF2. It is important to determine whether RFP is also found 
in the complex with DNA and whether E-cad/CTF2, p i20 and RFP can form a 
trimeric complex. As described in section 1.6.3 (Introduction), RFP is found in 
the nucleus and has been shown to have both transcriptional repressive and 
activating activities, as well as being present at sites of transcriptional regulation. 
Knocking down the expression of RFP with RNAi would provide some insight 
into whether RFP is required for the DNA-binding of E-cad/CTF2. It is also not 
clear whether the enhancement of the DNA-binding of E-cad/CTF2 by RFP 
involves ubiquitination. Investigation of the effect of ubiquitin and mutations 
within the RING finger domain of RFP on the DNA binding of E-cad/CTF2 
could clarify on this issue. At present, the DNA binding site of the E-cad/CTF2- 
pl20 complex is not clear. It is unlikely that it binds to the Kaiso-binding regions 
because p i20 promotes dissociation of Kaiso from DNA (Daniel et al., 2002). 
Thus, the E-cad/CTF2-pl20 complex may be involved in the regulation of 
transcription or chromatin remodeling of unknown gene(s). Determination of 
DNA binding sites could be addressed by performing CASTing (cyclic 
amplification and selection of targets) experiments or by ChIP cloning.
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It was found that the region of E-cadherin equivalent to E-cad/CTF2 has a 
transactivating property in yeast. This seemed particularly interesting as the 
regions of E-cad/CTF2 that are important for transactivation and DNA-binding 
are at opposite ends of the protein fragment. The CH3 domain and the most C- 
terminal region were most important for transactivation. DNA binding seems to 
be mediated through the CH2 domain or the most N-terminal region of E- 
cad/CTF2, since E-cad/CTF3 showed very weak DNA binding activities. 
However, transactivation by E-cad/CTF2 was not observed in mammalian cells. 
In fact, a decrease in transcription of the reporter compared to the control was 
observed in transactivation assays in HEK293 cells. Preliminary studies using a 
form of E-cad/CTF2 that does not contain the CH3 domain and the most C- 
terminal region, showed that this truncated form of E-cad/CTF2 showed less 
repression. The apparent discrepancies between the results of the transactivation 
assays in yeast and mammalian cells could be due to different binding proteins of 
the cytoplasmic domain of E-cadherin and differences in the transcriptional 
machinery. However it is difficult to conclude that E-cad/CTF2 has a general 
repressive activity in mammalian cells as the level of transcription from the 
control reporter plasmid containing only the Gal4 bd is only at very low basal 
levels. It is more useful to analyse potential effects of E-cad/CTF2 on 
transcription by the identification of specific target genes.
As a first step towards identifying E-cad/CTF2-mediated nuclear signalling 
pathways, the effect of E-cad/CTF2 on transcriptional regulation by two of its 
nuclear binding partners, P-catenin and p i20, was analysed. E-Cad/CTF2 was 
shown to suppress (3-catenin-mediated signalling pathways with reporter assays 
using the TOP-FLASH reporter, and with cyclin D1 and myc promoter reporters 
in SW620 cells. With NLS-tagged E-cad/CTF2, it was demonstrated that this 
suppression can occur in the nucleus. This is expected, since TCF/LEF-1 and E- 
cadherin compete for binding to p-catenin (Gottardi et al., 2001; Graham et al., 
2000; Sadot et al., 1998). Recently, it has been shown that the y-secretase- 
mediated cleavage product of N-cadherin, N-cad/CTF2, is also localised in the 
nucleus and regulates P-catenin-mediated signalling (Shoval et al., 2007; Uemura 
et al., 2006a). However, as discussed in section 4.6, there are functional
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differences between E-cad/CTF2 and N-cad/CTF2. In addition to different 
cellular localisations, N-cad/CTF2 enhances canonical Wnt-signalling pathways 
(Shoval et al., 2007; Uemura et al., 2006a), while E-cad/CTF2 suppresses it. As 
suggested in section 4.6 (Chapter 4), E-cad/CTF2 and N-cad/CTF2 may have 
different specific binding proteins, which may mediate differences in their effect 
on transcription as well as nuclear translocation.
With reporter assays, using the 4 X KBS reporter and the matrilysin promoter 
reporter in HEK293 cells, it is also shown that the expression of E-cad/CTF2 
potentiates the effect of p i20 on the relief of Kaiso-mediated transcriptional 
repression. With GST pull-down assays, it was shown that E-cad/CTF2 forms a 
trimeric complex with p i20 and Kaiso. These data suggest that the interaction 
between these three proteins influences gene transcription. It would be 
interesting to determine whether E-cad/CTF2 can strengthen the binding of p i20 
with Kaiso thereby enhancing its ability to dissociate Kaiso from DNA. This 
could be addressed with ChIP assays.
To determine whether p-catenin-TCF/LEF-1 and pl20-Kaiso gene targets are 
transcriptionally regulated by E-cad/CTF2, the levels of endogenous gene targets 
by reverse-transcriptase (RT)-PCR should be analysed. Many of the targets of 
canonical Wnt signalling are also regulated by Kaiso. Since E-cad/CTF2 appears 
to have opposite effects on TCF/LEF-1 and Kaiso, it may provide the cell with 
one way to separate the activities of these pathways. As described in sections
1.3.4 and 1.3.5 (Introduction), there are differences in the activation of (3-catenin- 
TCF/LEF-1- and pl20-Kaiso-mediated signalling. In particular, while pl20 and 
p-catenin are both released into the cytosol in conditions where E-cadherin is 
down-regulated, P-catenin is rapidly degraded and requires cellular activation 
with Wnt for its stabilization, p i20 is more stable in the cytosol, although a 
recent study has shown that Wnt signals can lead to p i20 stabilisation and 
enhancement of Kaiso sequestration from DNA (Park et al., 2006). In the future, 
other downstream targets of E-cad/CTF2 could be identified by using the MDCK 
cell line established in this study which stably expresses E-cad/CTF2-NLS under
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a tetracycline-inducible promoter. These cells could be used in a genomic or 
proteomic array to identify novel targets.
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CHAPTER 7
183
7 FINAL DISCUSSION
In this thesis the role of the y-secretase cleavage product of E-cadherin (E- 
cad/CTF2) in signalling is examined. It is shown that stimuli inducing an EMT in 
MDCK cells, treatment with HGF or activation of Ras, lead to the production of 
E-cad/CTF2. The crucial role of p i20 in the nuclear localisation of E-cad/CTF2 
is demonstrated using several experimental systems. Both phosphorylation and 
ubiquitination (possibly mediated by a novel ubiquitin E3 ligase RFP) are shown 
to be involved in the regulation of the nuclear localisation of E-cad/CTF2. 
Furthermore, E-cad/CTF2 forms a complex with DNA via p i20. DNA binding of 
E-cad/CTF2 is also enhanced by RFP. Moreover nuclear E-cad/CTF2 inhibits the 
activation of TCF/LEF-1-regulated promoters by (3-catenin. In addition it is also 
shown that E-cad/CTF2 acts in concert with p i20 to relieve transcriptional 
repression mediated by Kaiso.
As a signalling molecule, E-cadherin has the potential to provide information to 
the cell about the status of cell-cell contacts. Cleavage of E-cadherin at the 
membrane results in production of E-cad/CTF2 which can localise in the nucleus 
and modulate gene transcription. It will be important to determine whether this 
pathway plays a role in relaying signals from the membrane to the nucleus about 
the level of adhesion between cells and their neighbours.
As E-cad/CTF2 is released under conditions inducing an EMT, it is tempting to 
speculate that E-cad/CTF2’s role in signalling to the nucleus could be involved 
in this morphological transition. It is known that y-secretase-mediated cleavages 
are strongly enhanced by upregulation of MMPs or ADAMs which remove the 
ectodomain of y-secretase’s transmembrane protein substrate (Struhl and Adachi, 
2000). MMPs are involved in EMT and also in the progression to metastatic 
cancers (Lee and Murphy, 2004; Lochter et al., 1997; Page-McCaw et al., 2007). 
E-cadherin downregulation at cell-cell contacts is involved in EMT and E- 
cadherin loss has been shown to be causal in the progression of carcinogenesis 
(Perl et al., 1998). The released ectodomain of E-cadherin following MMP
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cleavage promotes invasiveness of cells and detection of high amounts of this 
fragment is strongly associated with advanced prostate cancer (Noe et al., 2001; 
Kuefer et al., 2003). It is now crucial to determine whether the likely intracellular 
end product of these cleavages, E-cad/CTF2, can also influence migration or 
invasiveness of cells through its signalling role in the nucleus, and whether it 
also may have a role in tumour progression. It could be speculated that nuclear 
E-cad/CTF2 could enhance or inhibit the process of EMT, either by acting as a 
positive signal or by providing a negative feedback mechanism (for example the 
ICD of y-protocadherins appears to upregulate the y-protocadherin gene locus 
itself (Hambsch et al., 2005)). Alternatively, nuclear E-cad/CTF2 may not affect 
this process, but have some other role. Insight into the physiological role of 
nuclear E-cad/CTF2 could be gained by examination of the phenotype of cells 
expressing E-cad/CTF2 in the nucleus.
It is important to use a system in which nuclear-localised E-cad/CTF2 can be 
studied in isolation in order to detemine whether any observed phenotypic 
changes are due to transcriptional changes, since as described in section 6.4.1 
(Chapter 6), cytoplasmic sequences of cadherins can act as dominant negatives 
for cell-cell adhesion. The biological role of E-cad/CTF2 in the nucleus alone 
needs to be elucidated. MDCK cell lines stably expressing E-cad/CTF2 
exclusively in the nucleus have now been established in this study. Although no 
clear phenotypic change could be detected in these cells upon expression of 
nuclear E-cad/CTF2 by light microscopy, a more detailed analysis of the 
phenotype is required. In particular it will be important to measure any changes 
in migration or invasiveness, and whether there is a difference in how the cells 
respond to HGF treatment. However p i20 seems to be highly involved in E- 
cad/CTF2’s nuclear function in the formation of a complex with DNA and also 
in its ability to modulate Kaiso-mediated repression. Therefore a cell line with 
more nuclear and cytoplasmic p i20 such as MDA-321 or L-fibroblasts, may be 
more suitable to observe any phenotypic changes associated with nuclear E- 
cad/CTF2.
It will also be of vital importance to assess what in vivo significance the nuclear 
localisation of E-cad/CTF2 has. It has been problematic to study the
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endogenously produced E-cad/CTF2 following HGF treatment as the amount 
produced is low relative to the amount of full length E-cadherin. As described in 
section 1.5.2 and 3.4, the amount of the Notch ICD produced by y-secretase 
cleavage is also very small relative to the full length protein. Thus it has not been 
possible to detect endogenously produced ICDs of either E-cadherin or Notch in 
the nucleus by immunostaining or nuclear fractionation. Nuclear access of the 
Notch ICD was demonstrated in Drosophila melanogaster embryos in a more 
sensitive approach by inserting the GAL4-VP16 chimera in the C-terminal 
region of Notch. This was expressed in embryos that also carry a Gal4UAS-LacZ 
transgene and allowed the detection of expression of the LacZ gene in response 
to Notch ligands, indicating nuclear translocation of the Notch ICD (Struhl and 
Adachi, 1998). A similar approach could be employed in Drosophila 
melanogaster by fusing GAL4-VP16 to the C-terminus of E-cadherin. This 
approach could provide insight into where, and at what stage, cleavage and 
nuclear localisation of E-cadherin occurs during development. It may also be 
useful to establish E-cadherin mutants that cannot be cleaved by y-secretase and 
determine what affect this has on phenotype.
As described in Section 1.5.4 (Introduction), regulation of y-secretase activity 
remains incompletely understood. An interesting question to answer is how 
cleavage of E-cadherin by y-secretase is upregulated during EMT. It seems very 
likely that the upregulation of extracellular metalloproteases is involved since as 
described in section 1.4.5 (Introduction), they are known to be upregulated by 
HGF, Ras and Snail, and provide y-secretase with its substrate for cleavage. The 
findings that y-secretase-mediated cleavages of both Notch and APP are 
upregulated by endocytosis (described in section 1.5.4) suggest that this may be a 
general mechanism for regulating y-secretase cleavage. In the case of Notch, 
ubiquitination was shown to be required for endocytosis and cleavage by y- 
secretase (Gupta-Rossi et al., 2004). It will be interesting to determine whether 
endocytosis of E-cadherin which occurs upon HGF treatment of MDCK cells is 
required for the observed production of E-cad/CTF2. Although it will be difficult 
to block endocytosis using dominant negative Dynamin or Epsl5 due to the low 
transfection efficiency of MDCK cells, an inhibitor of endocytosis known as
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Dynasore has been developed (Thompson and McNiven, 2006). This could be 
used to determine whether endocytosis is a prerequisite for y-secretase-mediated 
cleavage of E-cadherin in this system. Furthermore, it will be interesting to 
determine whether Hakai can enhance cleavage of E-cadherin since Hakai 
ubiquitinates and enhances endocytosis of E-cadherin in response to HGF (Fujita 
et al., 2002). CK1 may also provide a link between endocytosis and cleavage of 
E-cadherin, since it is known to induce E-cadherin endocytosis (Dupre-Crochet 
et al., 2007) and it was shown in section 5.5.2 of this thesis that it enhances the 
nuclear localisation of E-cad/CTF2. It would be interesting to determine whether 
E-cadherin cleavage is affected in E-cadherin constructs which are mutated at the 
site of CK1 phosphorylation.
An important finding from this thesis is that E-cad/CTF2 can modulate 
transcription from reporters containing binding sites for TCF and Kaiso 
transcription factors. As was expected, E-cad/CTF2 in the nucleus inhibits 
transcription from the TOP-FLASH reporter in SW620 cells in which |3-catenin 
signalling to TCF/LEF-1 is highly active. This is likely to be due to E-cad/CTF2 
competing with TCF/LEF-1 for binding to P-catenin. Furthermore transcription 
of P-catenin-TCF/LEF-1 gene targets cyclin D1 and myc are also inhibited in 
SW620 cells. Interestingly, analysis of reporters containing Kaiso binding sites 
indicated that E-cad/CTF2 in the nucleus can act together with p i20 to relieve 
Kaiso-mediated repression in HEK293 cells. Indeed E-cad/CTF2, p i20 and 
Kaiso form a trimeric complex. E-cadherin and Kaiso both bind p i20 within 
pl20’s Arm repeat domain, but the data in this thesis suggest that their binding to 
pl20 is not mutually exclusive. Instead the data in sections 6.4.3 and 6.4.4 
indicate that E-cad/CTF2 binding to Kaiso via p i20 enhances the ability of p i20 
to relieve Kaiso-mediated repression. Indeed it was also shown that in HEK293 
cells, transcription from a reporter construct of the promotor region of a known 
Kaiso target MMP-7 was enhanced by nuclear E-cad/CTF2 together with p i20.
A large number of Kaiso gene targets have both TCF/LEF-1 and Kaiso binding 
sites within their promotor regions. This may mean that nuclear E-cad/CTF2 
could suppress or enhance transcription of these genes depending on the levels of
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nuclear p-catenin, nuclear p i20 or other signals. Thus it is possible that E- 
cad/CTF2 in the nucleus may act to balance expression of these genes depending 
on which signalling pathways are activated. It seems likely that both p i20 and p- 
catenin are released into the cytoplasm when cadherins are downregulated, and 
thus could be available for nuclear signalling, p i20 is stable in the cytoplasm 
whereas P-catenin is rapidly degraded unless cells are stimulated with Wnt. 
Therefore in the absence of Wnt, p i20 nuclear signalling may be more 
prominent, and in these situations nuclear E-cad/CTF2 may enhance this. 
However upon stimulation with Wnt, p-catenin nuclear signalling is activated 
and under these conditions, E-cad/CTF2 seems to suppress this. To further 
understand the role of nuclear E-cad/CTF2 regulating the transcription of 
Wnt/Kaiso target genes, it will be important to examine the effect of nuclear E- 
cad/CTF2 on transcription of the same targets in the presence and absence of 
Wnt stimulation. Both AD AMI 0 and nuclear N-cad/CTF2 have been reported to 
enhance cyclin D1 expression (Maretzky et al., 2005; Shoval et al., 2007). It is 
possible that AD AMI 0 induction of cyclin D1 expression could be partly due to 
E-cad/CTF2-mediated derepression of Kaiso. Likewise it will be interesting to 
determine whether N-cad/CTF2 can also regulate Kaiso. There are also specific 
targets of both TCF/LEF-1 and Kaiso which seem likely to be either repressed or 
activated by nuclear E-cad/CTF2. For example MTA2, which contains 
methylated CpG dinucleotides in its promoter, has been shown to be repressed by 
Kaiso (Yoon et al., 2003). Although p i20 has not yet been shown to relieve 
repression of MTA2, p i20 does promote the dissociation of Kaiso from methyl 
CpG sites (Daniel et al., 2002). The effect of nuclear E-cad/CTF2 on MTA2 
expression could be determined by RT-PCR.
Determination of other gene targets of nuclear E-cad/CTF2 will also be of crucial 
importance to understanding its biological role. The existence of other targets is 
indicated by the formation of a complex of E-cad/CTF2 with DNA, via p i20. It 
is unlikely that this complex forms at Kaiso-binding sites in DNA, since p i20 
induces dissociation of Kaiso from DNA (Daniel et al., 2002). These targets 
could be determined using cells stably expressing nuclear E-cad/CTF2 in 
microarrays or proteomic arrays. RFP also enhances DNA binding of E-
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cad/CTF2, so it is possible that some of the known transcriptional targets of RFP 
could be regulated by E-cad/CTF2.
There is good evidence that both the downregulation of E-cadherin and 
upregulation of catenin molecules in the cytosol are involved in developmental 
processes and cancer progression. As E-cad/CTF2 is produced when E-cadherin 
is downregulated during EMT, and p i20 is involved in its nuclear localisation, 
determining the physiological role of nuclear E-cad/CTF2 could be of relevance 
to further understand development and disease.
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